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ABSTRACT 
Replication-defective and replication-competent recombinant human adenovirus 
type 5 vectors efficiently expressed the glycoprotein D (gD) or the transmembrane anchor 
truncated gD (tgD) of bovine herpesvirus type 1 (BHV-I) in v i m .  To facilitate the 
evaluation of the efficacy of immunisation with these recombinant adenoviruses in 
conferring protection against BHV-1 infection, a cotton rat (Sigmodon hispidus) model for 
intranasal BHV-1 challenge was developed. I used this model to assess the ability of 
different routes of immuaisation with the recombinant adenoviruses to elicit @specific 
systemic and mucosal immunity and confer protection against BHV-I challenge. 
[mmunisation with gD-expressing vectors induced better immunity and protection than 
immunisation with tgD-expressing viruses. Mucosal immunisation with the replication- 
competent virus was more efficient than that with the replication-defective vector in 
inducing @-specific antibody in the serum and the respiratory tract. In contrast, systemic 
immunisation with the two vectors stimulated similar @-specific antibody levels. These 
results indicate that the route of imrnunisation was crucial when assessing the efficacy of 
recombinant adenoviruses as vaccine vectors. The importance of the route of 
administration was further demonstrated by the finding that intranasal immunisation with 
the replication-competent vector stimulated higher antigen-specific IgA levels and 
antibody-secreting cell numbers in the respiratory tract than intradermal, intraperitoneal or 
enteric irnmunisation. Protection correlated with gD-specific antibody levels such that 
intranasal immunisation, even 3 months following vaccination, conferred complete, while 
intraderrnal or enteric immunisation conferred partial protection of the lungs of cotton rats 
dgainst intranasal BHV-1 challenge. Pre-existing active adenovirus-specific immunity 
stimulated by intranasal administration of wild type adenovirus significantly inhibited the 
development of @-specific antibody responses and protection against BHV- I challenge 
following imrnunisation with recombinant adenovirus. In contrast, passive transfer of 
adenovirus-specific antibody caused only a slight inhibition. Overall, mucosal and systemic 
immunisation with adenovirus vectors could induce antigemspecific immunity and 
protection against BHV-1 challenge. The level of @-specific immune responses and 
protection f?om challenge were, however, dependent on the characteristics of the 
heterologous protein, the replication-capability of the viruses, the route of immunisation 
and the presence or absence of preexisting adenovirus-specific immunity in the cotton rat. 
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deoxyribonucleic acid 
early transcription region 1 
early transcription region 3 
Epstein-Barr virus 
enzyme-linked immunosorbent assay 
enzyme-linked immunospot 
fetal bovine serum 
gut-associated lymphoid tissue 
glycoprotein D 
glycoprotein B 
glycoprotein C 
gastrointestinal 
gl ycoprotein 
hour(s) 
hemagglutinin 
human adenovirus 
hepatitis B 
human cytomegalovirus 
xviii 
HE 
Eav 
HN 
HPrv3 
HRSV 
HRV 
HSV 
IBR 
i.cerebr 
i.d. 
i .dud 
IFN 
IgG 
IL 
ism. 
1.n. 
1.t. 
i.v. 
i .vag 
k b ~  
kDa 
LCMV 
LN 
LP 
mAb 
MALT 
MDBK 
MEM 
MHC 
min 
MLP 
MOI 
MV 
NP 
OD 
PBS 
PBS-T 
pfu 
p i .  
PRV 
RNA 
RSV 
hemagglutinin esterase 
human immunodeficiency virus 
hemagglutinin neuraminidase 
human parainfluenza virus type 3 
human respiratory syncytial virus 
human rotavirus 
herpes simplex virus 
infectious bovine rhinotracheitis 
intracerebral 
i n t r a d e d ,  intradermdy 
intraduodend 
interferon 
immunoglobulin A 
immunoglobulin G 
immunoglobulin M 
interleukin 
intramuscular, intramuscularly 
intranasal, htranasaily 
intraperitoneal, intraperitoneall y 
intratracheal 
intravenous, intravenously 
intravaginal 
kilobase-pairs 
kilo-Dalton 
lyrnphocytic choriomeningitis virus 
lymph node(s) 
lamina propria 
monoclonal antibodfiies) 
mucosa-associated lymphoid tissue 
Madin Darby bovine kidney 
minimum essential medium 
major histocompatibility complex 
m u t e s  
major late promoter 
multiplicity of infection 
measles virus 
nucleoprotein 
optical density 
phosphate buffered saline 
PBS-tween 
plaque forming unit(s) 
pos tinfec tion 
pseudorabies virus 
ribonucleic acid 
respiratory syncytial virus 
xix 
S.C. 
SD 
SI 
SN 
SV40 
TBEV 
tgD 
Tfi 
UV 
VP 
VSV 
wt 
subcutaneous, subcutaneously 
standard deviation 
stimulation index 
s e w  neutralking 
simian virus 40 
tick-borne encephalitis virus 
truncated gD 
T helper (lymphocyte) 
ultraviolet light 
viral protein 
vesicular stomatitis virus 
wild-type 
Live recombinant human adenoviruses are an excellent delivery system for viral 
vaccine antigens (hder, 1995, Rosenthal et al., 1996). A great advantage of recombinant 
adenoviruses over other vaccination strategies is their capability to express large quantities 
of heterologous viral antigen in vivo in a similar manner as during a natural viral infection. 
Furthermore, adenoviruses naturally infect mucosaI tissues, and therefore can induce 
mucosal immunity. 
Induction of mucosal immunity is crucial in protecting against infections with 
mucosal pathogens such as bovine herpesvirus type 1 (BHV-1). Therefore, mucosal 
immunisation with recombinant adenoviruses that express BHV-1 proteins capable of 
inducing neutralising antibodies has the potential to serve as an effective vaccine strategy 
against infection and disease caused by BHV-1. Since immunisation of cattle with purified 
glycoprotein D (gD) of BHV-1 stimulates protective immunity against BHV-1 infection 
(Babiuk ef al., 1 987), gD expressed by adenovirus vectors would serve as  a good vaccine 
model to investigate mucosal immunity induced by recombinant adenoviruses. 
Cotton rats (Sigmodon hispidur) have been widely used in immunisation and gene- 
therapy research involving recombinant human adenoviruses because cotton rats support 
human adenovirus replication (Pacini et al., 1984). However, for evaluating gD-expressing 
adenovirus vectors in inducing protection against BHV- 1 challenge, the animal model must 
also support BW-1  replication. The development of a rodent model that supported the 
replication of both HAdS and BHV-1 made it possible to investigate the efficacy of 
different routes of immunisation with replication-defective and replication-competent 
recombinant adenoviruses expressing gD in inducing @-specific rnucosal immunity and 
protection against mucosal BHV- 1 infection. 
2.0 LITERATURE REVIEW 
2.1 Bovine herpesvirus type 1 and its control 
Bovine herpesvirus type 1 (BHV-I), a member of the Alphaherpesviridae 
subfamily, can cause a variety of diseases in cattle including infectious bovine 
rhinotracheitis (IBR), infectious pustular vulvovaginitis, conjunctivitis, encephalitis, 
generalised systemic infections, and abortions (Gibbs & Rweyemamu, 1977, Yates, 1982). 
In addition, BHV-1 infection of the respiratory tract may render cattle susceptible to 
potentially fatal secondary bacterial pneumonia, a respiratory disease syndrome called 
"shipping fever" (Yates, 1982). 
2.1.1 Conventional vaccines against BHV- 1 
Inactivated whole virus or attenuated live virus vaccines have been used 
commercially in the past decades to reduce economic losses due to BHV-1 infection 
(Tikoo et al., 1995a). Killed virus preparations may be safer than attenuated live vaccines; 
one of their disadvantages has been, however, the need to combine them with strong 
adjuvants in order to induce protective immune responses. In addition, immunity to killed 
vaccines is usually of short duration. 
Modified live virus vaccines have been developed by passage in vitro to produce 
attenuated isolates or by mutagenesis to produce temperature-sensitive mutants. They are 
used to control IBR in canle and appear to induce some level of protective immunity to 
B W -  1 without the use of adjuvants (Gerber et a!., 1978, Jericho & Babiuk, 1983). They 
can be administered not only systemically, but also intranasally (i.n.) (Crerber et al., 1978), 
providing the potential to induce strong local immunity in the respiratory tract. However, 
these vaccines do not prevent the establishment of a latent infection or reinfection with 
wild type virus (Kahrs, 1976, Nettleton & Sharp, 1980, Pastoret et al., 1980). Furthermore, 
they may induce abortions and adverse post-vaccinal reactions (Hyland et a[., 1974, 
Mitchell, 1 974). An additional disadvantage of conventional killed or live attenuated 
vaccines is that it is impossible to difkentiate, by serodiagnosis, between vaccinated and 
infected (e.g., latent carrier) animals, which may be crucial for eradication purposes. 
2.1.2 New generation BHV- 1 vaccines 
Since conventional vaccines do not always prevent infection or disease, new 
strategies of vaccination have been investigated. Advanced molecular biological and 
biochemical techniques have enabled us to develop genetically engineered modified live 
virus vaccines, subunit protein vaccines, recombinant live viral vectors and polynucleotide 
vaccines. All these new generation vaccination strategies provide the means to differentiate 
between vaccinated and naturally infected, carrier animals. 
Having identified viral encoded genes that influence the virulence of BHV-1, 
genetically engineered modified live viruses have been constructed by altering or deleting 
these genes (Tikoo et al., 1995a). The advantages of this approach over conventional live 
viral vaccines are that the virus is attenuated without the possibility of backmutation. 
Advances in protein chemistry and molecular biology have also resulted in the 
ability to identify, produce and purify large quantities of individual viral components 
necessary to elicit a protective immune response against the virus. It has been shown that a 
subunit vaccine consisting of one or several of the three major BHV-1 envelope 
glycoproteins (gB, gC and gD) induced a better level of immunity than a killed virus 
vaccine. This resulted in protection of all vaccinated cattle fiom mortality following 
challenge with BHV- I and PusteureIZa haemolytica (Babiuk et al., 1987). To enhance the 
protective immune responses induced by subunit BHV-I vaccines and to enable mucosal 
administration, lipid-based vehicles (e.g., liposomes) as delivery systems have also been 
investigated (Baca-Esaada et a[., 1997). 
Delivering the purified subunit protein to the animal is not the only way to induce 
immunity to one particular viral component. A viral protein can also be delivered by using 
live recombinant viml vectors expressing the gene for the desired protein (Perkus & 
Paoletti, 1996). Depending on the choice of the live vector, this strategy often has the 
advantage of inducing strong mucosal immune responses following mucosal 
administration of the recombinant virus (discussed in more detail in 2.4). 
Finally, the technique of DNA immunisation involves the in vivo delivery of the 
gene of a certain viral protein, usually in a circular plasmid form. DNA vaccines have 
induced cellular and humoral immune responses against different antigens, and protection 
against different diseases in animals (Hassett & Whitton, 1996, Shiver et al., 1 996). Genes 
of BHV-1 glycoproteins delivered intramuscularly (i.m.) or intrademally (i.d.) have also 
been shown to stimulate antigen-specific immune responses in cattle and mice (Cox et al., 
1993, Lewis et al., 1997; Ralph Braun and Syivia van h e n  Littel-van den Hurk 
personal communication). 
2.2 BEN-1 glycoproteins gD and tgD 
Protection of cattle firom disease following challenge with BHV-1 and Pastewella 
haemolytica has been achieved by immunisation with a subunit vaccine consisting of 
BHV- 1 gD (van Drunen Littel-van den Hurk et al., 1993). Immunisation with gD was 
found to be more efficient in reducing virai replication and clinical signs, and inducing 
cellular immune responses than vaccination with other BHV- 1 glycoproteins, such as gl3 
and gC (Babiuk et al., 1987, Hutchings et al., 1990, van Druneo Littel-van den Hurk ef al., 
1990, van Drunen Littel-van den Hurk et a/., 1993). Therefore, investigations have been 
concentrated on the further characterisation of gD in vitro and in vivo as a potential vaccine 
candidate against BHV- I .  
2.2.1 The characteristics of gD and its roles in wal replication 
Glycoprotein D is a homologue of herpes simplex virus 1 (HSV-1) gD (Leung- 
Tack et al., 1994, Tikoo et al., 1990) and is one of the major glycoproteins present in the 
envelope of BHV-I virions and plasma membrane of virus-infected cells (Marshall et al., 
1986, van Drunen Littel-van den Hurk et al., 1984). Its gene maps to the early transcription 
region of the BHV-1 genome and encodes a polypeptide of 41 7 amino acids (Tikoo et al., 
1990). Glycoprotein D is synthesised as a 63-kDa partially glycosylated precursor that 
leads to the formation of a 71 kDa mature protein, containing both N-linked and 0-linked 
oligosaccharides (van Drunen Littel-van den Hurk & Babiuk, 1 986). Analysis of purified 
gD by immunoprecipitation and Western blot assays indicated that gD produced by 
different mammalian expression systems can form dimers (Hughes et al., 1988, van 
&men Littel-van den Hurk et al., 1993, van h e n  LitteI-van den Hurk et al., 1997, van 
Drunen Littel-van den Hurk et al., 1984). Glycoprotein D is essential for viral replication 
(Fehler et aL, 1992). It may be involved in attachment (Liang et al., 199 1 ), penetration 
(Chase & Letchworth ID, 1994, Fehler et al., 1992), and h i o n  with cells (Tikoo et al., 
1990). Some B lymphocyte (Tikoo et al., 1993) and T lymphocyte epitopes (Leary & 
Splitter, 1990, Tikoo et al., 199%) have been identified on gD. 
2.2.2 The rationale for the construction of truncated gD 
Since gD remains mainly cell-associated following its production in BHV-I 
infected cells, it must be extensively purified to be used as a vaccine. In addition, effective 
production of gD is problematic since g D  is toxic to cells expressing it (Tikoo et al., 1990). 
Recently, an economical method to produce gD has been developed by engineering the gD 
gene to function under the control of a bovine heat-shock protein 70 gene promoter, which 
regulates the expression of gD in transfated Madin Darby bovine kidney (MDBK) cells 
(Kowalski et al., 1993). This system was designed to produce a transmembrane anchor 
truncated version of gD (truncated gD, tgD) in an expression system that is not cell- 
destructive. Truncated gD could be efficiently secreted into the medium of transfected 
MDBK cells. The tgD produced by the heat-shock system is 61 kDa in molecular weight 
and is antigenically similar to the authentic gD glycoprotein when analysed in vitm by a 
panel of gD-specific monoclonal antibodies (mAb) (Kowdski et al., 1 993). Furthermore, 
irnmunisation of cattle with tgD conferred protection against BHV- 1 challenge (van 
Drunen Littel-van den Hurk et al., 1994). 
The different cellular localisation of gD and tgD may result in different induction of 
immune responses. Questions about the influence of the antigen form on the induction of 
immune responses have been investigated in non-challenge mouse models: adjuvant 
formulation with the two subunit glycoproteins (Baca-Estrada et al., 1996), DNA 
imrnunisation with the genes of gD and tgD (Lewis et al., 1997; Braun, personal 
communication), and adenovirus-expressed tgD or gD (Papp et al., manuscript in 
preparation). 
2.3 Recombinant adenovirus vectors 
Live viral vectors provide an alternative for the delivery of individual viral antigens 
without the need for producing large quantities of purified protein. In addition, live 
recombinant viruses offer several other advantages compared to conventional or subunit 
vaccines. Most importantly, they provide the expression of the required antigen 
intracellularly - analogous to infection by the viral pathogen - without the danger of 
disease through loss of attenuation or improper inactivation of the vaccine. 
Among the different viral vectors available (e.g., pox, polio, adeno), adenovirus 
(Ad) vectors are often preferred because of their relatively low pathogenicity, stability, 
efficient large-scale production and the ease of manipulation of their genomes. They may 
also be more efficacious than poxvirus vectors (vaccinia) in inducing mucosal immunity 
(Gonin et aL, 1 996). Since adenoviruses are common in not only human but also in animal 
populations, research on their use may provide a potentially widely applied strategy for 
foreign gene delivery. 
2.3.1 [nfections caused by wild-type human adenoviruses 
Adenoviruses constitute a large group of DNA viruses that infect mammals and 
birds. Human adenoviwes (HAd) are endemic in human populations around the world, 
with about a dozen out of the hown 47 serotypes responsible for epidemic outbreaks of 
mainly respiratory and ocular infections. By the age of one year, more than 60 % of 
children have antibodies against at least one HAd serotype. By adulthood, 99% of the 
people are seropositive for HAd (for a review see Straus, 1984). The various Ad serotypes 
can infect and replicate at a number of locations in the body including the respiratory tract, 
the gastrointestinal tract, the eye and the urinary bladder (Horwitz, 1996, Straus, 1984). 
Adenovirus infection typically exhibits a short incubation period of 5- 10 days, but in more 
than 30 % of the cases, Ad continue to be excreted in the feces for months or years 
following the initial infection (Fox et a/., 1969). It is not known whether abortive infection 
of certain cell types such as fleshly isolated peripheral blood lymphocytes by Ad 
(Flomenberg et al., 1 997, Schranz et al., 1 979, Silver & Anderson, 1 9 88) may be related to 
persistence or latency in viva Nevertheless, Ad infections often remain subclinical, rarely 
spreading beyond the draining lymph nodes (LN) of the site of primary infection. On rare 
occasions, however, patients have died fiom acute infixtion of the lungs or liver, or from 
widely disseminated infection. 
Research interest began to focus on human adenoviruses after the finding that some 
serotypes were turnongenic in rodent models; no association between Ad infection and 
human turnours, however, has been detected to date. Subsequent studies lead to the use of 
adenoviruses as the model of choice for molecular biologists to study DNA replication, 
RNA transcription and splicing, and the molecular basis of cell transformation. Hence the 
biology of these viruses is well known (Shenk, 1996). 
2.3.2 Biology of human adenoviruses 
Adenoviruses contain a single, double-stranded, linear DNA genome of 
approximately 3040 kilobase pairs within a nonenveloped, icosahedral capsid. The 
replication cycle of the virus can be divided into two phases. The early phase corresponds 
to events occurring before the onset of viral DNA replication, while the late phase 
corresponds to the period afier initiation of DNA replication. During infection, the Ad 
virion enters the cell through receptor-mediated endocytosis and replication occurs in the 
nucleus, usually without integration of the viral DNA into the host genome. Late gene- 
expression occurs at approximately 8 hr post-infection (pi.). Transcription of the genes of 
most of the viral struchlml proteins is mainly driven by the major late promoter (MLP). 
Although adenoviruses do not lyse infected cells, one cell can often produce 10,000 virions 
(Shenk, 1996). Cultured human cells generally support the complete HAd infectious cycle; 
most simian and rodent cells do not (Blair et ab, 1989). Interestingly, infection of monkey 
and rodent czlls with HAd has shown that this restricted host range is not due to a lack of 
receptors. It is rather due to intracellular blocks arising tiom inappropriate interactions 
between cellular and viral components, for example, a block of an early step of viral DNA 
replication (Lucher, 1995). Therefore, early proteins are usually still expressed in cells of 
semipermissive species. 
Human adenovirus type 5 (HA&) possesses several advantages, which renders it a 
generally useful vector to express foreign genes in different mammalian systems. First, it 
replicates to high titres in human cells in vitro. The virions remain cell-associated well after 
the production of new virus is completed, which makes the concentration of large volumes 
of virus possible, simply by sedimenting infected cells. The handling and storage of 
adenoviruses are not difficult since the Ad virion is relatively stable. Furthermore, inserts 
of foreign genes are generally maintained without change through successive rounds of 
viral replication (Graham & Prevec, 1992). 
2.3.3 Replication-defective and replication-competent HAd5 vectors 
Recombinant human adenoviruses have become an attractive gene delivery system 
because of the ease of manipulation of their genome and the well-characterised methods for 
generating recombinant Ad vectors. To render the Ad virion capable of accommodating 
larger than 2 kbp of foreign DNA, either the early transcription region 1 or 3 (E 1 and E3, 
respectively) is most commonly deleted (Graham & Prevec, 199 1, Graham & Prevec, 
1992). Deletion of the E 1 region results in a vector (dE 1) that is replication-defective since 
E l  gene products are essential for the onset of DNA replication. Therefore, the vector can 
be propagated only in a cell line, which contains and expresses the left end of the Ad 
genome thus complementing the deficiency. Approximately 3 kbp can be deleted from E 1, 
with a replacement insertion of up to 5 kilobase-pairs (kbp) of foreign DNA. Transcription 
of foreign genes inserted in the E 1 deletion must be driven by a promoter introduced as part 
of the insert (Graham & Prevec, 1992). Since transcription of the foreign gene is completed 
before DNA replication, these vectors efficiently express their inserts in any normally 
HAdS permissive or semi-permissive cell without the need for viral replication. 
Deletion of the E3 region (dE3) does not dicrease the replication-competency of the 
vector in vitro, since E3 is not required for viral replication. E3-deleted vectors, therefore, 
can be propagated in any normally HA&-permissive cells. The function of E3 region 
proteins is not known; they probably play a role in modulating the host immune response. 
For example, infection with dE3 vectors results in an increased inflammatory response in 
the lungs of cotton rats compared to inoculation with HA& that contains the E3 region 
(Berencsi et al., 1994, Ginsberg et al., 1990, Ginsberg et al., 1989). It is possible that the 
absence of the 19 kDa glycoprotein encoded by the E3 region of HAd5, which is known to 
downregulate expression of MHC-I molecules on the surface of infected cells, results in an 
increase in the Ad-specific cytotoxic lymphocyte (CTL) response (Burgert & Kvist, 1987). 
Generally, dE3 vectors can accommodate 4 kbp of foreign DNA in their genome. In many 
replicationcompetent vectors used today, an SV40 promoter is introduced as part of the 
expression cassette. A heterologous promoter is not usually required, however, since 
expression of the foreign gene is efficiently driven by the MLP or E3 promoters (Graham 
& Prevec, 1992). Recombinant HAdS systems are also used in which both E 1 and E3 
regions are deleted (dE 1E3 vectors). They may accommodate up to 8 kbp of foreign DNA 
(Bett et al., 1 994, Bett et a[., 1993). 
Recombinant HAd5 vectors have been used to express antigens from a wide variety 
of heterologous viruses (Perkus & Paoletti, 1 996). High-level expression of foreign genes 
has been obtained from both dividing and quiescent cells of a variety of animal species, 
including human and other primates, rodent, canine and bovine cells infected with HAd5 
vectors. In recent years, Ad vectors have been studied as a recombinant vaccine delivery 
system against viral diseases (Imler, 1995) and turnours (Bischoff et al., 1996, Chen et al., 
1996, Zhai et al., 1996), and as gene transfer vectors for gene therapy (Bramson et a!., 
1 995, Brody & Crystal, 1 994, Rosenfeld et al., 199 1 ). 
2.3.4 Recombinant human adenoviruses as vaccine vectors 
The popularity of human adenovirus as a vaccine delivery system is largely due to 
the successful and safe immunisation of millions of US military recruits with enteric coated 
wild-type (wt) HAd4 and HAd7 as a prevention against acute respiratory disease outbreaks 
(Top et al., 197 1 a, Top et al., 1 97 1 b). Following these first trials, a number of recombinant 
adenoviruses have been constructed and tested in animals. Since HA& has been studied 
extensively and is less pathogenic compared to HAd4 and HAd7, it is often the strain of 
choice for the development of recombinant vaccines. 
Recombinant HAd5 vectors - even if unable to replicate - have proven to be 
effective in expressing foreign genes in vitro and in vivo. Systemic immunisation with both 
replication-competent and replicationdefective Ad vectors has induced humoral and cell 
mediated immune responses to the expressed viral antigen (Table 2.1), W e r ,  1995). In 
many cases, irnmunisation resulted in protection fiom viral challenge (Table 2.1 ). 
Immunisation with recombinant HAdS has even induced CTL to an intracellular parasite 
(malaria) antigen and protected mice against parasite challenge (Rodrigues et al., 1997). 
Systemic immunisation alone, with recombinant HAdS vectors, however, did not induce 
effective mucosal immune responses and protection fiom mucosal challenge (Table 2.1) 
(Gallichan et al., 1993, Rosenthal et al., 1996). 
Since it is important to induce local immunity at the site of pathogen entry, it may 
be necessary to administer recombinant adenoviruses to mucosal surfaces. A great 
advantage of HAdS vectors as a delivery system is that they naturally infect mucosal tissues 
(Prince et al., 1993, Rosenfeld et a[-, 199 1); therefore, they have the potential to deliver the 
foreign gene effectively to mucosal induction sites. Indeed, imunisation with recombinant 

Table 2.1 (cont) 
antigen vector animal rcpl. admin. immunc rcsponsc challcngc protect. rcfcrencc 
route to antigen (route) 
HSV gD epi. dE3 mouse i.p. serum Ab i.p. partial, d (Zheng er nl., 1993) 
rabies gp dElE3 mouse S.C. serum Ab, CTL S.C. yes, d (Xiang er a/., 1996) 
in.  serum Ab, CTL S.C. yes, d (Xiang et a!., 1996) 
oral no Ab S.C. no (Xiang et al., 1996) 
dE3 mouse oml serum Ab in some animals i.ccrcbr partial, d (Prevec et a/.,  1990) 
i. p. serum Ab 
skunk oral serum Ab 
i.cerebr yes, d (Prcvcc et al., 1990, 
Yarosh et al., 1996) 
i.ccrebr yes, d (Charlton et a/., 1992, 
Yarosh et a/., 1996) 
i.m. serum Ab ixerebr yes, d (Charlton et al., 1992) 
fox oral scrum Ab i.cerebr yes, d (Charlton et al., 1992) 
dog S.C. serum Ab (Prevec er al., 1990) 
in. serum Ab 
HCMVgB dE3 mouse i.p. CTL 
BCV HE dE3 cotton rat + i.n. serum and lung Ab, CTL, - 
spleen cell proliferation 
(Prevec et al., 1990) 
(Berencsi et al,, 1993) 
(Baca-Estrada et al., 1995) 
Lduod serum and intestinal Ab (Baca-Estmda er al., 1995) 
HRV VP7 dE3 mouse i.n. serum Ab in dams and oral yes, d (Both et a/.,  1993) 
suckling neonates 
i.v., i.p., serum Ab (Both et al., 1993) 
oral 
bPlV F, I-IN dE3 cotton mt + i.n. serum Ab i.n. yes, i of (Brckcr-Klassen er ul., 1995) 
l u n ~ s  
Table 2.1 (cont) 
ant igcn vector animal rcpl. admin. imn~unc response challenge protect. refcrcnce 
route to antigen (route) 
HIVEnv, Gag dE3 chimpanzee + i.n. serum, nasal, vaginal, - (Lubcck et al., 1994, 
PRV gD 
salivary Ab, spleen cell 
proliferation, PBL CTL 
i.v, 
dog +/- i . t .  serum Ab 
dE3 cotton rat + i.111. serum Ab 
mouse i.m. serum Ab 
dEIE3 cotton rat - i.m. serum Ab 
mouse i.m. serum Ab 
i.p. serum Ab 
1.n. serum Ab 
dElE3 rabbit ism., i.n. serum Ab 
yes, i 
yes, d** 
yes, d 
yes, d 
yes, d 
partial 
yes, d 
partial 
Natuk et al., 1993) 
(Lubcck et al., 1997) 
(Natuk et al., 1992) 
(Eloit & Adam, 1995) 
(Eloit & Adam, 1995) 
(Eloit & Adam, 1995) 
(Eloit & Adam, 1995, 
Gonin et al,, 1996) 
(Ganne el al., 1994) 
(Gonin et a/., 1996) 
(Eloit et al., 1990) 
TBEV NS1 dE1E3 mouse i . p  no Ab S.C. yes, d (Jacobs et al., 1994) 
MV N dElE3 mouse i.p. serum Ab, CTL 
EBV env dEIE3 cottontop - i.m. serum Ab 
tamarin 
i.cerebr partial, d (Fooks el al., 1995) 
i.m., i.p. yes, d (Ragot et al., 1993) 
HBsAg dElE3 chimpanzee - i.v. no Ab, only priming i.v. partial (Levrero et al., 199 1)  
HC ag-s dElE3 mouse i.p. serum Ab (Makimum et ul., 1996) 
i.p. CTL 
malaria CSP dE 1 E3 mouse s.c, i..m. Ab, CD8' IFN-y SC i.v. 
(Bruna-Romero er al., 1997) 
(Rodrigucs et al,, 1997) 
ip. iv, i.n. low Ab, no CDX' 1FN-y SC - (Rodrigucs et al., 1997) 
rcpl. = replication-capnbility of vector in the animal; d = protection (protecl.) from disease or death; i = protection from infection measured by viral recovery 
* better and longer lasting protection than ancr i.p. immunisation; ** lower doses protect than dE 1 E3 immunisation or imm. in mice 
adenoviruses in the respiratory as well as in the gastrointestinal tract has stimulated not 
only systemic but also mucosal immune responses to several foreign viral antigens (Table 
2.1). Most of the studies using rnucosal immunisation with recombinant viral vectors have 
focused on the generation of serum neutralising antibodies and short-term protection 
against challenge. Gailichan and co-workers (Gallichan et al., 1993) also investigated the 
generation of herpesvirus-specific CTL and the duration of immune responses following 
imrnunisation with a dE3 recombinant HAd5 expressing gB of HSV- 1. Long term HSV 
serum neutralising antibody responses were induced by both intraperitoneal (i.p.) and 
intranasal (i.n.) immunisation with the recombinant Ad, and splenic CTL responses were 
maintained for as long as 58 weeks following i.p. imrnunisation. They also found that i.n. 
administration was more efficient than i.p. immunisation in inducing mucosal IgA 
responses and protection against i.n. HSV challenge. In other studies, i .n. immunisation 
was more effective than systemic immunisation in inducing local Ad- and P-galactosidase- 
specific antibody production in the respiratory tract (van Ginkel et al., 1995). The 
importance of local stimulation in the mucosa is M e r  indicated by the finding that i.n. 
administration of recombinant HA& was more effective than gastrointestinal (g . i.) 
inoculation in inducing immunity in the respiratory tract (Collins et al., 1990). However, 
immunisation with recombinant Ad at a distant rnucosal site can be more effective than 
local stimulation. Intravaginal imrnunisation with recombinant Ad expressing HSV gB was 
less effective than i.n. imrnunisation in inducing vaginal @-specific antibodies (Gallichan 
& Rosenthal, 1995). 
2.4 The efficacy of recombinant viral vectors in the presence of antigen-specific 
immunity 
Immunity to a pathogen can be passively derived ( m a t e d  antibodies) or actively 
acquired (natural infection). Both passive and active immunity can significantly modify 
infection, viral gene expression, and disease caused by viruses (Renegar & Small, 1 994, 
Zinkernagel, 1993). Since the success of imrnunisation with recombinant live viral vectors 
depends on infection with the virus followed by foreign gene expression, immunity to the 
vector is expected to influence the efficacy of vaccination with recombinant viral vectors. 
2.4.1 Passive immunity to viral vectors 
The level of both mucosal and systemic antibody responses to a viral infection that 
takes place in the presence of passively acquired IgG can be reduced significantly 
(Kimman et al., 1987, Murphy et nl., 1986, Sabin et a[., 1963, Xiang & Ertl, 1992). The 
suppressive effect of virus-specific serum antibody on the induction of resistance to 
challenge is greatest when the virus vaccine is administered parenterally rather than 
mucosally (Murphy et al., 1989). One possible explanation for less inhibition following 
mucosal imrnunisation is that senun igG is less efficient in blocking mucosal than systemic 
viral infections. Therefore, the local induction of a mucosal IgA response, by mucosal 
infection, is less suppressed than is the induction of systemic IgG responses (Jayashree et 
al., 1 988, Kimman & Westenbrink, 1990). 
Similar to the neutralisation of any virus by virus-specific antibodies, live 
recombinant viruses may be inactivated by antibodies before they could enter cells and 
express their foreign gene. Studies with recombinant adenoviruses in mice showed that 
passive transfer of Ad-speci fic antibody into the venous circulation blocked the expression 
of the heterologous gene in hepatocytes, but did not affect gene-transfer into the lung 
(Yang el al., 1995a). In contrast, instillation of Ad-specific antiserum into the trachea 
blocked gene transfer to ainvay epithelia without affecting gene transfer to hepatocytes. 
Therefore, passively derived antibody is effective in neutralising virus depending on the 
site of the antibody transfer and virus idkction. 
Since neutralising antibody to the virus vector suppresses the expression of the 
foreign gene, it is likely that the induction of immune responses to the foreign gene product 
will be suppressed as well. Intraperitoneally administered vaccinia virus-speci fic antibodies 
inhibited, in a dose-dependent manner, HA-specific CTL responses following intravenous 
(i-v.) administration of a recombinant vaccinia virus expressing the HA protein of influenza 
(Johnson et al., 1993). They had no effect on the humoral response to HA or vaccinia, 
although inhibition was shown in a previous study (Johnson et al., 1988). The effect of Ad- 
specific passive antibody immunity on immunisation with recombinant adenoviruses 
remains to be determined. 
2.4.2 Active immunity to viral vectors 
Active immunity to a virus develops following natural mfection or experimental 
administration of the virus to the host. It involves the stimulation of different regulatory 
and effector immune responses including the expansion of antigen-speci fic lymphocytes 
and the development of immunological memory. Active immune responses specific for a 
virus vector may inhibit the foreign gene expression following administration of 
recombinant virus more than passive vector-specific antibody discussed earlier. First, 
active immunity is longer lasting than passively acquired antibody. Second, local 
production of antibodies following infection by the virus may be more effective in 
inhibiting viral infection than passively transferred antibody. Third, a virus infection 
induces not only humoral but also cell mediated immune responses. In accordance, 
adenoviruses have been shown to induce not only Ad-specific serum antibody, but also 
mucosal antibody responses (van Ginkel et al., 1 995, Yang et al., 1 995b) and cell mediated 
immue responses. Adenoviruses are able to stimulate T cell proliferative responses, MHC 
class 11-restricted C D ~ '  cells of the Thl subset, MHC class-I restricted CD4' and C D ~ '  
CTL (Flomenberg et al., 1995, Ginsberg & Prince, 1994, Rawle et nl., 1989, Sparer et al., 
1997, van Ginkel et al., 1997, Yang et aL, 1995% Yang ei aL, 1994, Yang ei al., 1995b, 
Yang & Wilson, 1995). 
Since adenoviruses are very common pathogens, it is very likely that many 
individuals (animals or humans) have developed some level of Ad-specific immunity by 
natural infection. Furthermore, if repeated administration of Ad vectors is necessary for 
optimal vaccination or gene therapy results, the host may develop substantial levels of Ad- 
specific immunity by the time of second administnition of the recombinant virus. 
Therefore, it is important to investigate the effect of active Ad-specific immunity on the 
efficacy of irnmunisation and gene-transfer by recombinant adenoviruses. 
Immune responses induced by administration of adenovirus can substantially 
diminish the efficiency of gene transfer following a second administration of recombinant 
Ad (Dong et a/., 1996, Kozarsky ef al., 1994, Mittal et al., 1993, Setoguchi et al., 1994, 
Smith et al., 1993, Yang et aL, 1995% Yei et al-, 1994). In spite of Ad-specific immunity, 
however, repeated administrations have been successful in expressing foreign genes in vivo 
(Bout et al., 1994% Crystal et al., 1995, Mastrangeli et al., 1993, Setoguch et al., 1994, 
Zabner et al., 1994). The level of Ad-specific immunity at the site of the second 
administration of the virus largely depends on the route and dose of, and the time passed 
since the first administration of the virus. Intraperitoneal immunisation with Ad did not 
affect foreign gene expression following administration of the vector to the lung (Setoguchi 
et ab, 1 994). In addition, inhibition of second foreign gene expression was less evident 3 
months after the first administration compared to 1 month later (Setoguchi et aL, 1994). 
The level of adenoviral gene expression may also influence the induction of Ad-specific 
immunity. Schulick et al. (1997) showed that i.v. pre-exposure to ultraviolet light 
0- i r rad ia ted  adenoviral vectors (with reduced viral gene expression but preserved 
capsid function) did not block foreign gene expression following subsequent i.v. 
administration of recombinaut Ad as much as pre-exposure to intact virus. 
Several immune effector mechanisms may be responsible for the elimination of 
Ad-infected cells. Transgene expression was shown to be completely or partly diminished 
as a result of destruction of virus-infected cells by MHC class I-restricted CTL O(ap1a.n et 
al., 1997, Yang et al., 1995a). In accordance, C D ~ '  T cell-deficient mice had prolonged 
transgene expression in hepatocytes (DeMatteo et al., 1997). Adenovirus-specific 
neutralising antibody in the ainvays, however, was sufficient to hlly block gene transfer to 
the airways (Yang et al., 1995a). Furthennore, it is not surprising that mice transiently 
depleted of c D ~ '  T cells before first administration supported longer expression of the 
foreign gene following second administration of the vector than control mice (Yang et al., 
1995b, Yang & Wilson, 1995), since CD4+ T cells are important in the development of 
both humoral and cellular effector mechanisms against adenoviruses (Yang et al., 1 995% 
Yang et al., 199%). 
The role of Ad-specific mucosal IgA in blocking gene-transfer to the lung of mice 
has been suggested. Yang et al. (199%) showed that tr;tilsient cD~+ cell depletion and 
intratracheal (it.) interleukin m)- 12 or interferon 0 - y  administration completely 
inhibited the formation of Ad-speci fic IgA following Ad administration. These treatments 
caused more efficient gene transfer to occur following a second administration of 
recombinant adenovirus. C D ~ +  T cell depletion did not affect the development of systemic 
CTL, responses and only partially inhibited Ad-specific IgG responses in the lung. 
Intratracheal IL-12 and IFN-y administration did not inhibit the levels of lung IgG. These 
results may suggest that Ad-specific mucosal IgA may be primarily responsible for the 
blockade of foreign gene expression by recombinant Ad in the mouse lung. 
Most research groups investigating the inhibitory effect of active vector-specific 
immunity on the efficacy of foreign gene-delivery have been mainly concerned about the 
level of expression of the foreign gene. Only a few have studied how immune responses 
induced by the foreign gene may be influenced by pre-existing vector-specific immunity. 
Kundig and co-workers (1993) irnmuised mice by the i.v. route with a recombinant 
vaccinia virus expressing 1 ymp hoc ytic choriomeningi tis virus (LCMV) nucleoprotein (NP). 
At different timepoints following first immunisation, they i.v. inoculated the animals with 
another recombinant vaccinia virus expressing vesicular stomatitis virus (VSV) 
glycoprotein (GP). They found that GP-specific B cell responses were suppressed for more 
than 9 months. The level of suppression depended on the dose of the first vaccinia virus 
administration (Kundig el al., 1993). Others infected mice i.v. with different doses of 
vaccinia virus, and later immunised them i.v. with recombinant vaccinia virus expressing 
haemagglutinin (HA) of influenza virus. Antibody titres specific for HA and survival rate 
after i.n. influenza challenge were reduced the greatest in mice infected with a high dose of 
non-recombinant vaccinia compared with titres in the control group (Andrew, 1989). 
Interestingly, there was no difference in vaccinia-specific CTL activity following infection 
with high or low dose of non-recombinant vaccinia virus, which supports the idea that the 
protective efficacy of the recombinant vector is dependent upon the level of pre-existing 
vaccinia-specific antibody? rather than CTL. 
The effect of active vector-specific immunity on iinmunisation with recombinant 
Ad was also investigated. Systemic pre-infection of mice with 10' plaque forming units 
@fL) of HAdS slightly inhibited antibody and CTL responses specific for the expressed 
foreign gene induced by a subsequent systemic administration of recombinant Ad (Xiang el 
al., 1 996). The possible inhibitory effect of infection with higher doses of Ad has not been 
investigated. It appears important to perform these experiments, since the usual dose of 
recombinant Ad used for immunisations or gene therapy experiments is 10' to 1 o9 pfu per 
animal (see references in Table 2.1). 
2.4.3 Immunity to the expressed antigen 
Both active and passive immunity to the expressed foreign gene may also inhibit 
the efficacy of immunisation with recombinant viral vectors. Indeed, immune responses to 
transgene-encoded proteins limited the stability of gene-expression after injection of 
replication-defective Ad vectors (Tri pathy et al., 1 996). Passive transfer of respiratory 
syncytial virus (RSV) antiserum suppressed the hurnoral immune response to RSV proteins 
expressed by recombinant vaccinia viruses (Gdetti et al., 1995, Murphy el a/., 1988), but 
did not inhibit CTL responses to the proteins (Galetti et al., 1995). In contrast, vaccination 
with recombinant vaccinia viruses has been successll despite existing active immunity to 
the expressed antigens (Flexner et al., 1988). In addition, the efficacy of vaccination of 
Iambs in surgically created gut-loops with HAdS expressing gD of BHV-1 was not 
inhibited by the presence of maternal antibodies to gD and Ad (Philip Griebel, manuscript 
in preparation). Data in the literature, therefore, seem contradictory but indicate that not 
only immunity to a viral vector but also to the foreign protein can cause suppression of the 
efficacy of vaccination with recombinant virus. 
2.5 Concerns about the safety of recombinant adenoviruses 
There are two main issues identified up to date regarding the limitation of 
application of recombinant adenovirus vectors. One, their efficacy in the presence of 
Ad-specific immunity, has been discussed. Another issue is their safety; it is important that 
recombinant adenoviruses do not shed extensively following in vivo administration. This 
would increase the possibility of infection of individuals and the recombination with wild 
type viruses. For gene therapy purposes, it is also desimble to maintain control over the 
extent of foreign gene expression. 
Replication-defective recombinant adenovimses are often considered safer than 
replicationcompetent vectors because foreign gene expression by replication-defective 
dE 1 viruses always correlates with the infectious viral dose. Furthermore, their spread in 
vivo and shedding to the environment have been suggested to be more limited than that of 
dE3 adenoviruses (Oualikene et al., 1 994). However, replication of a dE 1 virus may also 
take place during a simultaneous infection with wt HAdS, which theoretically raises similar 
safety concerns as administration of a replication-competent virus. Evidence for phenotypic 
complementation of recombinant dEl adenovirus expressing the cystic fibrosis 
transmembrane conductance regulator (CFTR) or P-galactosidase with wt HA& was found 
in human cells in v i m  (Imler et al., 1995, Oudikene et al., 1995) and in vivo following i.n. 
administration of the viruses to cotton rats (Imler et al., 1995). No in vivo trans- 
complementation of the recombinant Ad with wt HAG was observed, however, when 
recombinant virus was delivered i-v. or i.m. and wt HAdS was administered i.n. (Oualikene 
et al., 1995). 
In vivo spreading and shedding to the environment of both replication-competent 
and replication-defective adenoviruses can take place, even though replication-defective 
vectors have been suggested to be limited in their capability of in vivo dissemination. 
Replication-defective dEIE3 virus was not isolated from any organs of the cotton rat 
following i.m. delivery (Oualikene et al., 1994, Oualikene et a[., 1995), although foreign 
gene expression was found at the site of administration in the muscle (Huard et al., 1995). 
Following i.v. inoculation in the tail, no dEIE3 vector was isolated from any organ 
(Oualikene et al., 1995), although others detected foreign gene expression in the liver, 
kidney, tail and some muscles (Bout et ol., 1994b, Brody et al., 1994, Goldman et al., 
1995, Huard et aL, 1995). Following i-n. delivery, no virus was found in tissues other than 
those of the respiratory tract (Yei et aL, 1994). Others, however, found dElE3 virus 
following i.n. inoculation in both the respiratory tract and in the small bowel or faeces 
(Bout et al., 1994% Zabner et a!., 1994), in kidneys and liver (Oualikene et al., 1994) and 
in the oesophagus and spleen (Imler et aL, 1993). Foreign gene expression following i.n. 
inoculation of recombinant ciElE3 was also detected in the lung, liver and heart (Huard et 
al., 1995). Huard et al. (1995) also investigated many other routes of administration of a 
dElE3 vector: they found foreign gene expression in the heart, liver, lung, thymus and 
muscles following intracardiac delivery, in the peritoneum, diaphragm and liver following 
i.p. inoculation; in the lung, heart and thymus following buccal administration; and in liver, 
spleen, kidney, peritoneum, stomach, rectum, thymus and muscles following gastric-rectal 
inoculation. Thus, spreading of replicationdefective viruses is not always limited to the 
site of infection as generally believed, even following mucosal administration. 
Dissemination of replication-competent and replicationdefective adenoviruses 
were compared in only one detailed investigation, using im. and i.n. administration of 
adenoviruses in cotton rats (Oualikene et al., 1994). Following i.m. delivery, they detected 
dE3 virus in the liver, spleen, lungs, nasal-washes, poplietal and inguinal LN, while dE 1 E3 
virus was not isolated fiom any organs. Following i.n. administration of the dE3 vector, all 
tested samples (I iver, spleen, kidneys, lungs, nasal-wash, brain, gut, pop1 ietal and inguinal 
LN) were positive for adenovirus. In contrast, dElE3 was found only in the lungs, nasal- 
wash, kidneys and LN after i.n. administration of the virus. Others have shown that 
following i.p. inoculation of the dE3 vector, adenovirus could be detected in the liver, 
kidneys, spleen and lungs (Mittal et al., 1993). 
Oualikene et al. (1994) found that wt HAdS disseminated similarly to dE3 HAd5 
virus in the cotton rat. While wt HAdS was detected in every organ tested 3 days following 
i.n. delivery, at 7 days following inoculation it was found only in the lungs and nasal- 
washes (Oualikene et al., 1995). Interestingly, in a previous experiment, they detected 
HAdS in every organ tested 28 days following i.n. inoculation (Oualikene et al., 1994). 
In people, wt HA&, HAd7 and recombinant dl33 viruses were shed in the stool and 
also in the pharynx following oral hunisat ion (Schwartz et al., 1974, Tacket et al., 1992, 
Top et al., 197 1 b). In contrast, no evidence for Ad dissemination to the throat was found 
following oral administration of type 2 1 HAd in humans (Dudding et al., 1972). Extensive 
investigations and many years of experience with oral vaccination using HAd type 4 and 7 
in military recruits showed that replication-competent Ad can be used safely to imrnunise 
humans (Top ef al., 197 1 b). Dissemination of recombinant dE3 adenoviruses to different 
tissues in either humans or animals, however, has not been studied following 
gastrointestinal routes of administration. Furthermore, since different routes of 
administration, dose, detection systems and animal models have provided contradictory 
data (as described above), further studies are necessary to determine the capability of 
adenoviruses to disseminate following different routes of administration. 
2.6 Mucosal immunity and protection against viral infection 
It is important to discuss what elements may constitute protective immune 
responses against viruses, for two reasons. First, the immunisation strategy has to be such 
that the foreign gene expressed by the live vector would induce protective immunity 
against the respective mucosal viral infection. Second, understanding what the protective 
immune responses are against the viral vector itself, one may be able to design strategies to 
optimise the efficiency of vaccination using the viral vector. Since both BHV-I and HAd5 
primarily infect mucosal surfaces, it is important to investigate the induction and effector 
mechanisms of immune responses that protect the mucosa against viruses. 
2.6.1 Inductive and effector mechanisms of mucosal immunity 
The first line of defence against mucosal pathogens involves mechanical and 
physicocbernical cleansing mechanisms such as peristalsis or ciliary movement, mucous 
coat, proteolytic enzymes, innate humoral factors, and the physical characteristics of 
mucosal epithelial cells and junctions, which degrade and repel most pathogens. In 
addition, a large and highly specialised immune system protects the mucous membranes, 
and thereby also the body's interior, against potential insults from the environment 
(Sanderson & Walker, 1994). Since the aim of vaccination is to stimulate antigen-specific 
host-defenses, this section will address the inductive and effector mechanisms of antigen- 
specific mucosal immune responses and their role in protection against mucosal viral 
infection. 
A mucosal immune response involves priming at inductive sites, dissemination in 
the circulation and homing to effector sites of antigen-specific lymphocytes (for a review 
see Tomasi, 1994). These events are studied in the most detail for the gut-associated 
lymphoid tissue (GALT) but are thought to be similar for the organised mucosa-associated 
lymphoid tissues (MALT) of the respiratory tract. Briefly, live replicating and dead 
particulate antigens are thought to be taken up fiom the lumen of the gut or airways 
through specialised areas, microfold OM) cells, of the follicle associated epithelium. The 
antigen, usually unaltered in M cells, is then transported into the underlying lymphoid 
tissue containing professional antigen presenting cells (APC) and B and T cells, where 
antigen-priming of the lymphocytes takes place. M e r  antigen-induced activation, 
proliferation, and partial differentiation, both B and T cells migrate to the regional LN, 
fiom which - probably after further differentiation - they go via the lymph into the 
peripheral blood. These stimulated memory cells migrate to intestinal lamina propria (LP) 
or to mucosal tissues and exocrine glands outside the gut, notably also in the respiratory 
tract and in lactating mammary glands (Phillips-Quagliata & Lamm, 1994). The integrated 
dissemination of immune cells from GALT to all exocrine sites, the so called common 
mucosal immune system (CMIS), is the functional basis for oral vaccines. Evidence for the 
existence of a CMIS comes fiom studies of cell trafficking and from the observation that 
immunisation of one mucosal site often leads to detectable immune responses at distant 
mucosal sites (McDemoa & Bienenstock, 1979, Mestecky ef a/., 1994). In addition to 
lymphocyte activation in MALT, antigen taken up at mucosal surfaces may be directly 
transferred to draining LN and other peripheral lymphoid tissue, where activation of 
antigen-speci fic lymphocytes may occur @harakul et al., 1 98 8, Phillips-Quagliata & 
Lamm, 1994). Immune induction by antigen at these sites may contribute to the 
development and regulation of systemic and mucosal immunity following mucosal viral 
infection. 
Effector immune mechanisms against viruses that infect mucosal surfaces include 
both cell-mediated and humoral immune responses. Cellular elements such as natural killer 
cells, cD8+ and c D ~ "  T cells residing in the LP or as intraepithelial lymphocytes (EL)  
have been proposed to play a role in the clearance of virus infected cells (Kiyono & 
McGhee, 1 994, London, 1 994). C ytotoxic lymphocytes are induced following viral 
infection of the mucosa and are able to mediate protection against viral induced disease 
(Murphy, 1994). However, for viruses that replicate rapidly at mucosal surfaces, such as  
BHV- 1 and adenoviruses, the proliferaton of memory CTL may not be sufficiently rapid to 
alter significantly the peak titre of virus in the respiratory tract. Since disease is usually 
experienced when peak titres of viruses are attained, imrnunisation with antigens that 
induce predominantly C n  activity in the absence of antibody is expected to be less 
successful in restricting replication of challenge virus at mucosal surfaces than vaccination 
that induces sustained antibody response as well (London, 1994, Murphy, 1994). 
Furthermore, antibodies are thought to play an important role not only as a first line of 
defence in preventing viral infection of the mucosal epithelium and underlying tissues, but 
also in the induction of immune responses (uptake of viral antigens via immunoglobulin 
receptors on M cells) and in the clearance of viral infections (e.g., antibody dependent 
cellular cytotoxicity) (Kilian & Russell, 1994). 
2.6.2 Effector mechanism of antigen-specific antibodies at mucosal surfaces 
At rnucosal surfaces, antibodies may neutralise the infectivity of viruses by 
aggregation of virus (immune exclusion) or by prevention of their attachment and 
penetration to target cells. In addition, both IgG and IgA antibodies may act to neutralise 
viruses after their penetration to the host cell (Outlaw & Dimmock, 199 1). The major viral 
antigens that induce neutralising antibody responses are the surface proteins and 
glycoproteins of viruses. Although the same antigens and epitopes appear to be recognised 
by different classes of antibodies, IgA and IgG are more efficient than IgM in neutralising 
virus (Murphy, 1 994). 
In primates and rodents, antiviral IgA is likely to play the major role in clearance of 
primary viral infections and prevention of infection on re-exposure to virus. Compared to 
IgG, IgA is actively transported through the mucosal epithelium to the lumen, is less likely 
to cause 1 0 4  inflammation and is more stable at mucosal surfaces. These characteristics 
are likely due to IgA's secretory component a c w e d  in the epithelium, its poor capability 
to fix complement and to its polymeric nature (Underdown & Mestecky, 1994). 
Although serum IgG of primates and rodents is not transported actively across 
epithelium, IgG antibodies may gain excess to mucosal surfaces by passive diffusion 
(transudation). This is suggested by the correlation between serum and mucosal IgG titres 
(Wagner ei al., 1987) and by the observation that parenterally transferred IgG antibody can 
protect mice from mucosal virus infection (Eis Hubinger et al., 1993). In addition, virus- 
specific IgG produced by mucosal B cells may also contribute to total antiviral activity in 
mucosal secretions (Fazekas et al., 1 994). 
Evidence for the association of mucosal antibodies with resistance to viral 
infections have been provided by studying the effect of passively transferred and host 
derived antibodies on virus infection (Murphy, 1994, Renegar & Small, 1994). 
Furthermore, IgG and IgA antibodies have been compared for their efficacy in vivo. In one 
study, using monoclonal antibodies that recognise the same viral glycoprotein, mice 
passively imrnunised i.n. with IgG or IgA were protected equally against pulmonary Sendai 
virus infection (Mazanec et al., 1992). Monomeric and polymeric IgA were equally 
efficacious. These data are consistent with the similarities of IgG and IgA in their in vitro 
neutralising activities. In contrast, a neutralising polymeric IgA mAb specific for influenza 
HA, transferred systemically, was more effective in restricting the replication of influenza 
virus in the upper respiratory tract of the mouse than a comparable amount of IgG mAb of 
the same specificity (Renegar & Small Jr., 199 1). An important advantage of IgA 
antibodies in protecting against mucosal infections of the respiratory tract appears to be 
their abundance at mucosal surfaces due to their selective induction and their ability to be 
transported selectively across mucosal surfaces, rather than an inherently greater antiviral 
activity than that of IgG. 
2.6.3 Immunisation at mucosal surfaces 
Evidence strongly supports the concept of relative compartmentalisation of 
systemic and mucosal immune responses in mammalian species (Tomasi, 1994). Many 
experimental results have shown that mucosal immunisation is superior to parented 
immunisation in inducing immunity and protection at mucosal surtaces (Moldoveanu et al., 
1993, Ogra, 1996, Tamura & Kurata, 1996). Mucosal immunisation with live viruses is 
able to stimulate strong mucosal IgA responses in rodents and humans, which usually 
correlate better than serum antibody induced by systemic imrnunisation with protection 
against mucosal viral mfections. 
In addition, compartmentalisation also exists within the common mucosal immune 
system. There is especially a dichotomy between the gut and the upper aerodigestive tract 
with regard to homing properties and terminal differentiation of B cells (Mestecky et al., 
1994, Phillips-Quagliata & Lamm, 1994). Such a disparity may be explained by 
microenvironmental differences in the antigenic repertoire, or by differences in the 
lymphoid and vascular adhesion molecules involved in local B-cell extravasation. For 
example, although traffickmg of B cells between mucosal sites occurs, the concentration of 
virus-specific IgA-producing B cells at the site of antigenic stimulation is often much 
higher than that at more distant sites (Dharakul et al., 1988, Kantele et al., 1997). Such 
compartmentalisation within the CMIS may provide answers to why local immunisation of 
the respiratory tract is usually more efficacious than immunisation at a distant mucosal site 
such as the gut in inducing respiratory mucosal immunity and protection against challenge 
(Brownlie et al., 1993, McLean et al., 1996, Collins et al., 1990). There are exceptions, 
however: mucosal immunisation in the respiratory tract is sometimes more effective than 
local inoculation of liposome-vaccine or recombinant Ad in the vagina (de Haan et al., 
1995, Gallichan & Rosenthal, 1995). 
Mucosal adidstration of live replicating viral vaccines has been found to induce 
stronger mucosal immune responses and protection against challenge than inactivated 
vaccines (Couch et al., 1996, Ogra, 1996, Tamura & Kuata, 1996, Weeks-Levy & Ogra, 
1996). Non-replicating viruses usually induce immunity only following systemic 
immunisation (Momson & Knipe, 1996, Xiang et al., 1996; and see Table 2.1 .), although 
there are a few reports for replicationdefective viruses inducing immunity following 
mucosal administration (Bender et al., 1996, Gonin et al., 1996). Inactivated viral or 
subunit vaccines usually induce immune responses following mucosal vaccination only if 
combined with strong adjuvants such as cholera toxin or if delivered by liposomes 
(Michalek et al., 1994). It is possible that the MALT possesses selective regulatory and 
effector mechanisms to recognise and respond with induction of immunity only to 
potentially dangerous agents to avoid bystander tissue damage and immunologic 
exhaustion. 
The mucosal immune system is thought to be not only hyporesponsive compared to 
the systemic immune system but mucosal immune responses are also considered shorter 
lived than serum antibody responses (Slifka & Ahmed, 1996). However, mucosal 
immunisation of mice with high doses of live virus may result in long-term antibody 
production both in the serum (Irie et al., 1992, McNeal & Ward, 1995) and the respiratory 
tract (Hyland et al., 1994, Jones & Ada, 1987, Liang et al., 1994). Furthermore, 
recombinant HAd5 expressing gE3 of HSV-1 was capable of inducing long term humoral 
and cellular immunity to gE3 and protection against lethal doses of i n .  HSV-I challenge in 
mice (Gallichan et al., 1993). 
2.7 The cotton rat as a model for mucosal adenoviral infections 
The cotton rat (Sigmodon hispidus) has been used as an animal model to study the 
pathogenesis of various human and animal respiratory viruses such as human parainfluenza 
virus type 3 (HPW3), bovine parainfluenza virus type 3 @PU), human respiratory syncytial 
virus (KRSV), HAdS and bovine adenovirus @Ad) (Breker-Klassen et al., 1995, Mittal el 
a[., 1995, Murphy et al., 1981, Pacini et al., 1984, Porter et a/., 1991, Prince et al., 1978, 
Prince a al., 1993). In fact, the only rodents known to support HAd5 replication are cotton 
rats and hamsters (Hjorth et al., 1988). Mice are only semi-permissive for HAdS 
replication (Blair et al., 1989, Ginsberg et al., 1991). Using an i.n. challenge model in the 
cotton rat, HAdS replication in the lungs was shown to peak between day 2 and 5 p i .  
depending on the dose of virus administered intranasally (Pacini et al., 1984, Prince el al., 
1993). Irnrnunofluorescent and electronmicroscopic studies demonstrated that the virus 
primarily replicated in the bronchiolar epithelial cells of cotton rats (Prince et al., 1993). 
Histopathological changes were also observed. These changes could be divided into two 
phases: early, non-specific infiltration of neutrophils, macrophages and lymphocytes to the 
peribronchiolar and alveolar regions, and a later phase of the disease, which consisted 
almost exclusively of infiltration of lymphocytes (Prince et al., 1993). The molecular 
basis of adenovirus pathogenesis has been studied in cotton rat and mouse models 
(Ginsberg & Prince, 1 994). 
With the establishment of the i.n. HA& infection model, the cotton rat has become 
available for the preliminary evaluation of recombinant HA& vectors as vaccine delivery 
systems. Although recombinant adenoviruses have successfiAly delivered vaccine antigens 
to several mammals (primates, monkeys, carnivores, ruminants and rodents) (Graham & 
Prevec, 1992, Mer,  1995, Rosenthal et aL, 1996), only the species which are permissive 
for HAd5 replication, such as cotton rats, hamsters, cattle and primate species, are suitable 
for studies comparing replicationdefective and replication-competent HAd5 vectors. 
3.0 HYPOTHESES AND OBJECTIVES 
A laboratory rodent that supports the replication of both adenovirus and bovine 
herpesvirus type 1 (BHV-1) would provide a model to evaluate the efficacy of replication- 
defective and replicationcompetent adenovirus vectors expressing the glycoprotein D (@) 
of BHV- 1 in inducing @-specific immunity and protection against BHV- I challenge. 
Cotton rats are already known to support the replication of hurnan adenovirus. Since the 
cotton rat (Sigmodon hz3pidu.s) has served as a rodent model for many viral pathogens, the 
first hypothesis was that cotton rats can be used as a model for experimental BHV-1 
infection as well. 
lmmunisation of cattle with purified gD and transmembrane anchor truncated gD 
(tgD) of BHV-1 stimulates protective immunity against BHV-1 infection. These 
glycoproteins expressed by a recombinant adenovirus, therefore, have the potential to serve 
as a vaccine model to investigate mucosal immunity induced by recombinant adenoviruses. 
The second hypothesis was that recombinant human adenoviruses expressing gD or tgD of 
BHV-1 can induce mucosal immunity and protection against BHV-1 challenge in cotton 
rats. 
For @-specific immunity to develop it is crucial that cotton rat cells become 
infected with recombinant adenovirus and express the gD or tgD protein. Since adenovirus- 
specific immunity can prevent an infection or effective foreign gene expression by 
recombinant adenovirus, the third hypothesis was that pre-existing adenovirus-speci fic 
immunity inhibits the efficacy of immunisation with recombinant adenovirus. 
To examine whether the above hypotheses were correct, the following objectives 
were set: 
1. To investigate the capability of BHV-1 to replicate and cause pathological 
changes in cotton rats 
2. To determine the in virro expression of gD and tgD in cotton rat cells infected 
with recombinant adenoviruses 
3. To assess the ability of recombinant adenoviruses expressing gD or tgD to elicit 
@specific systemic and mucosal immunity and conk protection against intmasal BHV- 
1 challenge 
4. To determine the effect of adenovirus-specific active immunity and passive 
antibody-transfer on immunisation with recombinant adenovirus 
4.0 MATERIALS AND METEODS 
4.1 Virological assays 
4.1.1 Cell lines 
Cotton rat lung (CRL) cells were cultured and maintained as a stable cell line as 
previously described (Baca-Estrada et al., 1995). Madin Darby bovine kidney (MDBK) 
cells were obtained from the American Type Culture Collection (Rockville, MD, USA). 
The 293 cell line, which is a human embryonic kidney derived, human adenovirus type 5 
(HAd.5) transformed cell line expressing the El  region proteins of HAdS, was a gift fiom 
Dr. Frank L. Graham (McMaster University, Hamilton, ON). All three cell lines were 
propagated in minimal essential medium (MEM; with Earle's salts; Gibco/BRL 
Laboratories, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; 
Gibco/BFU), 2mM L-glutarnine and penicillin streptomycin solution (Sigma Chemical 
Co., St. Louis, MO) (growth medium). Each cell line was used up to passage number 50. 
4.1.2 Stock virus preparation and purification of BHV- 1 
The Cooper strain of BHV- 1 was obtained fiom the National Veterinary Services 
Laboratories, Ames, Iowa, USA, and propagated in MDBK cells. The field isolate 108 
strain of BHV-1 was obtained fiom Animal Diseases Research Institute (ADRI), 
Lethbridge, Alberta, Canada and passaged twice in MDBK cells. 
For use in vivo and most in vino experiments, the Cooper strain of BHV-I was 
concentrated by ultracentrifuging the culture supernatant of infected cells through a sucrose 
cushion. The pelleted virus was resuspended in phosphate buffered saline (PBS). For 
infection of CRL cells and cotton rats with BHV-1 108 strain, the culture supernatant of 
infected cells was used. For enzyme-linked immunosorbent assay (ELISA), BHV-1 was 
purified by ultracentri fbga tion on discontinuous NaK tartrate gradients as described (Misra 
et al., 198 1). Total protein content of the purified virus preparation was estimated by a Bio- 
Rad (Cambridge, MA) protein assay. Stocks of both strains of BHV- 1 were titrated on 
MDBK cells and were stored in small aliquots at -70 OC. 
4.1.3 Lnfection of CRL cells and MDBK cells with BHV- 1 
To determine the kinetics of BHV-1 growth, different multiplicity of infection 
(MOO of BHV-1 were added to CRL or MDBK cell monolayers. After 1 hour (h) of 
adsorption at 37 OC, excess virus was removed by washing cells twice with PBS and 
replaced with MEM supplemented with 2% FBS (Gibco/BRL) . At various timepoints 
postinfection @.is), cells and culture supernatants were harvested and stored at -70 O C .  All 
samples were further processed and analysed simultaneously. 
4.1.4 BHV- 1 titration 
Quantification of BHV-1 was performed by a plaque assay. Samples obtained 
following in vitro (cell culhlre inoculum) or in vivo (lung and trachea extracts) infection 
with BHV-1 were serially diluted in PBS, absorbed onto MDBK cell monolayers for 1 h, 
then overlaid with growth medium containing 1% agarose. Afler 3 days of incubation at 37 
"C, plaques were counted, and titres expressed as plaque forming units @fb) per ml of 
culture inoculum or per gram of tissue. 
4.1.5 Preparation and purification of adenoviruses 
The construction of HAdS vectors containing the gene of BHV- I gD or tgD in the 
El (gD-dElE3 and tgD-dElE3, respectively) or the E3 regions (gD-dE3 and tgD-dE3, 
respectively) were described previously (Mittal et al., 1996, van h e n  Littel-van den 
Hurk et al., 1993). The characteristics of these vectors are summarised in Table 4.1. 
Adenoviruses were propagated in 293 cells, and released from infected cells by 3 rounds of 
hezing and thawing. The cell debris was removed by centrifugation. The supernatant was 
used for admimstration to cotton rats in experiments described in sections 5.3.4, 5.3.5, 5.4, 
5.5.1, 5.5.2, 5.5.3, 5.5.5. In other experiments, the recombinant vectors were partially 
purified by centrifbgation in a discontinuous cesium chloride gradient. Adenoviruses were 
titrated by plaque assay and stored at -70 O C .  The adenovirus preparations contained no 
more than 0.1 pg gD per lo8 pfu virus, as measured by capture ELISA. For the in vie0 
assays the wild type (wt) HAd5 was purified by two rounds of continuous cesium chloride 
gradient centrifbgation (Graham & Prevec, 1991). Total protein content of each purified 
virus preparation was estimated by a Bio-Rad protein assay. For experiment 5.3.1, the 
purified adenoviruses were provided by Suresh K. Mittal. 
4.1.6 Titration of adenoviruses 
To quantify the amount of adenovirus in culture-inoculum or in tissue samples, 
adenovirus was titrated on 293 cells under a 1 % agarose overlay (Graham & Prevec, 199 1 ). 
Afier 5-8 days of incubation at 37 O C ,  plaques were counted, and titres were expressed as 
pfu per ml of culture inocuium or per gram of tissue. 
4.1.7 Immunoprecipitation and gel-electrophoresis 
Glycoprotein D and tgD expression by CRL cells infected by recombinant 
adenoviruses was determined by immunoprecipitation and gel-electrophoresis. 
Adenoviruses were adsorbed onto CRL cells for 1 h at 37 OC. Then the inoculurn was 
removed and replaced with methionine-free MEM (ICN Biomedicals Inc., Mississauga, 
ON). CEU cells infected with BHV-1 were used as a positive control. At 3 h pi .  75 pCi of 
EXPRESS Protein Labelling Mix containing L-[~~s] -methionhe (NEN Life Science 
Table 4.1 Recombinant human adenoviruses used in the studies 
HAd5 gD or tgD deletion regulatory sequences references: 
virus: gene: insertion in: in: promoter: poly A: 
-- - 
dE I E3 - - E l ,  E3 - - Graham and Prevec, 1992 
dE3 - - E3 SV40 SV40 Mittal et al., 1996 
gD-dElE3 gD El  region E l ,  E3 MLP multiple van Drunen Littel van den Hurk et al., 1993 
tgD-dE 1 E3 tgD E 1 region E I ,  E3 MLP multiple Mittal et al., 1996 
gD-dE3 gD E3 region E3 SV40 SV40 Mittal et al., 1996 
tgD-dE3 tgD E3 region E3 SV40 SV40 Mittal et al., 1996 
Products, Boston, MA) in 1.5 mI methionhe-fke medium was added to the plates. At 36 h 
or 20 h p.i. with adenoviruses and BEN- 1, respectively, supernatants were collected and 
cells were harvested and pelleted by centrifugation. Samples were mixed with RIPA buffer 
(150 mM NaCI; 50 mM Tris-HC1, pH 7.5; 10 mM EDTA; 1 % v/w sodium deoxycholate; 
I % V/V Triton X-100; 0.5 % w/v sodium dodecyl sulphate (SDS)) containing pooled gD- 
specific mAb and incubated on a rocker for 2 h at room temperature. Protein A coupled 
Sepharose beads (Pharmacia, Uppsda, Sweden), 100 mg/ml in RIPA buffer, were added 
and the mixture incubated on a rocker at 4 *C overnight The protein A Sepharose was 
pelleted by centrifugation and the pellet washed 5 times with RIPA buffer. Thirty pl 
sample buffer (70 rnM Tris-HC1, pH 6.8; 10 % v/v glycerol; 2 % w/v SDS; 2 % J3- 
mercaptoethanol; 0.05 % w/v bromophenol blue) was added to the pellet. Protein samples 
were boiled for 5 minutes before separation by gel-electrophoresis. Polyacrylarnide gel- 
electrophoresis (PAGE) was performed by using denaturing, discontinuous Laernmli gels 
(Laernmli, 1970). A stacking gel of 4 % and a separating gel of 10 % were used. Afier the 
separation was complete, the gel was fixed (methanol:water:acetic acid = 25:65: 10) and 
soaked in Amplify (Amersham Canada, Inc., Oakville, ON) prior to drying. The dried gel 
was then exposed to X-ray film (Eastman Kodak Company, Rochester, NY) at -70 "C. 
4.1.8 Immunoc ytochemistry 
Lmmunocytochernical staining of CRL cells infected with recombinant 
adenoviruses was used to demonstrate in situ expression of gD and tgD in vitro. Infection 
of CRL cells with BHV-1 at an MOI of 1 was used as a positive control. CRL cells were 
grown to confluence on LAB-TEK chamber slides (Nunc Inc., Naperville, E, USA) and 
incubated with virus at an MOI of 5 for 1 hour. Non-adsorbed virus was removed by 
washing with MEM and the slides were fiuther incubated with growth medium. Slides 
were fixed in cold acetone at different time points p.i., air dried, then incubated for 30 min 
with MEM with 1 % horse serum (Gibco). Slides were washed with PBS between each 
following step. Slides were incubated for 1 h at room 
monoclonal antibodies (rnAb) specific for gD, described by 
temperature with a 
Hughes et a/. (1 988) 
pool of 
and van 
Drunen Littel-van den Hurk & Babiuk (1986). Then, biotinylated horse anti-mouse IgG 
(Vector Laboratories, Burlingame, CA, USA) was added for 1 hour. Detection of bound 
antibody was performed by adding an avidin biotin complex (ABC)-horseradish peroxidase 
(HRP) (ABC-HRP kit, Vector). Slides were developed by a peroxidase substrate kit (DAB, 
Vector), counterstained with toluidine blue (Aldrich, Milwaukee, WI, USA), rinsed with 
distilled water and air dried. Brown staining indicating the presence of gD was examined 
by a light microscope (Olympus AH2). 
4.1.9 Quantification of gD and tgD by ELISA 
CRL cells were infected with recombinant adenoviruses to assess the kinetics of gD 
and tgD expression in vitro. Adenoviruses were adsorbed onto CRL cell monolayers at an 
MOI of 10 for 1 hour at 37 OC. Excess virus was removed by washing cells twice with 
PBS, followed by the addition of MEM supplemented with 2% FBS (GibcoEiRL). Cell 
monolayers were observed visually with the aid of a dissecting microscope. Cells and 
culture supernatants were harvested at various time-points p.i. and were frozen at -70 O C  
until all the samples could be processed simultaneously. 
The amount of gD and tgD in the samples was measured by ELISA. Cell pellets 
were mixed with 2x volume of RIPA buffer, centrifuged and the supernatants containing 
the cell extracts were used in the assay. Immulon-2 microtiter plates (Dynatech 
Laboratories, hc., Chantilly, Va.) were coated overnight at 4 O C  with a pool of mAb 
specific for gD in coating buffer (50 mM NaHCOfla2C03, pH 9.6). Between each step, 
plates were washed three times with PBS containing 0.05 % Tween-20 (Sigma; PBS-T). 
Culture supernatants and cell extracts were serially diluted in PBS containing 0.5 % bovine 
serum albumin (BSA; Boehringer-Maanheirn, Quebec, Canada) (PBS-BSA) and incubated 
for two hours at 37 OC. Purified gD was used as a positive control (a gift from Sylvia van 
Drunen Littel-van den Hurk). Plates were incubated with @-specific plyclonal rabbit IgG 
(a gift fmm Sylvia van Drunen Littel-van den Hurk), then with horseradish peroxidase- 
conjugated goat anti-rabbit IgG (Gibco5RL) for 2 h at room temperature for each step. 
Colour was developed using 0.15 mg/ml of 2,2'-azino-di-{3-ethyl-beIlZthiazoline 
Colour was developed using 0.15 m g m l  of 2.2'-azino-di-~3-rthyl-benzthi~oline 
sul fortatel ( ABTS: Borhringr-Mannhrirn) as a substrate. Absorbance was read at 405 nm 
~ v i t h  a reftrencr wavelength at 490 nrn using a microplate reader ( Bio-Rad model 3550). 
4.2 In vivo procedures 
4.1.2 Cotton rats 
Inbred male and female hispid cotton rats (Sig~~rodot~ hispidils). (Figure -I. 1 ). 3-5 
months of a g  and seronegative to adenovirus and BHV- 1. were obtained from bamer- 
mainraincd pathogen-free colonies at the Veterinary hfectious Disease Organization 
(VIDO. University of Saskatchewan) or from Virion Systems. Inc. (Rockcills. MD). 
Animals were handled according to the guidelines of the Canadian Council on Animal 
Care and the University of SasLatcheafan Commirtec on Animal Care and Supply. 
Figure 4.1 Cotton rat (Signtodon hispidus) 
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4.2.2 Immunisation and challenge protocols 
Cotton rats were anaesthetised with nitrous oxide-halothane (MTC 
Pharmaceuticals, Cambridge, Canada) (1 :2) during all immunisations and challenges. 
Blood samples were obtained by cardiac puncture. Animals were euthanised by a halothane 
overdose. 
For intranasal (i-n.) irnmunisation and challenge, viruses were administered in 50 p1 
volumes into the nares of cotton rats. Intraderma1 (i.d-) immunisation was performed by 
injecting 2 x 25 p1 virus suspension into two spots of the back skin of cotton rats. 
htraperi toned (i-p.) administration was given by injecting 500 pl virus inoculum into the 
peritoneal cavity. For the primary enteric imrnunisation, the duodenum was surgically 
exposed and lo8 pfu of adenovirus (500 pl), or PBS as  a control, was injected into the 
duodenum. The incisions were closed upon completion of the procedure. The animals were 
allowed to recover and were housed under normal conditions. The secondary, oral 
imrnunisation was perFormed by delivering lo8 pf3 of virus suspended in 500 p1 of 0 4  M 
NaHC03 into the oesophagus with a 20 gauge gavage needle. Evans blue dye was used to 
confirm that the inoculum was restricted to the site of administration and did not spread to 
the peritoneum or the respiratory tract following intraduodenal or oral delivery, 
respectively. Before intraduodenal or intragastiic imrnunisation, cotton rats were starved 
overnight. 
4.2.3 Production of adenovirus-specific hyperimmune serum 
Adenovirus-specific serum was raised in cotton rats by subcutaneous (s.c.) 
inoculation with complete Freund's adjuvant containing 10' pfu of HAd5. Animals were 
reimmunised with the same amount of virus in incomplete Freund's adjuvant four weeks 
later. Four weeks afier the second immunisation, serum from all animals was collected and 
pooled. The titre of Ad-specific antibodies was 2 x lo5, as determined by ELISA. The 
serum was stored at -20 "C until it was used in passive transfer experiments. 
4.3 Assessment of viral replication and spread in vivo 
4.3.1 Histopathology and immunohistochemistly 
The left lung of cotton rats was fixed in 10% neutral buffered formalin, processed 
routinely and embedded in paraffin wax. For histological evaluation, 5 p sections were 
cut and stained with hematoxylin and eosin (H&E). 
Unstained sections of fomalin-fixed lung f?om the same blocks were stained 
immuno- histochemically using an avidin-biotin complex method (Haines & C helack, 
1991). The slides (three per animal) were incubated with 1/5000 or 1/10000 dilutions of a 
pool, three parts to one, of two monoclonal antibodies directed against BHV- 1 gB (3F 11) 
and gC (1H6) glycopmteins respectively (gift from Dr. V. Misra) or with normal mouse 
serum at a 1f5000 dilution as a negative control. Formalin-fixed bovine fetal liver from a 
case of natural BHV- 1 infection was used as a positive control. Slides were treated with 
3,3'diaminobenzidine-HA solution as chrnogen and counterstained with hematoxylin. 
A positive reaction consisted of brown deposits, indicating the presence of BKV-1 
antigens. 
A scoring system of 0 (normal), 1 (mild), 2 (moderate), and 3 (severe) based on the 
severity of lesions in the lower respiratory tract was used for histological evaluation of the 
lungs. Lesions were graded separately for the bronchioles and alveoli. Bronc hiolar lesion 
scores considered the development of intranuclear inclusion bodies, degree and extent of 
epithelial necrosis and inflammation. Alveolar lesion scores were based on intranuclear 
inclusion bodies, necrosis, neutrophils and macrophages in alveolar septa, and type CI 
pneumocyte hyperplasia- 
4.3.2 Preparation of trachea and lung extracts 
One or three days after challenge with BHV-I, trachea and lungs were aseptically 
removed from euthanized cotton rats, placed in 1 ml MEM and fkozen at -70 "C. When all 
samples were collected, they were thawed, weighed and homogenised (Polytron 
hornogeniser, Brinkman Industries, Rexdale, Canada). Lungs were homogenised for 2 x 1 0 
seconds, while tracheae were homogenised for 3 x 10 s. Tissue-homogenates were 
centrihged to remove debris. Supernatants were collected and analysed for the presence of 
BHV- 1 by plaque assay or the presence of antigen-specific antibodies by ELISA. 
4.3.3 Adenovirus isolation fiom cotton rat tissues 
One or three days after inoculation of cotton rats with recombinant adenoviruses, 
various organs and tissues were removed under aseptic conditions and placed in MEM. All 
samples were frozen and kept at -70 OC until they could be processed simultaneously. All 
samples were then thawed, homogenised by a Polytron homogeniser (B-an Industries) 
and centrifuged to remove debris. To quantify adenovirus, the supernatants were analysed 
by plaque assay. Samples with no plaques were incubated on 293 cells in 6 well tissue 
culture plates and cells were observed daily for 7 days for plaque-formation. In case of 
negative results, cultures were frozen and thawed 3 times to release any adenovirus. The 
resulting crude cell suspensions were passaged in 293 cells one more time. If no plaque 
formation was noted 7 days pi. following the second passage, the sample was considered 
to be negative for adenovirus. 
4.4 Assessment of immune responses 
4.4.1 Isolation of lymphocytes 
Spleens, lymph nodes and bone marrow were removed aseptically, chopped, then 
gently pushed through a fine plastic mesh. Erythrocytes were lysed by Tris-buffered 0.83% 
N&CI and the resulting lymphocyte suspensions were washed twice with MEM. Lung 
lymphocytes were isolated from a piece of tissue that contained the right lung, the bronchi 
and the lower part of the trachea, which remained following separation of most of the 
trachea and the left lung for other assays. The tissue was cut into small pieces and 
incubated for 1 h in complete medium W M  supplemented with 10% FBS (Sigma), 2 
rnM L-glutamine (Gibco/BRL), 1 mM sodium pyruvate (Gibco/BRL), 100 pM non- 
essential amino acids (Gibco/BRL), 10 mM HEPES buffer, and LOO U/ml penicillin G, 100 
pglml streptomycin solution (Sigma), final pH of 7.21 containing 150 U/ml collagenase A 
(Wortkington Biochemical Co., Freehold, NJ) and 50 U/ml DNase I (Sigma). The digested 
lung tissue was then gently pushed through a plastic mesh. The lung cell suspension was 
centrifuged through a discontinuous Percoll (Pharrnacia) gradient and washed twice with 
MEM. Cells were resuspended in complete medium and incubated for one hour in a tissue 
culture flask to remove the adherent cell population. The purified lymphocyte population 
was then collected, washed, resuspended in complete medium containing 50 pM 2-ME 
(Sigma) and used in the ELISPOT and proliferation assays. 
4.4.2 Lymphocyte proliferation assay 
Antigen-specific T cell function in spleens was measured by lymphocyte 
proliferation assay. Lymphocytes were dispensed in 100 pl volumes (2 to 4 x 10' 
cells/well) into 96 well tissue culture treated plates (Costar, Cambridge, MA). Irradiated 
BHV- I ,  HAdS (20 mWlcmL W irradiation for 8 min, 1000 mT) or various concentrations 
of purified gD (0.1- 1 @ml) were added in 100 pl to triplicate wells. After 2 days in 
culture, 0.4 pCi [methyl-'~]-th~midine (Amersharn Canada, hc.) was added to all wells 
for the last 24 h of culture. Incorporation of thymidine into cellular DNA was assessed by 
harvesting cells onto glass fibre filter mats (Salctron, Sterling, VA) and the radioactivity 
determined using a J3 scintillation counter (Beckman, Richmond, BC). Proliferative 
responses were expressed as stimulation indices (So. 
counts per minute in the presence of antigen 
SI = 
counts per minute in the absence of antigen 
4.4.3 Antigen-specific ELISPOT assay 
An enzyme-linked immunospot (ELISPOT) assay was used to determine the 
number of gD- and adenovirus-specific antibody-secreting cells (ASC) in the spleen, bone 
marrow and the right lung. Nitro-cellulose based, hydrophobic, 96-well microtiter plates 
(Polyfiltronics, Rockland, MA) were coated overnight with purified gD (0.3 pg/well) or 
purified hAd5 (1 pglwell) in coating buffer at 4 O C .  Mer being washed three times with 
PBS under sterile conditions, plates were incubatd with complete medium for one hour at 
room temperature. Lymphocytes were then added to the plates (5 to 100 x 1 o4 cells/well) 
and incubated in complete medium for 8 hours at 37 OC. Following incubation, cells were 
removed by washing the plates with cold distilled water and PBS-T. The plates were 
extensively washed between each following step. To detect bound IgG, biotinyiated anti-rat 
IgG (Zymed, Mississauga, Ontario, Canada) in PBS-BSA was added to the plates for a 2 h 
incubation at room temperature. To detect bound IgA, rabbit anti-rat IgA (a gift from Dr. B. 
Underdown, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada) 
was added for 2 4 followed by incubation with biotinylated goat anti-rabbit antibody 
(Z ymed). Ali plates were then incubated with streptavidin-alkaline phosphatase, followed 
by spot development with 5-bromo4chloro-3-indolyl phosphate (BC1P)-Nitro Blue 
Tetrazolium (NBT) substrate. The numbers of spots in triplicate cultures were counted with 
the aid of a dissecting microscope. 
4.4.4 Collection of nasal- and lung-washes 
Nasal- and lung-washes were collected by using 2 crn long pieces of Teflon TFE 16 
TW Natural tubes (Cole-Parmer Instrument Company, Niles, IL) connected to 16 gauge 
needles (Baca-Estrach, personal communication). Cotton rats were euthanised before the 
procedure. For the nasal-wash, the tube was placed into an incision of the trachea and 0.3 
ml PBS was flushed through and collected at the nares. To obtain lung-washes, the tube 
was inserted in the trachea and 1 ml PBS was flushed in and out of the lungs 2 times. Wash 
samples were stored at -20 O C  until they were analysed simultaneously with serum samples. 
4.4.5 Antigen-specific ELISA 
Antibody levels specific for BHV-I and adenovirus in sera, washes or extracts From 
the lung and trachea were determined by ELISA. Immdon-2 microtiter plates (Dynatech 
Laboratories, Alexandria, VA) were coated overnight with purified tgD (0.05 pg/weIl), 
purified BHV- 1 or purified HAd5 (0.5 Mwell) in coating buffer at 4 OC. The plates were 
washed three times with PBS-T between each step. The plates were incubated with PBS- 
BSA for 1 hour at room temperature, then all the samples were serially diluted in PBS- 
BSA and incubated overnight at 4 OC. Bound IgG was detected using horseradish 
peroxidase-conjugated goat anti-rat IgG (Zymed). Bound IgA was measured by rabbit anti- 
rat IgA (a gift from Dr. B. Underdown), followed by incubation with horseradish 
peroxidase-conjugated goat anti-rabbit IgG (Gibco/BRL). Colour was developed using 0.15 
m g l d  of 2,2'-azino-di-[3-ethyl-behazoline sulfonate] (ABTS; Boehringer-Mannheim) 
as a substrate. Absorbance was determined at 405 nm with a reference wavelength at 490 
nm using a microplate reader (Bio-Rad model 3550). In experiments 5.3.1 ., antibody levels 
were expressed as the optical density (OD) at 405 nm. In other experiments, antibody titres 
represent the loglo of the inverse of the last dilution that resulted in an absorbance which 
was greater than the sum of the mean background absorbance plus 3 standard deviations 
(SD). Antibody titres specific for gD were identical regardless of whether purified BHV- 1, 
gD or tgD was used to coat the ELISA plates. 
4.4.6 BHV- I serum neutralisation assay 
BHV-1 neutralising assays were performed as described by van Drunen Littel-van 
den Hurk et al. (1984). Briefly, doubling dilutions of heat inactivated (56 O C ,  30 minutes) 
serum samples were mixed with 100 pfb of BHV-I and incubated for 1 hour at 37 OC. The 
virus-sample mixture was then plated on confluent MDBK cells in 96 well microtiter 
plates and incubated for 2 days. Serum neutralking (SN) titre was defined as the reciprocal 
of the highest serum dilution resulting in reduction of virus plaque formation by at least 
50% relative to the virus control. 
4.4.7 HA& serum neumlisation assay 
Ademvirus-neuaalising assays were performed as described previously by MittaI 
et al., 1 993, with minor modifications. Briefly, ten-fold dilutions of heat inactivated (56 O C ,  
30 minutes) serum samples were mixed with 100 pfb of hAd5 and incubated for I hour at 
37 O C .  The virus-sample mixture was then plated on confluent 293 cells in 24 well plates, 
incubated for 1 hour, then incubated for 8 days under a 1% agarose overlay until plaques 
were formed. Serum neutralising titre was defined as the reciprocal of the highest serum 
dilution resulting in reduction of virus plaque formation by at least 50% relative to the 
virus control. 
4.4.7 Statistical analysis 
Statistical analysis of the data was performed using a Student t-test. 
5.0 RESULTS 
5.1 Establishment of an intranasal BHV-1 challenge model in cotton rats 
The primary goal of this thesis was to assess mucosal and systemic immune 
responses induced by replication-defective and replication-competent recombinant HAdS 
vectors expressing gD of BHV-1. Since cotton rats support HAd5 replication, they provide 
a suitable model for such a project. However, to evaluate the efficacy of imrnunisation with 
recombinant adenoviruses in confaring protection against BHV- I challenge, a laboratory 
animal that supported BHV-I replication was necessary. The first objective of this thesis 
was to find out whether cotton rats are a suitable laboratory animal model for BHV-1 
infection. 
5.1.1 BHV- 1 glycoprotein expression in CRL cells following infection 
Viral replication can take place only if the cell becomes infected with the virus and 
viral proteins are appropriately expressed. To find out whether CRL cells expressed a 
major glycoprotein of BHV-L following adsorption of the virus, gD expression in CRL 
cells was monitored by imrnunoprecipitation, irnmunocytochemistry and ELISA. Results of 
imrnunoprecipitation provided evidence that gD was synthesised de novo in BHV-1 
infected CRL cells (see next section, Fig. 5.2.1). lmrnunocytochemical staining of BHV-I 
infected CRL cells indicated that gD was abundant in the perinuclear region as early as 2 h 
p.i. (Fig. 5.1.1 .a). The cell membrane stained positive for gD fiom 4 h p.i. on (data not 
shown). The peak production of gD was at 24 h pi., as measured by ELISA (Fig. 5.1. I .b). 
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Figure 5.1.1 gDexpression by BEN-1 infected CRL cells. CRL cell monolayers were 
infected with the Cooper strain of BHV-I at an MOI of 1. (a) At 2 h pi.,  gD-expression 
was detected by imunocytochemistry. Dark precipitation in the perinuclear region indicates 
@-specific staining (arrow). @) @-production in culture supernatants and cells was 
measured by ELISA at different timepoints p.i. Data are expressed as pg @/I o6 CRL cells 
in single cultures, and represent results from 2 experiments. 
5.1.2 BHV-I replication in CRL cells in vino and in cotton rats in vivo 
To determine whether BHV-I could replicate in CRL cells in vitro, the kinetics of 
virus production was monitored. The growth of BHV-1 in CRL cells was similar to that 
observed in MDBK cells (Fig. 5.1.2). In both cell lines, isolate 108 replicated to a slightly 
higher titre than the laboratory Cooper strain (Fig. 5.1.2). 
Since BHV-1 could replicate efficiently in CRL cells in vitro, next I assessed the 
capability of BHV-1 to replicate in vivo. Cotton rats were inoculated i.n. with the two 
different strains of BHV-1 and virus growth was monitored in the respiratory tract. Viral 
recovery from the trachea and lung increased compared to that at the beginning of 
inf~tion. BHV-1 titres peaked between day I and 2 postinfection (Fig. 5.1.3). Although 
both strains could replicate in the cotton rat, the 108 strain replicated to higher titres than 
the Cooper strain. From day 2 on, viral titres declined and virus was completely cleared 
from all animals by day 8. 
Cotton rats developed cellular and humoral immune responses to BHV-1 
glycoproteins. (Table 5.1.1). By day 8 pi., both the Cooper and 108 strains induced gD- 
and gB-specific antibody in the serum (Table 5.1.1 ) and the lung- and trachea-extracts (data 
not shown). The animals did not show any apparent signs of disease or changes in 
behaviour at any stage of the BHV- I infection period. 
5.1.4 Histopathological and irnrnunohistochemical evaluation of BHV- I infected 
cotton rat lungs 
To examine whether BHV-1 infection and replication caused any cell damage in 
the lung, sections of lungs from infected cotton rats were examined histologically. The 
results of histological evaluation of cotton rat lungs infected with the Cooper and 108 
strains of BHV-I are summarised in Fig. 5.1.4. No lesions were seen in the lungs of rats 
killed at 6 hours following infection. Randomly, rare intra-alveolar macrophages and 
indistinct intranuclear inclusion bodies in bronchiolar epithelial cells were seen on day 1 
postinfection. By day 2 p.i., rats infected with the 108 strain exhibited multifocal moderate 
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Figure 5.1.2 Kinetics of in vitro replication of BHV-I in cotton rat and bovine cells. 
CRL and MDBK cells were infected with the Cooper (a) and 108 @) strains of BHV- 1 at 
an MOI of 1 .  Total virus production at different timepoints pi .  was measured by plaque 
assay on MDBK cells. Data are expressed as the mean * SD pWrd of triplicate cultures. 
- - Cooper 
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Figure 5.1.3 Replication of BHV-1 in the respiratory tract of cot&on rats. Viral titres 
in the trachea (a) and the lung (b) were determined by plaque assay at different timepoints 
after i.n. inoculation of 5x10' pfu of the Cooper and the 108 strains. Results are expressed 
as  the mean pWg tissue fiom 2 or 3 animals per group. 
Table 5.1.1 Immune responses induced by intranasal inoculation of 
BHV-1 in cotton rats 
virus gDspeci fic gB-speci fic gD-speci fic BHV- 1 
serum Ab serum Ab spleen specific spleen 
lymphocyte lymphocyte 
IgG / k G  proliferation proliferation 
- - - -- -- - . -- - -- - - 
Cooper 0.57 / 0.09 0.365 / 0.09 2.9 6.0 1 
108 0.61'/0.13 0.465/0.154 3.05 6.49 
control 0.05 / 0.08 ' 0.05 / 0.08 1.1 f 0.3 t 1.1 + 0.4 : 
Conon rats were inoculated with 5 x 10' pfu of the Cooper or 108 strains of 
BHV- 1. Spleen lymphocyte proliferative responses and serum antibody responses 
specific for BHV-I or BHV-I glycoproteins were determined at 8 days post- 
challenge. 
* Mean OD-s at 1 : 10 dilution of serum samples measured by ELISA. 
** Mean stimulation index ( S o  at 1 pg gD/ml and 0.5 pg BHV-l/ml 
concentrations from 2 animals/group. In vitm stimulation was performed at 
different antigen concentrations with similar results. 
' OD of 0.6 1 value was equivalent with @-specific serum titre of 500. 
t Mean OD-s of samples on day 0 or day 2 p.i. (controls) at 1 : 10 dilution. 
: Mean stimulation index + SD of PBS controls or non-immunised animals as 
determined by experimental data from numerous experiments. 
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Figure 5.1.4 Quantitation of histological changes in the lungs of cotton rats 
inoculated with BHV-1. Lungs were collected at various time pints after i.n. infection 
with sx 10' p h  of the Cooper or the 108 strains and evaluated for histological lesions in the 
bronchioli (a) and alveoli (b). Lesions were scored according to the severity on a scale of 0 
(normal) to 3 (severe). Each bar denotes a mean of scores for 3 animals at 6 h, day 1 and 
day 4 p.i. and for 2 animals at day 2 and day 8 pi. 
bronchiolitis with the presence of intranuclear inclusion bodies in bronchiolar epithelial 
cells, epithelial cell necrosis and infiltration of neutrophils into the mucosa and lumen (Fig. 
5.1.5 .a.). Mu1 ti focal, moderate interstitial pneumonia with macrophage and neutrophil 
infiltration of alveolar septa, along with a few inclusion bodies in alveolar epithelial cells 
and occasional intra-lurninal cells were also seen (Fig. 5.1 -5 .b.). An inflammatory response, 
mild within the airways (1 of 3 rats) and moderate in the alveoli (3 of 3 rats), was present at 
day 4 p.i. Type I pneumocyte hyperplasia and macrophage infiltration of the septa were 
evident but inclusion bodies were absent. By day 8, a mild peribronchiolar lymphocytic 
infiltration was present along with alveolar septa1 infiltration of macrophages or 
macrophages and lymphocytes. The Cooper strain was less pathogenic for the cotton rats 
than the 108 strain, producing only mild focal lesions. Lesions persisted through day 4 and 
waned by day 8 p.i. 
To correlate histological changes with BHV-1 infection and replication, lung 
sections were examined by immunohistochemical staining for the presence of BHV-1 
antigens. In the lungs of cotton rats infected with the Cooper strain, only a few cells, 
randomly distributed throughout the alveoli, stained positively for BHV-1 antigens at 6 
hours. By day 1, in all three infected rats, there were several small positively-staining foci 
of bronchiolar epithelial cells, and in one animal alveolar epithelial cells were also positive. 
Such foci were moderately numerous by day 2, involving both bronchiolar and alveolar 
epithelium. They were also present in similar numbers and distribution on day 4, but were 
absent by day 8. 
Lungs of cotton rats infected with the 108 strain did not contain any detectable 
BHV-1 antigens at 6 h postinfection. Several moderately-sized foci of positive staining 
cells within the bronchiolar and alveolar epithelial cell population were found at day 1. 
Staining was widespread with moderate to large-sized bronc hiolar and alveolar positive 
foci by day 2 (Fig. 5.1.5. a & b). Many moderately sized foci were still present on day 4 but 
were absent by day 8. Specific staining was generally cytoplasmic in distribution and 
corresponded for the most part with histological lesions. 
Figure 5.1.5 Histological lesions in a BHV-I infected cotton rat lung. Lesions shown 
are at day 2 p-i. with the 108 strain. Note: (a) epithelial necrosis and luminal debris in a 
bronchiole (Bar, 10 pm) and (b) marked cellular infiltration of alveolar septa (Bar, 40 pm). 
Inset: intranuclear inclusion body in a desquamated alveolar epithelial cell (Bar. 5 pm). 
Figure 5.1.6 Immunohistochemical staining in a BElV-1 infected cotton rat lung. 
Immunohistochemical staining s h o w  is at day 2 pi .  with the I08 strain. Positive 
immunohistochemical staining (arrows) was noted multifocally in (a) the bronchiolar 
epithelium and @) the alveolar walls (Bars, 150 pm). 
5.1.5 Conclusions 
A BHV-I i.n. challenge model in cotton rats was established by demonstrating that 
BHV-1 replicated in CRL cells in vitro and in the respiratory tract of cotton rats in vivo 
without requiring prior adaptation of the virus. The 108 strain of  BHV- 1 replicated better 
than the Cooper strain both in vino and in vivo. Furthermore, lesion development was 
greater and viral antigen was more widespread in the lungs of animals challenged with the 
108 strain than in those challenged with the Cooper strain. Based on the observed 
differences between the two strains, I used the 108 strain in the majoriry of  the challenge 
experiments. 
5.2 In v i m  characterisation of recombinant adenoviruses 
Replication-competent and replication-defective recombinant adenoviruses 
carrying the gD or the tgD gene of BHV-1 were planned to be used for studying mucosal 
immune responses induced by adenovirus vectors in cotton rats. Since the level of gD or 
tgD expression, and the replication capability of the vector may influence the induction of 
immune responses, it was important to characterise the vectors in vitro. 
5.2.1 Replication capability of recombinant HAd5 vectors 
Although the capability of adenovirus vectors to replicate in CRL cells had been 
previously determined (Mittal et al., 1996), it was necessary to confirm these results for the 
new stocks of adenoviruses that were to be used in the following experiments. Such studies 
were important because of the theoretical possibility of the replication-defective viruses 
(gD-dE 1 E3 and tgD-dE 1 E3) rescuing the E 1 region during propagation in 293 cells. Table 
5.2.1 summarises the replicative capability of recombinant adenoviruses in different cells. 
Both gD-dE3 and tgD-dE3 viruses formed plaques on CRL cells, although the number of 
pfu as determined on CRL cells was 2-4 times lower than on 293 cells. The gD-dE 1 E3 and 
tgD-dE 1 E3 constructs did not form any detectable plaques on CRL cells. 
Table 5.2.1 Replicative capability 
of recombinant adenoviruses in cells 
of different species. 
CRL : cotton rat lung 
MDBK: Madin Darby bovine kidney 
293 : human embrionic kidney cells 
expressing E 1 proteins 
HAd5 replicates in 
recombinant 293 CRL MDBK 
virus cells cells cells 
5.2.2 gD and tgD expression by CRL cells infected with adenovirus vectors 
Expression of gD or tgD by 293 and CRL cells infected with recombinant 
adenoviruses has been previously shown (Mittal et al., 1996). It was important, however, to 
confirm expression of the foreign genes by the new virus stocks, after a few passages of the 
viruses in 293 cells. Expression of the foreign genes in CRL cells was also fkther 
characterised for the kinetics of expression and localisation of the foreign protein to 
provide background information for later in vivo experiments. All vectors expressed the 
appropriate foreign glycoproteins, detected by immuuoprecipitation and SDS-PAGE (Fig. 
5.2.1). Furthermore, gD was abundant in the pellet fiaction of CRL cell cultures infected 
with gD& 1E3 and gDdE3 vectors, while tgD expressed by the t g P d E  1E3 and tgD-dE3 
vectors was only detectable in the culture supernatants. 
@-specific irnmunocytochemical staining was used to determine the localisation of 
gD in CRL cells at different timepoints pi. with the gD-dE lE3 or gD-dE3 viruses. Cells 
infected by gD-dE3 expressed gD in different membrane compartments of the cells, and in 
the cell membrane, by 8 h psi. (Fig. 5.2.2.a). However, expression of gD in CRL cells 
infected with gDdE1 E3 was evident later and at lower levels than gD-expression 
following gD-dE3 infection (Figure 5.2.2). Furthermore, infection with gD-dE1 E3 caused 
significantly less cytopathic effect on CRL cells than infection with gD-dE3 at 22 h (Fig. 
5.2.2) and at 48 h p.i. (evaluated by visual observation of numerous cultures, data not 
shown). In contrast to @-expression, tgD expressed by tgD-dE 1 E3 or tgD-dE3 was hardly 
detectable; the cell-cultures appeared similar to the ones with gD-dE 1 E3 at 8 h p.i. (results 
not shown). However, flow cytometric analysis of CRL cells infected with recombinant 
adenoviruses showed that not only gD, but also tgD (although at lower levels) was present 
on the cell surface (data not shown). Interestingly, infection with tgD-dElE3 did not cause 
any cytopathic effect on CRL cells, while infection with tgD-dE3 caused a cytopathic effect 
by 48 h pi., similar to that following gD-dE 1 E3 infection (data not shown). 
mock 
dE3 
BHV-I 
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Figure 5.2.2 Expression of gD in CRL cells infected with recombinant adenoviruses. 
CRL cells were infected with gDdE lE3 or -3 viruses at an MOI of 5. At different 
times p.i., expression of gD was demonstrated by immunocytochemistry using a pool of 
gD-specific mAbs. Infection with a) gD-dE3, 8 h p.i. b) gD-dE 1 E3, 8 h p.i. c )  gD-dE3, 22 
h pi.  d) gD-dE 1 E3,22 h pi. Dark precipitation (full arrows) indicate presence of gD in the 
cells. Non-infected controls did not show gD-specific staining, similarly to the cell 
indicated with open arrow on (c). 
5.2.3 Kinetics of gD- and tgD-expression 
Immunocytochernical staining had suggested that differences in the kinetics of gD 
expression may exist between gD-dElE3- and gD-dE3-infected CRL cells. Furthermore, 
the total amount of tgD appeared less than that of gD following infection of CRL cells with 
the different adenoviruses. Such differences in the kinetics and quantity of foreign gene 
expression may influence the induction of immune responses in vivo; therefore, the 
production of gD and tgD at different timepoints p.i. with the recombinant adenoviruses 
was quantified by ELISA. While a hundred times more gD was produced by gD-dE3 than 
by gD-dE 1 E3 at 12 h pi., similar amounts of gD were found in the cell cultures at 48 h p.i. 
(Fig. 5.2.3. a & b). Therefore, as the immunocytochemical staining indicated, the kinetics 
of @-expression was slower in the gDaElE3- than in gD-dE3-infected CRL cells. 
Furthermore, the total production of gD by either gD-dE 1 E3- or gD-dE3-infected cells was 
higher than the production of tgD by the tgD-expressing vectors (Fig. 5.2.3). Interestingly, 
the supernatant and the cell fraction of cultures contained similar amounts of tgD. 
5.2.4 Conclusions 
The above results confirmed the replication-competence of dE3 and replication- 
deficiency of dEIE3 viruses in CRL cells. Furthermore, expression of gD and tgD was 
demonstrated in CRL cells following infection with the recombinant adenoviruses. 
Although higher total quantities of gD than tgD were produced, gD and tgD were found 
both cell-associated and in the culture medium. As expected, gD was more abundant in the 
cell fraction than in the supernatant of CRL cell-cultures. The kinetics of gD-expression by 
CRL cells infected with gD-dElE3 was slower compared to that following infection with 
gD-dE3. In addition, the gD-expressing vectors and the replicating vectors caused more 
severe cytopathic effect on CRL cells following infection than tgD-expressing and non- 
replicating vectors. The characterisation of foreign gene expression and capability of 
replication is important because these features may influence the induction of immune 
responses by recombinant adenoviruses. 
lo' ( c )  
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Figure 5.2.3 Kinetics of g D  and gD-expression by CRL cells infected with recombinant adenoviruses. CRL cells were infected 
with gD-dE I E3 or gD-dE3 (a & b) and tgD-dEI E3 or tgD-dE3 (c & d) viruses at an MOI of 5. At different times pi. ,  yD or tgD in the cell 
pellet (a and c) and the culture supernatant (b and d) were detected by ELISA. Values represent pg gD or tgD/ 1 o6 cells. 
5.3 Immunity induced by recombinant adenoviruses in cotton rats 
Recombinant adenoviruses gPdE 1 E3, tgD-dE 1 E3, 0 - d E 3  and tgD-dE3 were 
shown to express their foreign genes in CRL cells in vitro. Furthermore, an i.n. BHV- 1 
infection model was established in cotton rats, which provided a means of assessing the 
ability of imrnunisation to confer protection against BHV-I challenge in a laboratory 
animal model. Therefore, the next objective was to investigate the capability of 
recombinant HAd5 vectors expressing gD or tgD to induce immunity to BHV-1 and to 
confer protection against i.n. BHV-1 challenge in cotton rats. Since the induction of 
mucosal immunity is crucial in protection against infection with mucosal pathogens, the 
most important goal was to measure mucosal immune responses induced by recombinant 
adenoviruses. 
5.3.1 Immunity induced by recombinant adenoviruses expressing gD and tgD 
The first experiment was designed to compare the efficacy of gD- and tgD- 
expressing recombinant adenoviruses in inducing @specific immune responses and 
protection against BHV- 1 challenge. Furthermore, it was important to determine whether 
both replication-defective and replication-competent vectors could induce antigen-specific 
immune responses. To induce both systemic and mucosal immunity, adenoviruses were 
administered i.d. followed by an i.n. boost 3 weeks later. Figure 5.3.1 describes the 
experimental design. 
5.3.1 - 1  Systemic immune responses 
Antigen-specific systemic humoral immune responses in cotton rats were assessed 
by measuring serum antibody responses by ELISA. Both serum !gG and IgA specific for 
gD were induced by imrnunisation with gD- and to-expressing recombinant adeno- 
viruses, but not with dE3, dElE3 and PBS controls (Figure 5.3.2). The levels of these 
responses were higher following the secondary (day 42) than after the primary (day 21) 
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Figure 5.3.1 Experimental design: immunity induced by recombinant 
adenoviruses expressing gD and tgD. In the flowchart, arrows above the timescale 
indicate the time of treatment while arrows below indicate the time of serum 
sampling. The symbol t represents tissue samples collected From euthanised animals. 
i.n. = intranasal; i.d. = intradermal. 
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Figure 53.2 gD-specific serum antibody responses in cotton rats immuaised with 
recombinant adenoviruses. Cotton rats were inoculated with recombinant adenoviruses 
expressing gD or tgD, or with PBS by the intradermal route and boosted intranasally 3 
weeks later. gD-specific (a) IgG and (b) IgA levels in the serum at 3 and 6 weeks following 
the primary immunisation were measured by ELISA. The graphs show OD-s at 150 
dilution of the samples. Bars represent the mean OD * SD for 3-6 animals per group. 
immunisation. Imrnunisation with the gD-expressing vectors induced significantly higher 
serum IgG at day 42 than immunisation with the tgD-expressing vectors (P < 0.0 1 for gD- 
dE 1 E3 vs. tgD-dE 1 E3; P c 0.05 for gD-dE3 vs. tgD-dE3). The levels of @-specific serum 
IgA were not significantly different between groups immunised with any of the four gD- or 
tgD-expressing vectors, but they were all significantly higher than those of the PBS and 
control Ad groups. The recombinant adenoviruses induced similar Ad-speci fic serum I@ 
and IgA responses (Fig. 5.3.3). 
To determine the biological activity of antigen-specific serum antibody, BHV- 1 - 
and Ad-neutralising antibody assays were performed. hunisa t ion  with all Ad vectors 
resulted in Ad-neucralising antibody in the serum but only immunisation with gD- 
expressing vectors induced BHV- 1 SN titres significantly different from contro Is (Figure 
5.3 -4). SN titres induced by irnrnunisation with gDdE 1 E3 and gD-dE3 were significantly 
higher (P < 0.05) than those by tgD-dE 1E3 and tgD-dE3 (Fig. 5.3.4). 
Another way of evaluating systemic antibody responses is quantification of antigen- 
specific antibody-secreting B cells in the spleen. In addition, such information would help 
more accurately describe immune responses induced by the different recombinant 
adenoviruses. Therefore, the frequency of gD- and Ad-specific IgA and IgG secreting cells 
in the spleen were measured by ELISPOT. As expected, only those animals inoculated with 
gD- or tgD-expressing vectors had gD-specific ASC in their spleens, while all contained 
Ad-specific ASC, except for the PBS control (Fig. 5.3.5). Interestingly, the replication- 
competent vectors induced higher frequency of @-specific ASC in the spleen than did the 
replicationdefective adenoviruses (Fig. 5.3.5). The difference between gD-dE1 E3 and gD- 
dE3 groups was statistically significant (P < 0.01) for both IgG and IgA ASC frequencies 
(Fig. 5.3.5). 
Serum antibody and ELISPOT assays were performed on samples taken at both day 
42 (no challenge) and 44 (after challenge). The results were equivalent at these two 
timepoints. 
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Figure523 Adenovirus-specific serum antibody responses in cotton rats 
immunised with recombinant adenoviruses. Cotton rats were inoculated with 
recombinant adenoviruses expressing gD or tgD, or with PBS by the intraderma1 route and 
boosted intranasally 3 weeks later. Ad-specific (a) IgG and (b) IgA levels in the serum at 3 
and 6 weeks following the primary immunisation were measured by ELISA. The graphs 
show OD-s at 150 dilution of the samples. Bars represent the mean OD * SD for 3-6 
animals per group. 
6 weeks 
Figure 5.3.4 BW-1- and Ad-neutralising antibody titres in sera of cotton rats 
immunised with recombinant adenoviruses. Cotton rats were inoculated with 
recombinant adenoviruses expressing gD or tgD, or with PBS by the intraderma1 route and 
boosted intranasally 3 weeks later. Serum samples collected at 3 and 6 weeks following 
primary immunisation were analysed for (a) BHV-1- and @) HAdS-neutralking antibodies 
by virus neutralisation assays. Bars represent the mean value for 3 animals per group * SD. 
Figure 53.5 Frequency of gD- and Ad-specific antibody-secreting cells in the spleen 
of cotton rats immunised with recombinant adenoviruses. Cotton rats were inoculated 
with recombinant adenoviruses expressing gD or tgD, or with PBS by the intradermal route 
and boosted intranasally 3 weeks later. The frequency of (a) IgG and @) IgA antibody- 
secreting cells (ASC) in spleen lymphocytes isolated 3 weeks after the secondary 
irnmunisation were determined by ELISPOT assay. Bars represent the mean number of 
ASC/million lymphocytes * SD for 3 animals per group. 
Antigen-specific T cell activation induced by immunisation with recombinant 
adenoviruses was measured by spleen cell proliferation assays. At day 42, spleen cells of 
only those animals immunised with gD-expressing vectors responded with proliferation to 
in vitm stimulation with gD (Fig. 5.3.6). The stimulation indices (SI) in the gD-dE L E3 and 
gD-dE3 groups were higher than those in other groups (P c 0.01). In addition, Ad-specific 
proliferation of spleen cells was observed in all Ad-irnrnunised groups, with statistically 
higher stimulation indices than the PBS control (Fig. 5.3.6). At day 44, antigen-specific 
proliferative responses were similar to those detected at day 42, except for the mean gD- 
specific SI in the tgD-dE 1 E3 group, which was not statistically different from SI in the gD- 
dE3 and gD-dE 1 E3 groups at this later timepoint (data not shown). 
5.3.1.2 Antibody levels in the respiratory tract 
Local mucosd immune responses play a significant role in protection against 
respiratory viral infections; therefore, it was important to determine gD-specific antibody 
levels in the respiratory tract Animals that received @-expressing adenoviruses developed 
significantly higher levels of gD-specific IgG and IgA in the lung-washes (P < 0.05) and 
@-specific IgA in the nasal-washes (P < 0.001) than the other groups (Figure 5.3.7). No 
animals contained @-specific IgG in nasal-washes (Fig. 5.3.7.a.). In contrast to gD- 
specific antibody responses, Ad-specific IgG and IgA levels in the lung- and nasal-washes 
did not differ significantly between all groups immunised with recombinant adenoviruses 
(Fig. 5.3.8), but were significantly higher than those in the PBS group. BHV-I neutralising 
antibody titres in the lung- and nasal-washes were below detection level. 
Figure 53.6 g D  and HAd5 specific proliferative responses of spleen-lymphocytes of 
cotton rats immunised with recombinant adenoviruses. Cotton rats were immunised 
with recombinant adenoviruses expressing gD or tgD or inoculated with PBS by the 
intradermal route and boosted intranasally 3 weeks later. Spleen lymphocytes isolated 3 
weeks after the secondary imrnunisation were cultured in the presence of 0.05 pg/ml 
purified gD or 2.5 pg/ml UV-inactivated HA#. Bars represent the mean stimulation index 
(SI) * SD for 3 animals per group. 
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Figure 5.3.7 gD-specific antibody levels in nasal- and lung-washes in cotton rats 
immunised with recombinant adenoviruses. Cotton rats were immunised with 
recombinant adenoviruses expressing gD or tgD or inoculated with PBS by the intraderma1 
route and boosted intrauasally 3 weeks later. Washes were collected at 3 weeks after the 
secondary immunisation. gD-specific (a) IgG and (b) IgA levels at different dilutions were 
measured by ELISA. The graphs show OD-s at 1 :5 dilution of the samples. Bars represent 
the mean OD * SD for 3 animals per group. 

5 -3.1.3 Protection against BHV- 1 challenge 
Since irnmunisation of cotton rats with various HAd5 vectors expressing gD or tgD 
resulted in gD-specific immune responses, next, protection of the lungs against BHV-1 
challenge was evaluated. Titres of infectious BHV-1 recovered from the lungs were lower 
in all groups imrnunised with gD- or tgD-expressing vectors than in the lungs of the dE3, 
dElE3 and PBS control p u p s  (P < 0.05) (Table 5.3.1). There was more than a 2 loglo 
decrease in virus titres from the lungs of cotton rats imrnunised with the @-expressing 
vectors, and approximately a 1 loglo reduction in animals inoculated with the tgD- 
expressing vectors. BHV- 1 titres were significantly lower in the gD-dE 1 E3 and gD-dE3 
groups compared to the tgD-E 1E3 and tgD-dE3 groups (P < 0.05). 
Table 53.1 B W - I  recovery from lungs of cotton rats imrnunised 
with recombinant adenoviruses expressing gD and tgD and 
challenged with BHV-1- 
Lmmunisation with: Virus recovery (pWg lung tissue) 
dE1 E3 
dE3 
gD-dE 1 E3 
tgD-dE 1 E3 
gD-dE3 
tgD-dE3 
PBS 
Cotton rats were inoculated with 10' pfu of recombinant adenoviruses 
twice, 3 weeks apart by the intradermal and intranasal routes, 
respectively. One group was similarly inoculated with PBS. At 6 weeks 
after primary inoculation, animals were challenged with 10' pfb of 
BHV-1. Lungs were collected at 42 h post-challenge for virus isolation. 
Values are the means + SD for 3 animals per group. 
5.3.1.4 Immunity induced by UV-irradiated recombinant adenovirus 
To investigate whether BHV- 1 -specific immune responses observed in vivo could 
be the result of the administration of residual gD present in Ad preparations (even 
following purification), groups of cotton rats were inoculated i.p. with gD-dE3 or UV 
irradiated gD-dE3, both containing the same amount of gD (0.1 &animal). Immunisations 
were repeated 20 days later. Serum antibody responses specific for gD and Ad were 
measured by ELISA 20 and 27 days following the fvst immunisation. Intraperitoneal 
immunisation with intact gD-dE3 induced both gD- and Ad-specific serum IgG while the 
irradiated gD-dE3 preparation induced only Ad-speci fic antibody (Figure 5.3.9). Since 
protein antigens alone are even poorer immunogens following rnucosal imrnunisation than 
systemic immunisation, intranasal immunisation with 0.1 pg gD was not performed. 
Instead, cotton rats were inoculated by the i.n. route with irradiated non-purified gD-dE 1 E3 
containing a higher amount of gD (4 pg gD per cotton rat). Neither gD- nor Ad-specific 
serum antibody responses developed following i.n. administration with such inoculurn 
(data not shown). These results suggested that residual gD glycoprotein delivered together 
with adenovirus did not induce detectable @-specific antibody responses. 
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Figure 53.9 Antigen-specific serum antibody responses in cotton rats immunised 
with Live and ZTV-irradiated r~ombinant adenovirus. Cotton rats were imrnunised 
intraperitoneally with gD-dE3 (10' pfb) and boosted i.p. 20 days later (lo8 ph).  For the 
inoculation of another group of cotton rats, equivalent amounts of gD-dE3 were exposed to 
20 mwlcm2 W-radiation for 8 min before administration to animals. Serum levels of (a) 
@-specific and (b) Ad-specific IgG at day 20 and 27 following primary irnmunisation 
were detected by ELISA. The graphs show OD-s at 150 dilution of the samples. Bars 
represent the mean OD * SD for 3 animals per group. 
5.3.2 Immunity induced by mucosal administration of replication-defective and 
replication-competent recombinant adenoviruses 
Recombinant adenoviruses expressing gD were shown to induce higher levels of 
immunity and better protection against BHV-1 challenge than tgD-expressing vectors. 
Therefore, gD-expressing adenoviruses were used to address further questions about the 
induction of mucosal immunity in this thesis. Following i.d.-i.n. immunisation the 
replication-defective vectors induced similar antibody levels as the replicationcompetent 
vectors. Next, I investigated the capability of replicationdefective and replication- 
competent adenoviruses following only mucosal administration to induce gD-specific 
immunity and protection against BHV- 1 challenge. Cotton rats were imrnunised with gD- 
dE 1 E3 or gD-dE3 either by the i.n. or gastrointestinal (g.i.) route followed by i.n. BKV- I 
challenge (Figure 5.3.1 O), and systemic and mucosal immune responses were determined. 
5.3.2.1 Serum antibody responses 
To determine antigen-specific humoral responses, serum antibody titres specific for 
gD and Ad were measured 3 weeks after the primary intranasal or intraduodenal 
irnrnunisation and 3 weeks after the secondary i.n. or oral boost. Both gD-dE3 and gD- 
dEIE3 vectors induced gD-specific IgG and IgA in the serum following primary 
immunisation (Fig. 5 -3.1 1). Titres increased or decreased in some animals by 3 weeks after 
the boost, but the mean titres within a group did not change significantly (Fig. 5.3.1 1 ). The 
@-dl33 vector induced significantly higher levels of gD specific IgG than the gD-dEl 
vector (P < 0.001). All four imrnunisation regimens stimulated similar levels of Ad- 
specific IgG in the s e w ;  i.n. irnrnunisation, however, stimulated higher Ad-specific IgA 
than g.i. immunisation (data not shown). 
To measure biological activity of the gD-specific serum antibody, BHV-1 SN titres 
were determined. Immunisation by the i.n. and the g.i. routes with the gD-dE3 vector 
induced significantly higher BHV-1 SN titres than either irnmunisation regimen with the 
gD-dE 1 E3 vector or the PBS control (Fig. 5.3.12). 
immunisation immunisation challenge 
day 0 day 2 1 day 4 1 
.1 .1 5 - ,  
day 42 
group 1-5 
# of 
cotton 
1 3 gD-dElE3 lo8 i n  i.n. 108 5 x 1 0 ~  
2 4 gD-dE 1 E3 1 o8 i.duod. oral 108 5x10'  
3 3 gD-E3 1 o8 i.n. i.n. 108 5x10 '  
4 4 gD-dE3 lo8 i-duod. oral 108 5 x 1 0 ~  
5 4 PBS - i.n. i n .  108 5 x 1 0 '  
group 
# 
Figure 5.3.10 Experimental design: immunity induced by rnucosal administration 
of replication-defective and replication-eompetent recombinant adenoviruses. In the 
flowchart, arrows above the timescale indicate the time of treatment while arrows 
below indicate the time of serum sampling. The symbol t represents tissue samples 
from euthanised animals. 
i.n. = intranasal; i.duod. = intraduodenal. In the text, tables and other figures 
intraduodenai-oral irnmunisation is referred to as gastrointestinal (g-i.) irnmunisation. 
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Figure5.3.11 Antibody responses in cotton rats immunised with recombinant 
adenoviruses by rnucosal routes. Cotton rats were inoculated with recombinant 
adenoviruses gD-dElE3, @-dl33 or with PBS twice, 3 weeks apart by intranasal (i.n.) or 
gastrointestinal (g.i.) routes. @-specific (a) IgG and (P) IgA levels 3 weeks after the 
primary imrnunisation, and gD-specific (a) IgG and (b) IgA titres 3 weeks after the 
secondary immunisation in trachea-, lung-extrac ts and serum were measured by ELISA. 
Bars represent the mean loglo antibody titre for 3-4 anirnals/group * standard error of the 
mean. 
gD-dElE3 gD-dElE3 gD-dE3 gD-dE3 PBS 
i.n. g.i. i.n. g.i. i.n. 
Figure 5.3.12 BW-1-neutralising antibody titres in sera of cotton rats immunised 
with recombinant adenoviruses by different mucosal routes. Cotton rats were 
inoculated with recombinant adenoviruses gD-dE 1 E3, @-dE3 or with PBS twice, 3 weeks 
apart by intranasal (i.n.) or gastrointestinal (g.i.) routes. Serum samples collected at 6 
weeks following primary imrnunisation were analysed for BHV- 1-neutralising antibodies 
by virus neutralisation assay. Bars represent the mean logIo SN titre * SD for 3-4 animals 
per group. 
5.3.2.2 Antibody levels in the respiratory tract 
To determine the ability of the different immunisation regimens to induce antigen- 
specific humoral immune responses in the respiratory tract, lung- and trachea-extracts were 
analped for the presence of gD- and Ad-specific antibody. Immunisation with the gD-dE3 
vector induced significantly higher @-specific IgA and IgG in the lung (P < 0.00 1 ) and 
trachea (P < 0.0 I) than imrnunisation with the gD-dE 1 E3 virus and the PBS control (Figure 
5.3.1 1 ). Titres of gD-specific IgG in the respiratory tract correlated with those in the serum, 
while the relative ratio of lung/serurn @-specific IgA compared to lungherum IgG 
suggested that IgA was locally produced in the lung (Figure 5.3.1 1). gD-specific ASC were 
found in the lungs and mediastinal LN of animals immunised i.n. with gDdE3 but not with 
gD-dE 1 E3 (data not shown). BHV-1 neutralking antibody titres in the lung- and trachea- 
extracts were below detection Ievel. 
5.3.2.3 Protection against BHV- 1 challenge 
Since mucosal imrnunisation with the adenovirus vectors induced irnmune 
responses in the serum and the respiratory tract, we assessed the ability of these immune 
responses to confer protection against i.n. BHV-I challenge. Table 5.3.2 shows the results 
of BHV-I recovery from the trachea and lungs 24 hours after i.n. BHV-1 challenge. 
Intranasal imrnunisation with the gD-dE3 vector resulted in BHV-I titres in the lung below 
detection limit in 2 of 3 animals and a minimal titre in one animal: the mean virus titre was 
significantly different fiom that in the gD-dEIE3 i.n. and the PBS control groups (P < 
0.00 1 ). In addition, g.i. immunisation with the gD-dE3 vector partially reduced BHV- 1 
titres in the lung of 3 out of 4 animals. In the trachea, BHV-1 titres were only partially 
reduced in each imrnunisation group with the vectors, and means were not significantly 
different fiom the PBS control. 
Table 53.2 BHV-1 recovery from the trachea and lung of cotton rats 
imrnunised with recombinant adenoviruses by the mucosal route and 
challenged with BHV-I 
immunisation mean & s.E.' logio BHV-I titres 
vector route trachea lung 
PBS control intranasal 4.68 + 1.15 5.12 k 0.15 
gD-dE 1 E3 in tranasal 2.79 k 0.55 5.22 2 0.18 
gD-dE 1 E3 gastrointestinal 3.09 ,+ 0.45 5.10 k 0.27 
gD-dE3 in tranasal 1 .OO + 1.22 0.70 + 0.86 
gD-dE3 gastrointestinal 2.89 + 1.22 3.48 + 0.76 
Animals were imrnunised twice with recombinant adenovirus or PBS and 
challenged with BHV- I .  Trachea and lung homogenates obtained one day after 
challenge were tested for the presence of BHV-I by plaque assay. 's.E. = standard 
error of the mean 
53.3 Immunity induced by different routes of immunisation with gD-dE3 
The results of the previous experiment indicated that following mucosal 
administration, the replication-competent Ad was more efficient in inducing immunity to 
BHV-I than the replication-defective vector. In the following studies, therefore, the gD- 
dE3 virus was used to investigate the potential of different routes of imrnunisation with 
recombinant Ad to induce @-specific immune responses in the respiratory tract. Cotton 
rats were inoculated with gD-dE3 by the i-d., i.n. and g.i. routes (Figure 5.3.13) and both 
systemic and mucosal immunity were determined. 
irnmunisation immunisation BHV-1 boost 
day 0 day 24 day 4 1 
3. 5- J, 
day 45 
group 1-4 
1 5 gD-dE3 2 x lo7 i.n. i-n. Cooper lo4 ; 5 
2 5 gD-dE3 2 x 1 o8 i-duod. oral Cooper 10" 5 
3 4 gD-dE3 2 x 10' i.d. i.d. Cooper lo4; 5 
4 5 PBS - i.n. i.n. Cooper 10"; 5 
group 
# 
Figure 5.3.13. Experimental design: immunity induced by different routes of 
immunisation with gDdE3. In the flowchart, arrows above the timescale indicate the 
time of treatment while arrows below indicate the time of serum sampling. The symbol t 
represents tissue samples from euthanised animals. 
i.n. = intranasal; i.duod. = intraduodenal. In the text, tables and other figures 
intraduodenal-oral immunisation is referred to as gastrointestinal (g.i.) immunisation 
* Pwified BHV- I was used for this inoculation. 
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5.3.3.1 Serum antibody responses 
Serum antibody titres specific for gD and Ad 3 weeks following secondary 
immunisation were determined by ELISA. All routes of immunisation with gD-dE3 
induced @-specific IgG and IgA in the serum, which were significantly different from the 
PBS control (P < 0.001) (Figure 5.3.14). Serum @-specific IgG levels were not different 
between groups imunised by different routes. However, the mean @-specific IgA titre in 
the serum of i.n. h u n i s e d  animals was higher than that in the i.d. group (P < 0.02), 
(Figure 5.3.14). In contrast, all three immunisation regimens stimulated similar levels of 
Ad-specific IgG and IgA in the serum (data not shown). 
To measure biological activity of the gD-specific serum antibody, BHV- 1 SN titres 
were determined. Immunisation by each regimen induced similar BHV- 1 SN titres, which 
were significantly higher than that in the PBS control (P < 0.01), (Figure 5.3.15). 
5 -3.3.2 Antibody levels in the respiratory tract 
To determine the ability of the different immunisation regimens to stimulate 
antigen-specific humoral immune responses in the respiratory tract, lung- and nasal-washes 
were analysed for the presence of gD- and Ad-specific antibodies. Each route of 
immunisation with the gD-dE3 vector induced significantly higher titres of @-specific IgA 
and IgG in the lung than the PBS control (P < 0.001); (Figure 5.3.14). However, only 
mucosal immunisation, and not i .d. immunisation, resulted in significantly higher levels of 
antibody in the nasal-washes than the PBS control (P < 0.01), (Figure 5.3.14). Both 
regimens of mucosal immunisation induced significantly higher levels of @-specific IgA 
in the lung- and nasal-washes than the i.d. route of immunisation (P < 0.001), (Figure 
5.3.14). Similarly, both i.n. and g.i. immunisation induced higher titres of Ad-specific IgA 
in the lung- and nasal-washes than the i.d. immunisation (P < 0.05), (data not shown). 
BHV- 1 neutralking antibody titres in the lung- and nasal-washes were below detection 
level. 
: (b) 
nasal wash 
lung wash 
g.i. i.d. PBS 
Figure 53.14 Antibody responses in cotton rats immunised with recombinant 
adenovirus by different routes. Cotton rats were inoculated with recombinant adenovhs 
gD-dE3 or with PBS twice7 3 weeks apart by htranasal (i.n.), gastrointestinal (g.i.) or 
intradermal (i.d.) routes. @-specific (a) IgG a d  (b) IgA titres in nasal-, lung-washes and 
serum at 6 weeks after primary imrnunisation were measured by ELISA. Bars represent the 
mean loglo * SD antibody titre for 4-5 animals/group. 
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rn day 45 
I T 
PBS 
Figure53.15 BHV-1-neutralising antibody titres in sera of cotton rats 
immunised with recombinant adenovims by different routes. Cotton rats were 
inoculated with recombinant adenovirus gD-dE3 or with PBS twice, 3 weeks apart 
by intranasal (i.n.), gastrointestinal (g-i.) or intradermd (i.d.) routes. Senun samples 
collected at different timepoints were analysed for BHV- l -neutralking antibodies 
by virus neutralisation assay. Bars represent the mean loglo * SD SN titre for 4-5 
animals per group. 
The higher ratio of lung/serum @-specific IgA compared to lunglserum gD- 
specific IgG levels indicated that antibody may be locally produced in the lung of cotton 
rats irnmunised by the mucosal route but not of those inoculated intrademally. Therefore, 
the frequency of gD- and Ad-specific ASC in lung lymphocytes as well as in the 
mediastinal LN and spleen was determined by ELISPOT assay. The frequency of antigen- 
specific IgG and IgA secreting cells in the lung was higher following mucosal than i.d. 
irnmunisation (Table 5.3.3). There was no statistical difference in the numbers of ASC in 
the spleen between the gD-dE3 -imrnunisation groups. Mediastinal lymph nodes contained 
only a low number of antigen-specific IgA secreting cells from cotton rats immunised with 
gD-dE3 by every route. Generally, the &equency of IgA committed ASC was higher than 
that of IgG producing ASC in each lymphocyte population examined (Table 5.3.3). 
Table 5.3.3 Frequency of gD- and adenovirus-specific antibody-secreting 
cells in lymphocytes from tissues of cotton rats immunised with recombinant 
adenovirus by different routes 
lympho- immunisation gD-speci fic ademvirus-specific 
CYte ASC/million* ASC/million* 
source w kA k A  
lung gD-dE3 / i.n. 95 460 44 900 
gD-dE31 g.i. 140 400 32 900 
gD-dE31 i.d. 17 25 2.5 59 
PBS 1 i.n. 4 22 2 22 
MLN gD-dE3/ i.n. nd 1 nd 7 t 
gD-dE31 g.i. nd 4.5 nd 10 
gD-dE3/ i.d. nd 2.5 nd 3 
PBS I i.n. nd nd nd 1 
. pp - - - - -- 
spleen : gD-dE3/ in .  nd 5.1 k 2  3.4 k 3.2 15 + 5.6 
gD-dE31 g.i. 6 k 8 . 8  26k24-6 31.7k28.1 59+,58 
gD-dE31i-d. 2.2k3.86 7i-5.2 I 1  k4.5 21 ,+ 9.3 
PBS / i.n. nd nd nd nd 
Cotton rats were inoculated with gD-dE3 or with PBS twice, 3 weeks apart by the 
intranasal (in.), gastrointestinal (g.i.) or intraderma1 (i.d.) route. Six weeks after the 
primary irnmunisation spleen, lung and medias~al  lymph node (MLN) 
lymphocytes were isolated and used in the ELISPOT assays. 
*Mean values of the number of antigen-specific antibody-secreting cells (ASC) 
per million lymphocytes in the lung and the MLN were determined in cultures of 
pooled cell populations. 
: Mean f: SD of ASCImillion lymphocytes from individual spleen cell 
populations. 
t nd = not detected (less than 1 ASC/million) 
5.3.4 Immunity and protection induced by different routes of irnmunisation 
Results of the previous experiment suggested that i.n. immunisation with gD-dE3 
induced better BHV-1-specific immunity in the respiratory tract of cotton rats than i.d. 
imrnunisation. The next experiment was designed to determine whether different routes of 
immunisation with gD-dE3 resulted in different protection of the cotton rat respiratory tract 
against BHV-1 challenge. Cotton rats were inoculated with gD-dE3 i.n. or id. followed by 
i.n. BHV- I challenge (Figure 5.3.16). 
immunisation immunisation challenge 
day 0 day 28 day 49 
5- 5- 
.It 
day 50 
group 1-3 
group 
# 
# of 
cotton 
"tS Per 
group 
inoculum dose route Istrain dose 1 
imrnunisation 
@ fu) primary secondary 
i.n. BHV- 1 
challenge 
gD-dE3 2 x 10' i.n. r.n. 108 5 x 1 0 ~  
gD-dE3 2 x 10' i.d. i.d. 108 5 x lo7 
PBS - i.n. i.n. 108 5 x 1 0 ~  
Figure 5.3.16. Experimental design: immunity and protection induced by different 
routes of immunisation. In the flowchart, arrows above the timescale indicate the time 
of treatment while arrows below indicate the time of serum sampling. The symbol t 
represents tissue samples collected From euthanised animals. 
in .  = intranasal; i.d. = intradermal. 
5.3.4.1 Antibody responses in the serum and the respiratory tract 
To confirm the results of the previous experiment, gD- and Ad-specific antibody 
responses were measured in the serum and lung- and trachea-extracts of cotton rats 
imrnunised with gD-dE3 by the i-n. and i.d. routes. Similarly to earlier data, @-and Ad- 
specific serum IgG levels in animals imrnunised i.n. did not differ from those immunised 
by the inndermal route; however, @-specific IgA levels in the respiratory tract were 
significantly higher in animals immunised intranasally compared to those inoculated 
intradermally (P < 0.00 1); (Fig. 5.3.17). 
5 -3 -4.2 Antigen-specific antibody-secreting cells in different tissues 
To identify potential sites for antibody production in the cotton rat following 
different routes of immunisation with gD-dE3, the Frequencies of gD- and Ad-specific 
ASC in lung, mediastinal LN, bone marrow and spleen lymphocytes were determined. In 
the lung, frequencies of antigen-specific IgG and IgA secreting cells were higher following 
i.n. immunisation than i.d. immunisation (Table 5.3.4), similarly to previous observations. 
Mediastinal lymph nodes also contained higher number of antigen-specific IgG secreting 
cells from cotton rats immunised i.n. compared to those inoculated intradennally. In 
contrast, spleens contained higher numbers of antigen-specific ASC following i.d. 
immunisation than i.n. inoculation. Both routes of immunisation with gD-dE3 resulted in 
gD- and Ad-specific IgA and IgG secreting cells in the bone marrow, while inoculation 
with PBS did not. 
5.3.4.3 Protection of cotton rats against B W -  1 challenge 
Since both routes of immunisation with gD-dE3 induced immune responses in the 
serum and the respiratory tract, we assessed the ability of these immunisation protocols to 
confer protection against BHV-1 challenge. Table 5.3.5 shows the results of BHV-I 
recovery from the trachea and the lung one day after intranasal BHV-1 challenge. 
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Figure 5.3.17 Antibody responses in cotton rats immunised with recombinant 
adenovims by different routes. Cotton rats were inoculated with recombinant adenovirus 
gD-dE3 or with PBS twice, 3 weeks apart by intranasal (in.) or intraderma1 (id.) routes. 
@specific (a) IgG and (b) IgA titres in trachea-, lungextracts and serum at 6 weeks after 
primary immunisation were measured by ELISA. Bars represent the mean loglo * SD 
antibody titre for 4-5 animals/group. 
Table 5.3.4 Frequency of gD- and adenovirus-specific antibody-secreting 
cells in lymphocytes from tissues of cotton rats immunised with recombinant 
adenovirus intranasally or intradermdy 
lymphocyte imrnunisation @specific adenovirus-specific 
source ASC/million* ASC/million* 
gD-dE3 / i.n. 46 600 62 1600 
gD-dE3 I i.d. 'nd 35 15 200 
PBS I i.n. nd nd nd 20 
MLN gD-dE3 1 i.n. 25 40 10 30 
gD-dE3 / i.d. nd 40 nd 20 
PBS / i.n. nd 20 nd 5 
bone marrow gD-dE3 I i.n. 4.5 3 9 23 
gD-dE3 I i.d. 3 2 17 3 
PBS 1 i.n. nd nd nd nd 
spleen gD-dE3 / i.n. nd 1 5.5 9 
gD-dE3 /id. 35 10 35 5 
PBS I i.n. nd nd nd nd 
Cotton rats were inoculated intranasally (in.) or intrademally (i.d.) twice, 3 weeks 
apart, with recombinant adenovirus gD-dE3 or PBS as a control. Six weeks after the 
primary irnrnunisation all animals were challenged i.n. with BHV-1. Spleen, bone 
marrow, lung and mediastinal lymph node (MLN) lymphocytes, isolated 1 day after 
challenge, were used in the ELISPOT assay. 
*Mean values of the number of antigen-specific antibody-secreting cells (ASC) 
per million lymphocytes were determined in cultures of pooled cell populations of 
5 animalslgroup. 
'nd = not detected (less than 1 ASC/million) 
Table 5.3.5 Effect of the route of immunisation with gDE3 recombinant 
adenovirus on the protection of cotton rats against intranasal BW-1 
challenge 
immunisation / route virus isolation (loglo pfdg tissue) 
trachea lung 
gD-dE3 / i.n. 
gD-dE3 / i-d. 
PBS 1 i n  
Cotton rats were inoculated intranasally ( i n )  or intradermally (i.d.) twice, 3 
weeks apart with gD-dE3 or PBS as a control. Six weeks after the primary 
immunisation animals were challenged with BHV-1 intranasally. One day 
post-challenge trachea and lung were removed, homogenised and tested for the 
presence of BHV-1 by plaque assay. 
* Significant difference from other groups (P < 0.05) 
Intranasal immunisation with the gD-dE3 vector resulted in BHV- 1 titres below 
detection limit in the lung of 4 of 5 animals and a minimal titre in one animal; the mean 
virus titre was significantly different fiom the PBS control group (P < 0.001). The i.d. 
immunisation also resulted in reduced BHV-1 titres in the lung compared to the PBS 
control (P < 0.01) (Table 5.3.5). The level of protection in id. immunised groups was 
similar to that determined in a separate experiment (data not shown). BHV-1 titres in the 
lung were significantly lower in animals immunised i.n. than in those inoculated i.d. (P < 
0.001). BHV-1 titres in the trachea were partially reduced in the i.n. imrnunisation group 
compared to the i.d and PBS groups (P < 0.05). 
5.3.5 Duration of immunity induced by intranasal administration of gD-dE3 
In order to confirm protection of the lungs against BHV-1 challenge histologically 
and to W e r  characterise the kinetics and duration of antigen-specific immunity induced 
by i.n. administration of gD-dE3, cotton rats were immunised i.n. with gD-dE3 followed by 
i n .  BHV-1 challenge 6 and 15 weeks following primary immunisation (Figure 5.3.18). 
challenge 
immunisation imrnunisation group 1 & 2 
challenge 
group 3 & 4 
day 0 day 2 1 day 42 day 102 
.1 4 .1 5 - ,  
day 45 day 70 day 105 
group 1 & 2 group 3 & 4 
imunisation 
- - - - - - - -  - .- - pp 
1 7 gD-dE3 lo8 i n .  i.n. 108 5 x 1 0 '  
2 7 PBS - i.n. i.n. 108 5 x 10' 
3 7 gD-dE3 lo8 i.n. i.n. 108 5x10' 
4 5 PBS - i.n. i.n. 108 5 x 1 0 '  
i.n. BHV-1 
challenge 
inoculum dose route 
@fU) primary secondary 
Figure 5.3.18 Experimental design: duration of immunity induced by intranasal 
administration of g W 3 .  In the flowchart, arrows above the timescale describe time of 
treatment while arrows below describe time of serum sampling. The symbol 1. represents 
tissue samples collected from euthanised animals. 
in. = intranasal 
strain dose 
(pfu) 
5.3.5.1 Kinetics of serum antibody responses 
Figure 5.3.19 shows gD- and Ad-specific serum IgG and IgA levels at different 
time points following i.n. irnmunisation with gD-dE3. Serum antibody specific for gD 
(Figure 5.3. Wa) and BHV-I SN antibodies (Fig. 5.3.20) were induced by the primary 
immunisation with gD-dE3 and their levels increased following secondary immunisation. 
These levels were maintained for at least 3 months. The kinetics of Ad-specific responses 
were similar to gD-specific antibody responses (Figure 5.3.1 9.b). 
5.3 S.2 Duration of antibody responses in the respiratory tract 
Interestingly, not only the levels of antigen-speci fic serum anti bodies were 
maintained, but the titres of antibodies in lung-extracts were similar at 3 weeks and at 12 
weeks following secondary immunisation (data not shown). To determine whether antigen- 
specific ASC were maintained locally in the lung and in peripheral lymphoid tissues, 
ELISPOT assays were performed 15 weeks following primary immunisation. Both gD- and 
Ad-specific ASC were found in the lung, bone marrow and spleen of gD-dE3-immunised 
animals (Table 5.3.6). The numbers of antigen-specific ASC in the lungs at 15 weeks 
following primary immunisation were similar to those at 6 weeks after immunisation 
determined in previous experiments (5.3.3; 5 -3.4). 
5.3.5.3 Protection against BHV- 1 challenge determined histologically 
Previous results of BHV-1 recovery from the respiratory tract have indicated that 
protection of the lungs against BHV-1 challenge was achieved by i.n. immunisation with 
gD-dE3. However, evidence for the lack of infection of cotton rat lungs in situ was 
necessary to confirm the protective ability of i.n. immunisation with gD-dE3 against 
BHV-I infection. Therefore, lungs of cotton rats were examined by histological and 
immunohistochemical methods for evidence of virus-associated tissue damage and BHV- 1 
replication 3 days after challenge. Lungs of cotton rats in the control groups had lesions of 
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Figure5.3.19 Kinetics of gD- and Ad-specific antibody responses in the serum of 
cotton rats immunised intranasally with recombinant adenovims. Cotton rats were 
inoculated with gDdE3 or with PBS twice, 3 weeks apart. Titres of IgG and IgA 
antibodies specific for (a) gD and (b) HAdS at different timepoints p.i. were determined by 
ELISA. Error bars represent the SD of loglo antibody titres for 7 animals/group. Control 
animals maintained background levels of antibody during the study (not shown). 
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Figure 5.3.20 Kinetics of BHV-1-neutralising antibody titres in the 
serum of cotton rats immunised with recombinant adenovirus intranasally. 
Cotton rats were inoculated with gD-dE3 or PBS twice, 3 weeks apart. Serum 
samples collected at different timepoints following immunisation were analysed 
for BHV- 1 -neutralking antibodies by virus neutralisation assay. Points represent 
the mean loglo SN titre, while enor bars show the SD for 7 animals per group * 
SD. Control animals maintained background levels of SN antibody during the 
study (not shown). 
Table 5.3.6 Frequency of gD- and adenovirus-specific antibody-secreting 
cells in lymphocytes from different tissues of cotton rats immunised 
intranasally with recombinant adenovirus 
lymphocyte immunisation @-specific adenovirus-specific 
source ASC/million* ASC/million* 
- - -  
lung gD-dE3 600 16 I100 36 
PBS I4 ndt 19 nd 
- -- - - 
bone marrow gD-dE3 4 2 29 17 
PBS nd nd 2 nd 
spleen gD-dE3 2 nd 7 I 1  
PBS nd nd nd nd 
Cotton rats were inoculated intranasdy twice, 3 weeks apart, with recombinant 
adenovirus gD-dE3 (7 animals) or PBS as a control (5 animals). Twelve weeks after 
the secondary immunisation all animals were challenged intranasally with BHV- I .  
Spleen, bone marrow and lungs lymphocytes were isolated 3 days after challenge 
and used in the ELISPOT assays. 
*Mean values of the number of antigen-specific antibody-secreting cells (ASC) 
per million lymphocytes were determined in cultures of pooled cell populations. 
'nd = not detected (less than 1 ASC/milIion) 
a multifocal mild interstitial pneumonia with type II pneurnocyte proliferation and 
infiltration of few macrophages (Table 5.3.7). Small foci involving one or two cells 
positive for BHV-1 antigen were also demonstrated, usually associated with foci of 
interstitial pneumonia. in contrast, lungs from the two groups of immunised cotton rats did 
not have any lesions or BHV- 1 replication foci, indicating significant protection following 
vaccination. In contrast to the lung, no lesions associated with BHV-1 infection were found 
in the lower part of the trachea of either immunised or control animals. 
In accordance with the results of in situ lung examination, BHV- 1 was isolated only 
from lungs of control animals but not from lungs of immunised animals, challenged at 
either 6 or 15 weeks following the primary immunisation (Table 5.3.7). In addition, mean 
virus titre in the trachea of imrnunised animals was significantly lower than that in PBS 
controls (P < 0.01 ) (data not shown). 
Tabte 5.3.7. Effect of intranasal immunisation with recombinant 
adenovirus on the protection of the lungs of cotton rats against intranasal 
BHV-1 challenge 
weeks immunisation virus isolation BHV- 1 interstitial 
following first (pfidg lung specific foci pneumonia 
immunisation tissue k SD) 
- -  - -  -- - 
6 gD-dE3 nd' 0/7 0/7 
6 PBS control 5.086 f 0.286 717 7/7 
15 gD-dE3 nd 0/7 017 
15 PBS control 3.8 15 k 0.94 1 4/5 515 
Cotton rats were inoculated intranasally twice, 3 weeks apart with gDaE3 or 
PBS as a control. Six or fifteen weeks after the primary imrnunisation animals 
were challenged with BHV-1 intranasally. Three days post-challenge lungs 
were removed and were tested for BHV-1 replication (virus isolation and 
BHV-I specific foci) and pathological changes (interstitial pneumonia) in the 
lungs. 
*nd = not detected (c 10 pfuflung) 
5.3.6 Conclusions 
Results in sections 5.3.1 - 5.3.5 indicated that immunisation with recombinant 
adenovirus vectors expressing BHV-1 gD or tgD was capable of inducing gD-specific 
immune responses in the cotton rat. Furthemore, immunisation by the i.d.-i.n. route 
resulted in partial protection of the lungs of cotton rats against i.n. BHV-1 challenge. 
Immunisation with @expressing vectors induced better immunity and protection than 
@-expressing recombinant adenoviruses. Results from these experiments also showed 
that after mucosal administration, the replication-competent gD-dE3 vector induced higher 
levels of @-specific immunity and reduced BHV-1 titres from the respiratory tract after 
challenge to a higher degree than the replicationdefective gPdE I E3 vector. 
Different routes of irnrnunisation with gD-dE3 (i.p., i.d., i-n., g-i.) were capable of 
inducing antigen-specific immune responses. The highest level of immunity in the 
respiratory tract and protection against i.n BHV- 1 challenge was achieved by the i.n. route 
of immunisation. Furthermore, the immunity induced by i.n. administration of gD-dl53 may 
have been long-lasting as indicated by the fact that antigen-specific immune responses 
were maintained at high levels for at least 12 weeks following secondary irnmunisation. 
5.4 Adenovirus dissemination following different routes of delivery 
In the previous experiments, several interesting findings appeared regarding the 
induction of immune responses following inoculation with recombinant adenoviruses. 
First, the replicationdefective gD-dElE3 virus was less efficient than the replication- 
competent gDdE3 vector in inducing immunity following mucosal administration, while 
they were equally efficient following systemic inoculation. Second, intraderma1 
immunisation with recombinant adenovirus induced @-specific immunity in the 
respiratory tract, even though systemic immunisation with protein antigens rarely induces 
mucosal immunity (Michalek et al., 1994). Third, intraduodenal-oral immunisation induced 
almost equivalentJevels of antibody in the respiratory tract as did the i.n. immunisation, 
although enteric irnrnunisation is usually less efficacious in inducing immunity in the 
respiratory tract than i.n. immunisation (Mestecky et al., 1994). 
Based on these observations one of my hypotheses was that replication-defective 
and replication-competent vectors had different capabilities of spreading systemically 
following mucosal immunisation. Furthermore, adenovirus may be able to spread to the 
respiratory tract following intmdermal, intraduodenal and oral immunisation, thereby 
inducing local immunity directly in the respiratory tract. Therefore, the next objective was 
to determine the capability of replication-defective and replication-competent adenoviruses 
to disseminate in the cotton rat following different routes of inoculation. 
5.4.1 Adenovirus isolation from different organs 
Tissues of cotton rats were examined for the presence of adenovirus following 
administration of gD-dE 1 E3 or gD-dU by different routes. Cotton rats received 1 pfb of 
adenovirus by the i.d., i.n., oral or intraduodenal route. Tissues were collected at day 3 
following inoculation with gD-dE3, because the peak of adenovirus replication in cotton 
rats has been determined to be around day 3 following i.n. inoculation (Pacini et al., 1984). 
Both day 1 and day 3 samples were collected following inoculation with gD-dElE3, 
because more virus was expected to be present in the tissues at an earlier timepoint pi. in 
the case of a non-replicating adenovirus (Ginsberg et al., 199 1 ). Following isolation from 
tissues, adenoviruses were detected by plaque assay on 293 cells. Results are shown in 
Tables 5.4.1, 5.4.2 and 5.4.3. The day 1 and day 3 data for gD-dE 1 E3 are described 
together, because the main interest of this study was to provide evidence for the presence of 
adenovirus in tissues, and not the kinetics of spreading of adenovirus. 
Following intradermal inoculation with gD-dE lE3, adenovirus was isolated fiom 
most samples except for the alimentary tract and spleen (Tables 5.4.1 and 5.4.2). 
Intradermal administration of gD-dE3 resulted in virus spread to most tissues except for the 
alimentary tract and nasal-washes (Table 5.4.3). 
Following intranasal inoculation with gD-dE 1 E3, adenovirus was isolated from all 
tested samples at either day 1 or day 3 (Tables 5.4.1 and 5 A.2). lntrmasal administration of 
gD-dE3 provided similar results at day 3 (Table 5.4.3). Data obtained at day 1 following 
in. inoculation with gD-dE3 were similar to those at day 3 (results not shown). In a 
separate experiment, adenovirus was isolated fkom the lung in 2 of 7 animals even at 3 
weeks following i.n. inoculation with gD-dE3. Intranasal inoculation of wild type KAd5 
provided similar results at day 3 to those obtained by i.n. administration of gD-dE3 at day 3 
p.i. (data not shown). 
AAer intragastric inoculation with gD-dElE3, adenovirus was isolated from most 
tested organs except for the mediastinal LN, ileum, liver and the skin (Tables 5.4.1 and 
5.4.2). All tested samples proved to be positive for adenovirus following intragastric 
delivery of gD-dE3 (Table 5.4.3). However, the stomach of babies suckling a mother 
infected by the intragastric route by gD-dE3 did not contain detectable adenovirus (data not 
shown). 
Intraduodenal inoculation of cotton rats with gD-dE 1E3 resulted in adenovirus 
spread to each tested organ (Tables 5.4.1 and 5.4.2). Adenovirus was even detected in the 
vaginal wash fiom one animal (data not shown). Following intraduodenal administration 
with gD-dE3, adenovirus was isolated fiom all samples except for nasal-washes or only 
fiom the duodenum and the rnesenteric LN in one animal (Table 5.4.3). 
Table 5.4.1 Adenovirus isolation from tissues of cotton rats 1 day following 
inoculation with gPdElE3 by different routes 
tissue pfidg tissue adenovirus following (route of inoculation) 
- 
nasal-wash ndhd 3000 500 ndhd 
trachea 20lnd 1 lo5 3000 ndnd 
lung ndhd 200 1600 ndnd 
rnediastinal LN ndhd + nd ndnd 
- - - 
oesophagus ndhd 3000 20 ndhd 
stomach ndnd nd nd ndnd 
duodenum ndhd + + +/+ 
ileum ndhd + nd +/+ 
feces ndhd nottested + +/+ 
mesenteric LN ndhd + 20 +/+ 
spleen nd nd 50 ndhd 
liver nd/200 nd nd ndnd 
skin injection site 1000/2000 n.a. n.a. n.a. 
skin +I1 00 nd nd +/+ 
Values are from individual animals (animal #1  / #2 in the same group). 
+ = First or second passage was positive for adenovirus 
nd = not detected (second passage was negative for adenovirus) 
n.a. = not applicable 
Table 5.4.2 Adenovirus isolation from tissues of cotton rats 3 days 
following inoculation with gDaEIE3 by Werent routes 
tissue pWg tissue adenovirus following (route of inoculation) 
-- - - 
intraderma1 intranasal intragastric intraduodenal 
nasal-wash + 4000 nd nd/+/nd 
trachea + 2000 + nd/ 1 00/+ 
lung + 1 lo5 100 nd/+/+ 
medias tinal LN + + nd nd/70/nd 
oesophagus 10 2000 20 nd/+/nd 
stomach nd + + nd/1 00/500 
duodenum nd + nd 200/500/ 1000 
ileum nd + nd nd/+/nd 
feces nd 20 nd nd/+!nd 
mesenteric LN + nd nd +/+/nd 
- - . - -. - 
spleen nd 100 10 nd/+/+ 
liver 30 40 nd nd/+/+ 
skin injection site 50 n.a. n-a. n.a. 
skin nd + nd nd/+/+ 
Values are from individual animals (animal #11#2 / #3 in the same group). 
+ = First or second passage was positive for adenovirus 
nd = not detected (second passage was negative for adenovirus) 
n.a. = not applicable 
TabIe5.4.3 Adenovirus isolation from tissues of cotton rats 3 days 
following inoculation with gD-dE3 by different routes 
tissue pWg tissue adenovirus following (route of inoculation) 
intradennal intmasal intragas tric intraduodenal 
nasal-wash ndhd 3000/3000 400/2000 nd/nd/nd/nd 
trachea n d 2  0 3 0001 1000 200012000 20/nd/20/20 
lung 2 0/40 10% o5 1 0*/ 1.2 x 1 0' nd/nd/+RO 
mediastinal LN +/nd +I+ nd/+ 1 O/nd/200/200 
oesophagus +/ 10 300/200 1500140 nd/nd/ 1 012 0 
stomach ndnd 1 O/+ nd/+ ndhd13 0012000 
duodenum ndhd +/+ nd/+ +/+/ 1 0012000 
ileum ndhd nd/+ +/+ + h i /  1 01 1 000 
feces ndhd nd/+ ndhd ndlnd/ 1001 1 000 
rnesenteric LN 201 10 501 1 000 20/40 +/+/2 OO/+ 
- - - - - - - - - 
spleen 100/80 nd/+ nd/+ nd/nd/20/ 1 000 
liver 50/30 1 O/+ nd/ 10 nd/nd/500/+ 
skin injection site 1 000140 n.a. ma. ma. 
skin +/nd nd/+ nd/+ ndnd  1 0140 
Values are from individual animals (animal #1 1 #2 / #3 / #4 in the same group) 
+ = first or second passage was positive for adenovirus 
nd = not detected (second passage was negative for adenovirus) 
n.a. = not applicable 
5.4.2 Conclusions 
Results of adenovirus isolation following inoculation of gD-dE 1 E3 or gD-dE3 
indicated that both recombinant adenoviruses are capable of systemic dissemination 
following different routes of administration. As a result, adenovirus could be found in the 
respiratory tract even following inoculation at a distant site (intradermal or intraduodenal). 
Higher levels of adenovirus were found in the respiratory tract following intragastric 
administration than after intraduodenal administration. This observation indicated that 
adenovims may have spread to the airways following administration of the virus to the 
oesophagus. Therefore, this method of inoculation may not exclusively involve the delivery 
of adenovirus to the alimentary tract. 
5.5 Effect of adenovirus-specific immunity on imrnunisation with recombinant 
adenovirus 
As described in section 5.3, imrn~sat ion with recombinant adenovirus vectors 
expressing gD induced @-specific immunity and partial protection of cotton rats against 
i.n. BHV-1 challenge. Outside laboratory conditions, however, one has to take into 
consideration the possibility that the vaccinee population may have acquired Ad-specific 
active or passive immunity prior to immunisation. Furthermore, the efficacy of repeated 
administration of adenovirus in inducing immunity to the heterologous protein may be 
limited because of Ad-specific immunity, which developed following a previous 
immunisation. Therefore, it is important to investigate the effect of immunity to HAd5 on 
the efficacy of imrnunisation with recombinant HAd5 vectors. The cotton rat model is 
especially suitable to conduct these studies because these laboratory animals support HAd5 
replication. 
5.5.1 Effect of HAd5-specific active immunity on intranasal and 
gastrointestinal immunisation with recombinant adenovirus 
The most common way for an animal or human to acquire Ad-specific immunity is 
to be naturally infected by the virus through the respiratory tract. Following infection, 
memory type Ad-specific active immunity develops. Since HA& preferentially targets 
respiratory mucosal tissues in cotton rats, intranasal infection with wt HAdS in cotton rats 
was chosen as a model to induce active Ad-specific immunity. The experiment described in 
Figure 5.5.1 was designed to assess whether i.n. infection of naive cotton rats with wt 
HAd5 had an effect on the immunity induced by i.n. immunisation with recombinant 
adenovirus. Considering the importance of local mucosal stimulation, I also wanted to find 
out whether imrnunisation at a different mucosal site (enteric) would be affected by i.n. 
infection with wt adenovirus. Animals were infected with wt HAdS 2 weeks before 
imrnunisation with gD-dE3 in order to induce strong cellular and humoral immunity 
against Ad by the time of immunisation. The efficacy of immunisation with gD-dE3 by the 
i.n. and gi. mutes was then assessed by measuring gD- and Ad-specific immune responses 
and protection of lungs against BHV- 1 challenge. 
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@fU) 
- 
gD-dE3 5 x lo7 i.n. i.n. 108 5x lo7 
gD-dE3 5 x LO' i.duod. oral 108 5 ~ 1 0 '  
gD-dE3 5 x 10' i.n. i.n. 108 5x10' 
gD-dE3 5 x 10' i.duod. oral 108 5x10' 
PBS - i n .  i.n. 108 5x10' 
Figure 5.5.1 Experimental design: effect of HAdS-specific active immunity on 
intranasal and gastrointestinal immunisation with recombinant adenovirus. In the 
flowchart, arrows above the timescale indicate the time of treatment while arrows below 
indicate the time of serum sampling. The symbol t represents tissue samples collected 
fiom euthanised animals. 
i.n. = intranasal; i.duod. = intraduodenal. In the text, tables and other figures 
intraduodenal-oral immunisation is referred to as gastrointestinal (g.i.) immunisation. 
5.5.1.1 Serum antibody responses 
At the time of immunisation with gD-dE3, 2 weeks following HAdS-infection, all 
HAd5-infected animals developed Ad-speci fic serum antibody responses similar to those in 
Figure 5.5.10. These results indicate that cotton rats were successfully infected with H A 6  
and induced Ad-specific immune responses. Furthermore, Ad-specific IgG and IgA titres 
were significantly higher in the serum of HA&-infected cotton rats compared to non- 
infected animals at all timepoints following imrnunisation with gD-dE3, as expected 
(Figure 5.5.2). 
Three weeks after primary hun i sa t ion  with gD-dE3, all immunised animals 
developed significantly higher levels of @-specific IgG and IgA in the serum than those 
measured in the serum of PBS-control animals (P < 0.001) (Figure 5.5.2). Non-infected 
cotton rats, however, developed higher mean @-specific antibody titres than HAd5- 
infected animals when the route of gD-dE3 immunisation was i-n. (P < 0.0 1 ). In contrast, 
mean $-specific antibody titres were not significantly higher in non-infected compared to 
HAd5-infected groups, when immunised with gD-dE3 by the gastro-enteric route (Figure 
5.5.2). 
To measure the biological activity of the @-specific antibody, BHV-1 SN titres 
were determined. BHV-I SN titres were significantly lower in HA&-infected than in non- 
infected animals between groups irnrnunised with gD-dE3 by the same route (P e 0.00 1 ) 
(Figure 5.5.3). 
5 -5.1.2 Antibody responses in the respiratory tract 
To determine the ability of the different immunisation regimens to induce antigen- 
specific humoral immune responses in the respiratory tract, lung and trachea extracts were 
analysed for the presence of gD- and Ad-specific antibody. Intranasal immunisation with 
gD-dE3 induced significantly lower gD-specific IgG and IgA levels in the trachea of 
HAdS-infected than non-infected animals (P < 0.001) (Figure 5.5.4). In contrast, gD- 
specific tracheal antibody levels induced by g.i. inoculation were not significantly affected 
+, i.n. +, g.i. - y  1.n. -y  g.1. PBS 
Figure5.5.2 gD- and Ad-specific serum antibody responses in cotton rats 
immunised with gD-dE3 by different routes following HAd5 infection. Cotton rats 
were intranasally inoculated with wt HAd5 (+ symbol) or PBS (- symbol) as a control. Two 
and three weeks following infection, cotton rats were immunised with gD-dE3 by the 
intranasal ( i n )  or gastrointestinal (g.i.) routes or with PBS as a control. gD- and Ad- 
specific (a) IgG and (b) IgA levels in the serum at 3 weeks following the primary 
irnmunisation were measured by ELISA. Bars represent the mean loglo * SD antibody titre 
for 3-4 animalslgroup. 
-, g.i. -, PBS 
Figure 5.53 BHV-1-neutralising antibody titres in the sera of cotton rats 
irnmunised with g W 3  by different routes following aAdS infection. Cotton rats 
were intranasally inoculated with wt HAd5 (+ symbol) or with PBS as a control (- symbol). 
Two and three weeks following infection the animals were immunised with gD-dE3 by the 
inhanasal (i.n.) or gastrointestinal ( g i . )  routes or with PBS as a control. Serum samples 
collected at 3 weeks following primary irnmunisation were analysed for BHV- I - 
neutralking antibodies by virus neuhalisation assay. Bars represent the mean loglo SN titre 
* SD for 3-4 animals per group. 
0 
+, i.n. +, g-i. -, 1.n. -, g.1. -, PBS 
Figure 5.5.4 gD- and Ad-specific antibody responses in the trachea of cotton rats 
immunised with gDdE3 by different routes following BAdS infection. Cotton rats 
were intranasally inoculated with wt HAdS (+ symbol) or with PBS as a control (- symbol). 
Two and three weeks following infection cotton rats were irnmunised with gD-dE3 by the 
inhanasal (i.n.) or gastrointestinal (g.i.) routes or with PBS as a control. gD- and 
Ad-specific (a) IgG and @) IgA levels in tracheal-extracts at 3 weeks following the primary 
irnrnunisation and 1 day after BHV-I challenge were measured by ELISA. Bars represent 
the mean loglo * SD antibody titre for 3-4 animalslgroup. 
by pre-infection with HA&. Interestingly, higher Ad-specific IgG levels were detected in 
the trachea of g.i. immunised, than i.n. immunised HA&-infected animals (P < 0.0 1 ). 
The mean of @-specific lung-IgG titres in each immunisation group was higher 
than that in the PBS controls (P < 0.01); (Figure 5.5.5). However, HAd5-infected animals 
had significantly lower gD-specific IgG levels in their lungs than non-infected animals (P < 
0.0 1 ). Furthermore, gD-speci fic lung IgA was induced only in non-HAd5-infec ted animals, 
with significantly higher titres than those in the HAdS-infected and PBS control groups (P 
< 0.01); (Figure 5.5.5). In accordance, only non-iofected animals contained @-specific 
IgA and IgG ASC in the lung tissue (similar numbers in the i.n. and g.i. immunisation 
groups) as determined by ELISPOT (data not shown). Adenovirus-specific IgG and 1gA 
levels in the lung, measured by ELSA, resembled those observed in the serum (Figures 
5.5.2 and 5.5.5). 
5.5.1 -3 BHV- 1 recovery from lungs following challenge 
Since HAd5 infection affected antigen-specific immune responses induced by a 
subsequent irnrnunisation with gD-dE3, its effect on protection of lungs against BHV-1 
challenge was investigated. Indeed, significantly more BHV- l was isolated from the lungs 
of HAd5 -infected than non-infected animals imrnunised with gD-dE3 ; (Figure 5.5 -6). 
BHV- 1 titres in the gastro-intestinal immunisation group were not significantly affected by 
pre-infection with HAd5. Each immunisation group contained less BHV- I in the lung than 
the PBS control (P < 0.05). 
+, i.n. +, g.i. . * -, i n .  -, g.1. -, PBS 
Figure 5.5.5 g D  and Ad-specific antibody responses in the lung of cotton rats 
immunised with gD-dE3 by different routes following HAd5 infection. Cotton rats 
were inoculated intranasally with wt HAdS (+ symbol) or with PBS as a control (- symbol). 
Two and three weeks afier infection cotton rats were immunised with gD-dE3 by the 
intranasal (i.n.) or gastrointestinal (g.i.) routes or with PBS as a control. gD- and Ad- 
specific (a) IgG and (b) IgA levels in lung-extracts at 3 weeks following the primary 
immunisation and 1 day after BHV- 1 challenge were measured by ELISA. Bars represent 
the mean logl antibody titre * SD for 3 -4 animaIs/group. 
-,g.~. - 9 PBS 
Figure 5.5.6 BHV-1 recovery from lungs of cotton rats immunised with gD-dE3 by 
different routes following EAdS infection. Cotton rats were inoculated intranasally with 
wt HAd5 (symbol +) or with PBS as controls (symbol -). Two and three weeks following 
infection the animals were immunised with gD-dE3 by the intranasal (i-n.) or 
gastrointestinal (g.i.) routes or with PBS as a control. Three weeks after the primary 
immunisation with gD-dE3 animals were challenged with BHV- 1 intranasally. One day 
post-challenge lungs were homogenised and tested for the presence of BHV-I by plaque 
assay. Bars represent the mean logl antibody titre * SD for 3 -4 animals per group. 
5.5.2 EfEect of active HAdS-specific immunity on intraduodenal immunisation 
with recombinant adenovirus 
Results described in section 5.4 suggested that it is more appropriate to administer 
adenoviruses intraduodenally rather than orally if one wants to study the induction of 
immune responses induced by immunisation in the alimentary tract. By doing so, direct 
spread of adenovirus to the respiratory tract can be avoided. Therefore, the next experiment 
had two aims: first, to study gD-specific immune responses induced by intraduodenal 
immunisation alone; second, to determine the effect of Ad infection on the efficacy of a 
subsequent intraduodenal immunisation with gD-dE3 (Figure 5.5.7). HA&-infected and 
uninfected cotton rats were immunised with gD-dE3 by the intraduodenal route and 
challenged with BHV-1 3 weeks following secondary immunisation. gD- and Ad-specific 
immune responses and protection against B W -  1 infection were determined. 
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Figure 5.5.7 Experimental design: effeet of active EIAd5-specific immunity on 
intraduodenal immunisation with recombinant adenovirus. In the flowchart, arrows 
above the timescale indicate the time of treatment while arrows below indicate the time 
of serum sampling. The symbol t represents tissue samples from euthanised animals. 
5.5.2.1 Antibody responses 
At the time of irnmunisation with gD-dE3, HA&-infected animals developed Ad- 
specific serum antibody responses similar to those in Figure 5.5.1 1, 2 weeks following 
HA&-infection. These animals did not develop gD-speci fic antibody responses (Fig. 5.5.8) 
or BHV-1 SN titres (background level of 0.3 loglo titre) following intraduodenal 
immunisation with gD-dE3. Intraduodenal immunisation with gD-dE3, however, induced 
@-specific IgG and I g A  titres in the serum, lung- and nasal-washes (Fig. 5.5.8) and 
BHV-1 SN titres (loglo titre 1.29 * 0.41 5, significantly different from background) in those 
animals that were not pre-infected with HAdS. Interestingly, the two immunisation groups 
had similar levels of Ad-specific lung IgG and serum IgA following immunisation with 
gD-dE3 (Fig. 5.5.9). Serum antibody responses including SN titres were almost identical 
following primary and secondary imrnunisations (data not shown). 
Both gD-specific (Figure 5.5.8) and Ad-specific (not shown) antibody levels in 
lung- and nasal-washes correlated with those measured in lung- and tracheal-exmcts 
prepared from the same animals, respectively. These observations confirmed that the two 
methods for assessing antibody levels in the respiratory tract are equally appropriate. 
To determine local immune responses in the gut, the frequency of gD- and Ad- 
specific ASC in the mesenteric LN was measured by ELISPOT. Interestingly, significant 
numbers of gD- and Ad-specific ASC in the mesenteric LN were detected in only those 
animals that were not infected with HAdS before immunisation with gD-dE3 (Table 5.5.1 ). 
These results are in accordance with ELISPOT data obtained from animals of the previous 
experiment (data shown here, in Table 5.5.1). The frequency of antigen-specific ASC in the 
spleens was not different between infected and non-infected groups (Table 5.5.1). 
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Figure 5.5.8 Effect of adenovirus-specific active immunity on the induction of gD- 
specific antibody responses following immunisation with gD-dE3 by the 
intraduodenal route. Cotton rats were inoculated i.n. with wt HAdS (+ symbol) or with 
PBS as controls (- symbol). Two and five weeks following infection the animals were 
immunised with gD-dE3 or with PBS as a control by the intraduodenal route. gD-specific 
(a) IgG and @) IgA levels in the nasal- and lung-washes and the serum at 6 weeks 
following the primary imrnunisation were measured by ELISA. Insets: (a) trachea-, lung- 
extract and serum IgG; (P) trachea-, lung-extract and serum IgA. Bars represent the mean 
logl antibody titre * SD for 6 animals/group. 
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Figure 5.5.9 Adenovirus-specific antibody responses in cotton rats immunised with 
gD-dE3 by the intraduodenal route following i.n. aAdS infection. Cotton rats were 
inoculated i.n. with wt HAd5 (+ symbol) or with PBS as controls (- symbol). Two and five 
weeks following infection the animals were immunised with gD-dE3 or with PBS as a 
control by the intraduodenal route. Ad-specific (a) IgG and @) IgA levels in the nasal- and 
lung-washes and the serum at 6 weeks following the primary immunisation were measured 
by ELISA. Bars represent the mean loglo antibody titre * SD for 6 animaldgroup. 
Table 5.5.1 Effect of active adenovirus-speciiic immunity on the frequency of 
gD- and adenovirus-specific antibody-secreting cells in lymphocytes of cotton rats 
immunised with recombinant adenovimses 
experiment immunisation gD-specific 1gGAg.A HAd5-specific IgGAgA 
~ ~ ~ l m i l l i o n '  ~ ~ ~ l r n i l l i o n *  
mes LN spleen mes LN spleen 
- - - 
5.5.1. -5.5.2. - ,  PBS nd I nd nd I nd nd I nd nd I nd 
Cotton rats were inoculated with wild type HAd5 (+ symbol) or with PBS as controls 
(- symbol) intranasally. 
' Two and three weeks after infection with HAd5 the animals were immunised with 
gD-dE3 by the gastrointestinal route (intraduodenal-oral). Three weeks after the 
primary imrnunisation animals were challenged with BHV-I intranasally. One day 
post-challenge mesenteric LN and spleen lymphocytes were isolated and used in the 
ELISPOT assays. 
Two and five weeks after infection with HAd5 cotton rats were immunised by the 
intraduodenal route with gD-dE3 or PBS as a control. Three weeks after the secondary 
irnrnunisation animals were challenged with BHV-1 intranasally. Three days post- 
challenge mesenteric LN and spleen lymphocytes were isolated and used in the 
ELISPOT assays. 
Mean values of the number of antigemspecific antibody-secreting cells (ASC) per 
million lymphocytes were determined in cultures of pooled cell populations from 4-8 
animals. 
nd = not detected (less than 1 ASC/million) 
n = not tested 
5.5 -2.2 Protection against BHV- 1 challenge 
Since KAdS infection affected antigen-specific immune responses, I investigated 
whether it affected protection of the respiratory tract against BHV-1 challenge. 
Significantly less BHV- I was isolated &om the lungs of animals that were not pre-immune 
to HAdS before gD-dE3 immunisation compared to those that were (Table 5.5.2). Virus 
titres in the trachea, however, were not decreased by either immunisation regimen 
compared to the control. 
Table 5.5.2 Effect of adenovirus-specific immunity on immunisation 
with gDdE3 as reflected in BHV-1 recovery following challenge 
immunisation virus isolation (loglo pWg tissue) 
trachea lung 
+ , gD-dE3 intraduodenal 2.942 -t 0.533 2.997 +_ 0.7 15 
- , gD-dE3 intraduodenal 2.756 +, 0.381 < 1 .O +_ 0.0 
- , PBS 2.494 + 0.275 4.06 1 + 0.430 
Cotton rats were inoculated intranasally with 2 x 10' pfb wt HAd5 (+ symbol) 
or with PBS as controls (- symbol). Two and five weeks later cotton rats were 
irnmunised with -3 or PBS as a control intraduodenally. Three weeks after 
the secondary immunisation animals were challenged with BHV- I intranasally. 
Three day post-challenge trachea and lung were removed, homogenised and 
tested for the presence of BHV- I by plaque assay. 
Significant difference from other groups (P < 0.00 1). 
5.5.3 Long-term effect of infection with HAd5 on intranasal immunisation with 
recombinant adenovirus 
The previous experiments have shown that active immunity to HAdS inhibited the 
efficacy of different routes of imrnunisation with gDdE3. It is possible, however, that by a 
later timepoint p.i. with HA&, some components of Ad-specific cellular or humoral 
immunity decline resulting in less inhibition of the induction of @-specific immunity by 
immunisation with gD-dE3. To test this hypothesis, cotton rats were infected with HAd5 
13 weeks before immunisation with gDdE3 (Fig. 5.5.10) and the effect of HAd5-infection 
on the level of immunity induced by recombinant adenovirus was assessed. 
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Figure 5.5.10 Experimental design: long-term effect of infection with EAd5 on 
intranasal immunisation with recombinant adenovirus. In the flowchart, mows 
above the timescale indicate the time of treatment while arrows below indicate the time 
of serum sampling. The symbol t represents tissue samples from euthanised animals. 
i.n. = intranasal 
5.5.3.1 Kinetics of adenovirus-specific serum antibody responses 
To determine the levels of Ad-specific serum antibody at 13 weeks compared to 
that at 2 weeks following in. infection with HA*, Ad-specific IgG and IgA titres in the 
s e m  were measured by ELISA. Ad-specific IgG titres continually increased during the 
study (Figure 5.5.11). IgA titres did not rise further following the eighth week of the 
experiment (Figure 5.5.1 1 ). Mean Ad-specific antibody titres were significantly higher at 
week 13 compared to those at week 2 pi. (P < 0.00 1). 
-+-  IgA 
Weeks postinfection 
Figure 5.5.11 Kinetics of adenovirus-specific serum antibody responses in cotton rats 
infected with wild type HAdS. Sera collected at different timepoints p.i. in. with 10' pfb 
of HAdS were analysed for Ad-specific (a) IgG and (b) IgA by ELISA. Values represent 
the mean loglo antibody titre * SD for 10 animals. 
5.5 -3 -2 Antibody responses following immunisation with gD-dE3 
Although immunisation with gD-dE3 induced @-specific IgG and I g A  antibodies 
in the serum, lung- and tracheal-extncts in both HAdS-infected and non-infected animals 
(significantly higher titres than the PBS control, P < 0.001), HAdS-infected animals 
developed significantly lower @-specific antibody than non-infected cotton rats (P < 
0.01). IgA levels in the trachea were not significantly different between the two 
immunisation groups (Figure 5.5.12). BHV-1 neutdising titres in the serum were also 
lower in the HAdS-infected group than in the non-idkcted group (P c 0.001); (Figure 
5.5.12). As expected, imrnunisation with dE3 control virus did not induce any gD-specific 
antibody (data not shown). In contrast to gD-specific humoral responses, all animals 
immunised with adenovirus developed similar levels of Ad-specific antibody by week 1 9 
(data not shown). 
5.5.3.3 Antibody-secreting cell frequencies 
To determine whether the frequencies of gD- and Ad-specific ASC were affected 
by a previous HAd5 infection, ELISPOT assays were performed. Although immunisation 
with gD-dE3 induced antigen-specific ASC in the lung, bone marrow and spleen of both 
HAdS-infected and non-infected animals, @-specific ASC frequencies in the lung were 
higher in the non-infected compared to the HA&-infected group (Table 5.5.3). 
.4denovirus-specific ASC frequencies were similar or higher in the HA&-preinfected 
group compared to other groups. 
trachea 
lung 
EZBI serum 
m 
- S  PBS 
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Figure 5.5.12 Effect of adenovirus-specific active immunity stimulated 13 weeks 
earlier on the induction of gDspecfic antibody responses. Cotton rats were inoculated 
with wt HAdS (+ symbol) or PBS as a control (- symbol) hiranasally. Thirteen and sixteen 
weeks following infection the animals were immunised in. with gD-dE3 or with PBS as a 
control. @specific (a) IgG and @) IgA levels in the trachea- and lung-extracts and the 
serum at 6 weeks following the primary immunisation with gD-dE3 were measured by 
ELISA. (c) Serum samples collected at 6 weeks following primary immunisation with 
gD-dE3 were anal ysed for BHV- l -neutralking antibodies by virus neutralisation assay. 
Bars represent the mean logl antibody titre * SD for 5-8 animals/group. 
Table 5-53 Effect of active adenovirus-specific immunity on the frequency of 
gD- and adenovirus-specific antibody-secreting cells in lymphocytes of cotton rats 
immunised with recombinant adenoviruses 
lymphocyte immunisation @-specific adenovirus-specific 
source  million*  mil million' 
lung + , gD-dE3 4 26 280 4600 
- , gD-dE3 20.5 186 100 1940 
- , dE3 not tested 
- , PBS nd nd nd nd 
bone + , gD-dE3 nd 1.3 30 4 1 
marrow 
- , gD-dE3 nd 2 4.5 18 
- , PBS nd nd nd I 
- - 
spleen + , gD-dE3 1.7 nd 8 20 
- , gD-dE3 1 1.7 14 9 
- , dE3 nd nd 14 1 1.5 
- , PBS nd nd nd nd 
Cotton rats were inoculated with wild type HAd5 (+ symbol) or with PBS as a 
control (- symbol) intranasally. Thirteen and sixteen weeks later the animals were 
irnmunised i.n. with gD-dE3 or with PBS. Three weeks after the secondary 
immunisation animals were challenged with BHV-1 intranasally. One day post- 
challenge lung, bone marrow and spleen lymphocytes were isolated and used in the 
ELISPOT assays. 
' Mean values of the number of antigen-specific antibody-secreting cells (ASC) 
per million lymphocytes were determined in cultures of pooled cell populations 
from 3-8 animals. 
nd = not detected (less than 1 ASC/million) 
5.5.3.4 B HV- 1 recovery after challenge 
Since antigen-specific immune responses induced by immunisation with gD-dE3 
were affected by a previous i.n. HA# infection, we investigated whether protection of the 
respiratory tract against BHV-1 challenge was different between the immunisation groups. 
Table 5.5.4 shows that hunisat ion with gD-dE3 significantly reduced BHV-1 titres in 
the lung compared to the dE3 and PBS controls. Infection with HAd5 before immunisation 
with gD-dE3, however, resulted in significantly more BHV-1 in the lungs compared to 
those in animals irnmunised with gD-dE3 alone. In addition, virus titres in the trachea were 
lower compared to the controls only in those animals that had not received HAd5 infection 
before gD-dE3 immunisation (P < 0.00 1); (Table 5.5.4). 
Table 5.5.4 Effect of adenovirus-specific immunity on immunisation with 
recombinant adenovirus as reflected in BW-1 recovery following challenge 
irnmunisation virus isolation (loglo pfdg  tissue) 
trachea lung 
+ , gDE3 intranasal 
- , gDE3 intranasal 
- , dE3 
- , PBS 
Conon rats were inoculated with wt HAdS (+ symbol) or PBS (- symbol). Thirteen 
and sixteen weeks later the animals were imrnunised intramsally with gD-dE3, dE3 
or with PBS. Three weeks after the secondary irnmunisation animals were 
challenged with BHV- 1 iatranasally. One day postchallenge trachea and lung were 
removed, homogenised and tested for the presence of BHV- 1 by plaque assay. 
Significant difference from other groups (P < 0.001) 
5.5.4 Effect of adenovirus-specific passive immunity on systemic and rnucosal 
immunisation with recombinant adenovinrs 
Previous results showed that i.n. iafection with HA& had an inhibitory effect on 
@-specific humoral immune responses and protection against BHV- 1 infection induced by 
imrnunisation with gD-dE3. Infection with a pathogen, however, is not the only way to 
acquire immunity to the pathogen. Young animals, for example, may have obtained Ad- 
specific antibodies from their mother without having been infected with adenovirus. To 
investigate the effect of passive Ad-specific immunity on subsequent immunisation with 
recombinant adenovirus by different routes, serum-mfer experiments were designed. In 
the first experiment, cotton rats were inoculated with Ad-hyperimmune or normal cotton 
rat senun i.p., followed by i.n. and i.p. immunisation with gD-dE3 (Fig. 5.5.13). Induction 
of antigen-specific immune responses and protection against BHV- 1 challenge were 
determined. 
5.5.4.1 Haiflife of adenovirus-specific antibodies following passive transfer 
Before imrnunisation with gD-dE3, it was important to examine whether cotton rats 
contained Ad-specific antibody following i.p. passive transfer of Ad-specific hyperimmune 
serum. Furthermore, knowing the kinetics of the decay of this antibody would help 
interpret results and facilitate future studies. Figure 5.5.14 shows Ad-specific IgG and IgA 
titres in the serum at different timepoints after inoculation of Ad-specific hyperimmune 
senun. At day 1 after the passive transfer, both IgG and IgA, specific for HAdS, were 
detected in the serum. These titres were higher than those detected in the serum of cotton 
rats 2 weeks following i.n. infection with HA& (see 5.5.3.1). The halflife of both serum 
IgG and IgA of the cotton rat was estimated to be 6-7 days. 
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Figure 5.5.13 Experimental design: effeet of adenovirus-specific passive immunity 
on the efficacy of immunisation with recombinant adenovirus. In the flowchart, 
arrows above the timescale indicate the time of treatment while arrows beiow indicate 
the time of serum sampling. The symbol f- represents tissue samples from euthanised 
animals. 
i.n. = intranasal; i.p. = intraperitoneal. 
* Transfer of adenovirus-specific hyperimmune cotton rat serum. 
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Figure 5.5.14 Kinetics of the decay of adenovirus-specific antibodies in the serum of 
cotton rats following passive transfer of adenovirus-specific serum. Two animals were 
i.p. injected with 1 ml of pooled Ad-specific hyperimmune serum. Adenovirus-specific 
serum anti body levels at different timepoints following passive transfer were measured by 
ELISA. Values represent the mean titre from 2 animals. 
5.5 -4.2 Antibody responses following imrnunisation with gD-dE3 
To determine whether the presence of Ad-specific antibodies in the cotton rat 
affected the levels of gD-specific antibody responses induced by immunisation with gD- 
dE3, antigen-specific antibody titres in the senun, trachea- and lung-extracts were 
measured. Each immunisation regimen resulted in gD- and Ad-specific antibodies in the 
senun and the lung-extract, as well as BHV-I SN antibodies, of significantly different 
mean titres fiom PBS controls (Table 5.5.5). Serum neutmlising antibody titres and gD- 
specific IgG levels, however, were significantly higher in those animals that had received 
control serum compared to those that had been injected with Ad-immune serum before the 
i.n. immunisation with gD-dE3. In addition, there was a trend in all other samples that Ad- 
specific antibody inhibited the induction of @-specific immunity, even though these 
differences were not significantly different (Table 5 -5 -5). 
5.5.4.3 BHV- I recovery following challenge 
Since the presence of Ad-specific antibodies in the cotton rat slightly affected gD- 
specific immune responses, I investigated whether it affected protection of the respiratory 
tract against BHV- 1 challenge. BHV- I titres in both the lung and trachea were significantly 
lower in those i-p. immunised animals that were naive for adenovirus compared to those 
that had received Ad-specific senun (P < 0.0 1) (Figure 55-15), In addition, BHV- 1 titres in 
the trachea were significantly lower in those i.n. immunised cotton rats that had been 
injected with control serum compared to those with Ad-specific senun (P < 0.01); (Figure 
5.5.15). However, mean virus titres from the lungs were lower in each immunisation group 
than in the PBS control. In addition, the mean BHV-1 titre in the trachea was significantly 
lower in animals immunised intranasdly with gD-dE3 than in the PBS control (P < 0.05). 
Table 5.5.5 Effect of adenovirus-specific passive immunity on antigen-specific 
antibody titres from cotton rats immunised with gD-dE3 
sample immuni gD-speci fic logl adenovirus-specific logl BHV- I 
-sation ELISA titre f SD ELISA titre loglo SN 
serum + , i.p. 3.3 k 0- 17 0.76 t 0.4 3.2 * 0.0 1.8 f 0.18 0.6 + 0.0 
+ , i.n. 2.9 k 0.3* 1.33 + 0.9 3.5 + 0.0 1.69 2 0.0 0.6 + O.O* 
-, i.p. 3.8 k 0.8 1.235 0.8 3.4 f 0.17 1.83 2 1.15 1.2 + 0.5 
- , 1.n. 3.8 t, 0.52* 1.76 f 0.7 3.6 + 0.17 2.2 + 0.17 1.2 f 0.3* 
- , PBS 1.0 + 0.0 0.3 + 0.0 1.0 + 0.0 0.3 -t- 0.0 0.3 t 0.0 
lung + , i.p. 1.5k0.17 0.9-t-0.17 1.83k0.23 1.7 +_ 0.0 0.3 * 0.0 
extract + , i.n. 1.39 -t 0.0 1.46 f 0.4 2.2 2 0.17 1.7 + 0.0 0.3 k 0.0 
- , i.p. 1.7k0.35 1.13k0.5 2.3 f 0.55 1.23 -t 0.4 0.3 + 0.0 
- , 1.n. 2.0 + 0.57 2.16 k 0.4 2.86 .t 0.4 3.13 k 0.63 0.3 f 0.0 
- , PBS 0.3 k 0.0 0.3 k 0.0 0.3 k 0.0 0.3 f 0.0 0.3 + 0.0 
trachea + , i .p. 0.3 k 0.0 0.3 + 0.0 0.8 k 0.55 1.0 k 0.7 0.3 t 0.0 
extract + , i.n. 0.3 + 0.0 0.3 k 0.0 1.0 + 0.0 0.77 t 0.8 0.3 k 0.0 
- , p 0.67 k 0.3 0.3 k 0.0 1.36 + 0.35 0.77 f 0.4 0.3 k 0.0 
- , 1.n. 0.77 + 0.4 0.3 k 0.0 1.5 k 0.17 1.6 + 0.17 0.3 2 0.0 
- , PBS 0.3 k 0.0 0.3 + 0.0 0.3 + 0.0 0.3 + 0.0 0.3 + 0.0 
Cotton rats were inoculated with hyperimmune adenovirus-specific (+ symbol) or 
normal (- symbol) cotton rat serum. One day later the animals were immunised with gD- 
dE3 intranasally (i.n.) or intraperitoneally (i.p.) or with PBS as a control. Three weeks 
after immunisation animals were challenged with BHV-1 intranasally. One day post- 
challenge trachea and lung were removed, homogenised and tested for the presence of 
antigen-specific antibody simultaneously with serum samples by ELISA or serum 
neutralisation assay. 
* Significant difference between the two groups (P < 0.05) 
trachea 
rn lung 
T 
+, imp. +, i.n. -, 1.p. -, 1.n. . -, PBS 
Figure 5.5.15 Effect of adenovirus-specific passive immunity on the protection of 
cotton rats imrnunised with gD-dE3 against B W - 1  infection. Cotton rats were 
inoculated intraperitoneally with Ad-specific (+ symbol) or normal (- symbol) cotton rat 
serum. Twenty-four hours later cotton rats were irnrnunised by the i.n. or the i.p. routes 
with gD-dE3 or with PBS as a control. Three weeks after irnmunisation with gD-dE3 
animals were challenged with BHV-1 intranasally. One day postchallenge lungs and 
tracheae were homogenised and analysed for the presence of BHV-1 by plaque assay. Bars 
represent the mean loglo antibody titre * SD for 3 animals per group. 
*Significantly different fiom PBS controls (P < 0.001) 
5.5.5 Effect of adenovirus-specific passive immunity on different routes of 
mucosal immunisation with recombinant adenovirus 
Results of the previous experiment indicated that pre-existing Ad-specific passive 
immunity inhibited @-specific immune responses induced by irnmunisation with gD-dE3 
in some animals. Furthermore, there was iess protection against BHV-1 infection in 
Ad-immune compared to naive animals. To confirm these results and to determine whether 
the route of immunisation influenced the level of @-specific immunity in animals with 
passive immunity to Ad, cotton rats were imrnunised with gD-dE3 by the i.n. and the 
intraduodenal routes following passive transfer of Ad-specific or normal cotton rat senun 
(Figure 55-16). Induction of antigen-specific immune responses and protection against 
BHV- 1 challenge were determined. 
5.5.5.1 Antibody responses 
Interestingly, no statistical differences were observed 3 weeks following 
immunisation with gD-dE3 between the means of gD-specific antibody titres from animals 
that had received normal cotton rat serum before immunisation compared to those that 
received Adspecific serum (Figure 5.5.1 7). Intranasal irnmunisation with gD-dE3 in both 
groups induced gD-specific IgG and IgA in the serum and lung-washes and IgA in the 
nasal-washes. However, there was a trend that animals that recieved Ad-specific 
hyperimmune sera had less @-specific antibodies. Intraduodenal irnmunisation also 
induced gD-specific serum IgG but it did not stimulate IgA in any of the samples. 
Adenovirus-specific antibodies were detected in each gD-dE3-immunised group. However, 
the mean Ad-specific titres were higher in the samples from intramsally immunised 
animals (Figure 5.5.18). 
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2 5 ad-spec* gD-dE3 5 x 1 o7 Lduod. 
3 5 normal gD-dE3 5 x lo7 i.n. - 
4 5 normal gD-dE3 5 x lo7 i.duod. - 
5 4 normal PBS - i.n. .. 
rats Per 
group 
Figure 5.5.16 Experimental design: effect of adenovirus-specific passive immunity 
on different routes of mucosal immunisation with recombinant adenovirus. In the 
flowchart, arrows above the timescale indicate the time of treatment while arrows below 
indicate the time of serum sampling. The symbol t represents tissue samples collected 
from euthanised animals. 
i.n. = intranasal; i.duod. = intraduodenal; i.p. = intraperitoneal. 
* Transfer of adenovirus-specific hyperimmune cotton rat serum. 
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Figure 5.5.17 Effect of adenovirus-specific passive immunity on the induction of g D  
specific antibody responses in cotton rats immunised with gIME3 by different 
mucosal routes. Cotton rats were inoculated intraperitoneally with Ad-specific (+ symbol) 
or normal (- symbol) cotton rat serum. Twenty four hours later cotton rats were imrnunised 
with gD-dE3 by the inhanasal (i.n.) or the intraduodenal (i.duod.) routes or with PBS as a 
control. @-specific (a) IgG and (b) IgA levels in the nasal- and lung-washes and the serum 
at 3 weeks following immunisation with gD-dE3 were measured by ELISA. Bars represent 
the mean logl antibody titre * SD for 4-5 anirnals/group. 
'' i (a) 
7 
nasal wash 
lung wash 
+,i.n. +,duod -,i.n. -, duod -, PBS 
Figure 5.5.18 Adenovirus-specific antibody responses in cotton rats immunised with 
recombinant adenovirus by the intraduodenal route following passive transfer of 
adenovims-specific serum. Cotton rats were inoculated intraperitoneally with Ad-specific 
(+ symbol) or normal (- symbol) cotton rat serum. Twenty four hours later the animals 
were immunised with gD-dE3 by the intranasal (i.n.) or the intraduodenal (i.duod.) routes 
or with PBS as a control. Adenovirus-specific (a) IgG and (b) IgA levels in the nasal- and 
lung-washes and the serum at 3 weeks following imrnunisation with gD-dE3 were 
measured by ELISA. Bars represent the mean loglo antibody titre * SD for 4-5 
anirnals/group. 
5.5.5 -2 Antibody-secreting cell frequencies 
To determine whether the frequency of antigen-specific ASC in the lung and the 
spleen were affected by passive immunity against adenovirus, ELISPOT assays were 
performed. Each immunisation regimen induced gD- and Ad-specific lung-ASC while the 
PBS control did not (Table 5.5.6). Intraduodenal irnmunisation induced only IgA secreting, 
but not IgG secreting cells in the lung. In contrast, i.n. immunisation induced high numbers 
of both IgA and IgG gD- and Ad-specific ASC in the lung. These numbers were somewhat 
lower in the Ad-specific serum-transfer groups than in the normal imrnunised groups. 
Spleens contained only a low Frequency of antigemspecific ASC (Table 5.5.6). 
5.5 25.3 BHV- 1 recovery after challenge 
To determine whether Ad-specific passive immunity influenced the protection of 
the respiratory tract against BHV- 1 infection, BHV- I titres were measured in the lung and 
trachea I day after viral challenge. htranasal immunisation with gD-dE3 resulted in 
reduced B W -  I titres from the respiratory tract compared to the PBS control (P < 0.0 l), 
while intraduodend immunisation did not (Fig. 5.5.19). Interestingly, animals inoculated 
with Ad-specific serum contained significantly higher BHV-I titres in their lungs than 
animais that received normal cotton rat senun before i.n. immunisation with gD-dE3 (P < 
0.05), despite no significant differences in @-specific and BHV- 1 SN antibody levels (Fig. 
5.5.17). 
Table 5.5.6. Effect of passive adenovirus-specific immunity on the frequency 
of gD- and adenovirus-spedfic antibody-secreting cells in lymphocytes of 
cotton rats hmunised with recombinant adenoviruses 
lymphocyte immunisation @-specific adenovirus-specific 
source ~ ~ ~ / r n i l l i o n '  ~ ~ ~ / r n i l l i o n *  
l u g  + , gD-dE3 i.n. 200 900 3 70 1050 
+ , gD-dE3 i-duod nd 2.5 nd 6 
- , gD-dE3 i.n. 510 1250 360 460 
- , gD-dE3 Lduod. nd 20 nd 25 
- , PBS c. nd nd nd nd 
spleen + , gD-dE3 i n .  1.5 nd 10 8.3 
+ , gD-dE3 i.duod 1 nd 1.2 nd 
- , gD-dE3 i.n. 1 nd 22 4.8 
- , gD-dE3 i-duod. nd nd nd nd 
- , PBS c. nd nd nd nd 
Cotton rats were inoculated intraperitoneally with hyperimmune Ad-specific (+ 
symbol) or normal (- symbol) cotton rat serum. One day later the animals were 
immunised with gD-dE3 intranasall y (i.n.) or intraduodenally (i.duod.) or with PBS 
as a control. Three weeks after immunisation the animals were challenged with 
BHV- I intranasally. One day post-challenge lung and spleen lymphocytes were 
isolated and used in the ELISPOT assays. 
Mean values of the number of antigen-specific antibody-secreting cells (ASC) 
per million lymphocytes were determined in cultures of pooled cell populations 
from 4-5 animalslgroup. 
nd = not detected (less than 1 ASC/million) 
trachea 
Figure 5.5.19 Effect of adenovirus-specific passive immunity on the protection 
against BHV-1 infection in cotton rats immunised with recombinant adenovirus. 
Cotton rats were inoculated intraperitoneally with adenovirus-specific (+ symbol) or 
normal (- symbol) cotton rat serum. Twenty four hours later the animals were immunised 
with gD-dE3 by the intnmasal (i.n.) or the intraduodenal (Lduod.) routes or with PBS as a 
control. Three weeks after imrnunisation with gD-dE3 animals were challenged with BHV- 
1 intranasally. One day post-challenge lungs and tracheae were homogenised and tested for 
the presence of BHV-1 by plaque assay. Bars represent the mean loglo antibody titre * SD 
for 4-5 animals per group. 
5.5.6 Conclusions 
Results indicate that immunity to adenovirus may inhibit @-specific antibody 
responses induced by subsequent immunisation with gD-dE3. Pre-infection with HAd5 i.n. 
negatively affected the efficacy of i.n. imrnunisation not only at 2 weeks, but also at 13 
weeks after HAd5 infection. At 13 weeks following infection, however, this inhibitory 
effect was smaller than at 2 weeks after HAd5-infection. Inhibition of gD-specific antibody 
responses and protection against BHV- 1 challenge was also observed after intraduodenal- 
oral and intraduodenal immunisahons following HAdS-infection. 
In contrast to active immunity, passively acquired Ad-specific antibody had little 
inhibitory effect on the level of immune responses induced by irnmunisations with gD-dE3 
by different routes. Interestingly, however, protection against BHV- 1 challenge was 
significantly inhibited by passive transfer of Ad-specific antibody. 
Results also indicate that even one i.n. immunisation with gD-dE3 induced gD- 
specific antibody responses in the respiratory tract and partial protection against i.n. BHV- 1 
challenge. Furthermore, intraduodenal immunisation alone was able to induce gD-specific 
immunity in the serum and the respiratory tract. 
6.0 DISCUSSION 
6.1 Establishment of an intranasal B E N 4  challenge model in cotton rats 
Cotton rats provide an excellent model for investigating immune responses induced 
by recombinant HA& vectors because they support HAd5 replication. However, to 
evaluate the protective efficacy of immunisation with recombinant HA& expressing gD of 
B W -  I ,  an animal model that supports BHV- 1 replication is necessary. Since cotton rats 
have served as a rodent model for many viral pathogens, there was a probability that they 
could also support BHV- I replication. 
BHV- I replicated in the respiratory tract of cotton rats without requiring prior 
adaptation of the virus. The histological lesions seen in the lung of each rat, namely 
necrotising bronchiolitis with the presence of intmnuclear inclusion bodies in epithelial 
cells, were consistent with lesions observed following BHV- I infection in cattle (Jericho & 
Darcel, 1978). Pulmonary lesions in cattle are highly variable and inconsistently present, 
both in natural and experimental infections (Yates, 1982). In the cotton rats, 
irnmunohistochernical staining confirmed that BHV-1 became established in the lung and 
was the cause of the pathological changes as specific viral staining was demonstrated in the 
lesions in the terminal bronchioles and alveoli. The normal behaviour and absence of 
clinical signs in the corton rats indicated that while BHV-1 became established and could 
replicate within the respiratory tract, the infection was mild and subclinical. Nevertheless, 
the fact that BHV-1 infection in cotton rats mimics the disease in cattle in terns of 
pathology suggests that this may be a valid laboratory animal model for use in development 
and evaluation of new vaccination strategies against BHV-1. 
I have not investigated whether in vivo passage of BHV-1 in cotton rats would 
increase BHV-1 infectivity in these animals. I have shown, however, that different BHV-1 
strains have slightly different capabilities to replicate in cotton rats. The 108 strain 
replicated better than the Cooper strain in both CRL cells and in cotton rats. Lesion 
development was greater, viral antigen was more widespread and higher titres of BHV-1 
were evident in the lungs of animals challenged with the 108 strain than with the Cooper 
strain. The more virulent nature of the 108 strain as compared to the Cooper strain in cattle 
has been previously suggested (unpublished observation), further supporting the similarity 
of the cotton rat model to bovine disease. Considering the observed differences between 
the two strains, I used the 108 strain in most of the challenge experiments. 
Since vaccination-challenge studies are very expensive in cattle, a useful model for 
i.n. BHV-I infection was established by determining that BHV-I can replicate in cotton 
rats. Furthermore, since no other laboratory rodent has been shown to support the 
replication of both HAd5 and BHV-I, the cotton rat became the most appropriate small 
animal model for comparing replication-defective and the replication-competent vectors 
regarding their effectiveness in inducing immunity to gD and conferring protection against 
BHV- 1 challenge. 
6.2 Immunity induced by recombinant adenoviruses in cotton rats 
Immunisation of cotton rats with recombinant adenoviruses induced protective 
immune responses against i.n. BHV-I challenge. Protection of the lung from infection 
measured by BHV-I recovery correlated with the absence of BHV-1 replication in situ 
(Table 5.3.7), which provided evidence that measuring BHV-1 titres in the lung is a 
satisfactory method to assess protection from infection. The level of gD-specific immune 
responses and protection from BHV- 1 challenge were dependent, however, on the type of 
foreign gene expressed by the vectors, the replication-capability of the viruses and the route 
of irnrnunisation. These differences and the possible mechanisms involved are discussed 
below. 
6.2.1 Immunity induced by tgD- and gD-expressing recombinant adenoviruses 
Expression of the foreign gene is a prerequisite for the development of an antigen- 
specific immune response. Therefore, before immunising cotton rats, I tested the ability of 
recombinant adenoviruses to express gD or tgD in CRL cells in vib-o. All vectors expressed 
the appropriate foreign gene. The total production of gD was higher, however, than that of 
tgD by 3 days pi. (Fig. 5.2.3.). Furthennore, the majority of gD was cell associated, while 
tgD was found in similar amounts in the culture-supernatant and in the cell pellet (Fig. 
5.2.1-3). Glycoprotein D has been known to be abundant in membrane compartments of 
cells it is expressed by (van Drunen Littel-van den Hurk et al., 1990, van Drunen Littel-van 
den Hurk et a[., 1984) while tgD is efficiently secreted into the medium (Kowalski et al., 
1993). The more efficient accumulation of gD in cells was expected since authentic gD 
contains a trammembrane anchor region while tgD does not. Finally, infection with tgD- 
expressing adenoviruses caused less cytopathic changes than @-expressing adenoviruses 
in CRL cells. This could be the reflection of the toxic nature of gD described before (Tikoo 
ef nl., 1 990). 
To determine whether differences between tgD- and gD-expressing vectors 
observed in vitro influenced @-specific irnmune responses and protection against BHV- 1 
challenge in vivo, cotton rats were imrnunised with recombinant adenoviruses and then 
challenged with BHV- I . @-specific antibody levels, spleen cell proliferative responses 
and protection against BHV-1 challenge were lower in animals imrnunised with tgD- than 
@-expressing vectors (Fig. 5.3.2-8). These results may simply be explained by lower 
levels of expression of tgD than gD following immunisation, suggested by in vim data 
(Fig. 5.2.3). Such an explanation is plausible since a high dose of subunit gD vaccine 
induced higher levels of antigen-specific immune responses than a low dose of gD (Baca- 
Estrada et al., 1996). However, the actual amount of gD expressed in vivo following 
immunisation with live vectors is not known. It is possible that the cumulative production 
of tgD (Fig. 5.2.3) resulted in similar total amounts of tgD as gD in the cotton rat. 
Furthermore, several observations and published data suggest that the antigen-dose is not 
the only explanation for the lower immunogenecity of secreted molecules compared to cell- 
associated proteins. There are examples in the literature demonstrating that the cellular 
localisation of an antigen - whether it is retained intracellularly, expressed on the surtace 
of cells or secreted into the medium - influenced its immunogenicity. Cell surface 
anchoring increased the level of immune responses induced by VP7 of rotavirus compared 
to those stimulated by a genetically engineered secreted form of the protein, or the 
authentic form, which is retained in the endoplasrnic reticulum (Andrew et al., 1990). Cell 
surface expression of a dengue virus and a bovine leukaemia virus (BLV) envelope protein 
resulted in enhanced irnmunogenicity of the protein compared to the authentic form which 
is retained iotracellularly (Gatei et al., 1993, Men et al., 199 1 ). In addition, a cell surface- 
anchored and a secreted protein may stimulate different levels of antigen-specific antibody 
isotypes and cytokines (Cardoso et al., 1996, Inchaupse et a!., 1997). Immunisation of mice 
with recombinant adenoviruses expressing gD induced higher @-specific IgGZa and I M - y  
production than immunisation with vectors expressing tgD. In contrast, vaccination with 
both recombinants induced similar levels of gD-specific IgGl (Papp et al., manuscript in 
preparation). Lewis et al. (1997) obtained similar results following immunisation with 
poiynucleotides. In this case, i.m. inoculation of plasmids encoding gD induced 
predominantly IgG2a isotype responses, while plasmids encoding tgD stimulated mainly 
IgGl antibodies. This reference is especially noteworthy since the level of expression of 
tgD was equivalent to that of gD following in v i m  transfection of mouse cells (Jeffrey 
Lewis, personal communication). However, the most clear evidence against the exclusive 
influence of the dose of the antigen on the level of immune responses was obtained by 
imrnunisation of mice with purified gD and tgD proteins. Hundred times as much tgD 
induced similar levels of @-specific IgG and BHV-1 neutralising serum Ab responses as 
gD (Baca-Estrada et al., 1996). In vivo results described in this thesis and the above 
references are also in accordance with in vitro experimental data showing that purified tgD 
is less efficient than gD in stimulating proliferative responses of spleen cells from gD- or 
tgD-immunised mice or cattle (Baca-Estrada et aL, 1996, Tikoo et a!., 1995b). These 
results suggest that not only the amount, but also the characteristics of the protein may 
affect immune responses to an antigen. Authentic gD can, perhaps, induce higher antibody 
levels than tgD because extracellular @-aggregates or gD accumulated in cell membranes 
might form repeated B-cell epitopes which could trigger T-cell independent B-cell 
responses. Particulate antigens and highly organised viral envelope structures bearing 
repeated B cell epitopes, indeed, are more likely to stimulate efficient B cell responses than 
soluble antigens (Bachmann & Zinkernagel, 1996). Alternatively, gD's capability to form 
dirners and to concentrate in cell membranes may make it more accessible for professional 
APC such as dendritic cells. The more efficient uptake of gD than that of tgD by these 
APC may lead to more efficient presentation and processing, and subsequently higher 
levels of immune responses induced by gD than tgD. Better presentation of professional 
APC might also lead to stronger Thl type responses, often characterised by the 
predominance of IgG2a and IFN-y, and better protection than presentation by mainly B 
cells (Rossi-Bergmann el al., 1993). There is evidence that IgGZa provides better 
protection against viral challenge than the presence of other isotypes (Ishizaka et al., 1995). 
Furthermore, live respiratory tract virus infections usually induce strong IgG2a and IFN-y 
levels, which correlate with protection against a second viral challenge (Zinkemagel, 
1993). 
Inflammation is often necessary for the induction of immune responses. The need 
for adjuvants in most protein based vaccines can also be explained by the capability of the 
adjuvant to induce an inflammatory response. Since gD-expression resulted in a stronger 
cytopathic effect than tgD-expression (section 5.2.2), it is possible that gD-expression 
caused stronger inflammation than tgD-expression at the site of inoculation. The potential 
of gD to elicit strong inflammation and to be presented effectively by professional APC 
may explain why irnrnunisation with recombinant adenoviruses expressing gD induced 
better antigen-specific immune responses than immunisation with adenoviruses expressing 
tgD. The above information and data in the literature suggest that gD may be a more 
suitable vaccine antigen than tgD following administration by a delivery system based on 
the in vivo expression of antigen, such as Ad vectors and DNA immunisation. 
6.2.2 Immunity induced by replication-defective and replication-competent 
recombinant adenoviruses 
Replication-defective and replication-competent adenoviruses were both 
efficacious, following id.-i.n. immunisation, in inducing immunity to gD and conferring 
protection against BHV-1 challenge (Fig. 5.3.4). The gD-dE3 vector was more efficient, 
however, than gD-dEIE3 in stimulating @-specific ASC in the spleen than gD-dE1E3 
(Fig. 5.3 S). The difference between the capacity of replication-defective and replication- 
competent adenoviruses to induce gD-speci fic immunity was further demonstrated 
following mucosal administration. The gDdE3 virus was more effective than gD-dE 1 E3 in 
inducing systemic and mucosal antibody responses following mucosal immunisation alone 
(Figures 5.3.1 1 - 12). 
The dose of adenoviruses used in my studies (1 0' to 1 0' pfu/animal) was based on 
information in the literature. It is possible that mucosal administration of a higher dose of 
gD-dE 1 E3 could induce comparable immune responses to those induced by a Low dose of 
gDdE3. Data in the literature indicate, however, that replication-defective and replication- 
competent adenoviruses usually induce different levels of immunity or protection, 
especially following mucosal administration. For example, although im. immunisation 
with both dE3 and dE 1 E3 vectors expressing gD of pseudorabies virus (PRV) could induce 
antibody responses against gD of PRV (Eloit & Adam, 1995), protection against viral 
challenge required irnmunisation with a hundred times as much dE 1 E3 as dE3 (Eloit & 
Adam, 1995). Moreover, oral administration of a dE3 vector expressing a rabies 
glycoprotein induced immunity to rabies glycoprotein while dE 1 E3 virus did not (Prevec et 
al., 1990, Xiang et al., 1996). Intranasal immunisation with a dE 1 E3 vector induced few 
antigen-specific C D ~ +  T cells and low s e m  antibody responses, while i.m. or S.C. 
immunisation induced strong immune responses (Rodrigues et aL. 1997). In general, 
replication-defective dElE3 vectors have rarely been reported to be effective following 
rnucosal adrninistration, while such references are plentiful using replication-competent 
dE3 vectors (Table 2.1). All these data in the literature are consistent with my findings, and 
indicate that the route of immunisation is crucial when assessing the efficacy of 
recombinant adenoviruses as vaccine vectors. 
There are several possibilities as to why systemic, but not mucosal immunisation 
with the replicationdefective vectors induced high levels of @-specific antibody 
responses. First, systemic spread of Ad vectors may have been necessary for the induction 
of efficient @-expression and induction of gD-specific immunity. In this case, only low 
@-specific immunity could have developed following irnmunisation with gD-dE I E3 
because the mucosal barrier would limit the systemic spread of the non-replicating vector. 
In contrast, a replicationcompetent Ad may disseminate equally well following mucosal 
and systemic immunisation due to replication. Indeed, replication-competent dE3 Ad has 
been isolated from more organs than replication-defective dElE3 Ad following i n  
administration to cotton rats (Oualikene et al., 1994). According to other data, however, the 
dE I E3 vector expressed foreign genes very efficiently in different tissues following 
mucosal administration @-hard et al., 1995). Information in the literature about the 
capability of replicationdefective Ad to disseminate systemically is controversial and 
seems to be a function of the route and dose of Ad inoculation, detection assays and animal 
model. Moreover, information regarding the spread of adenoviruses following i.d. 
administration has not been reported. My data indicate that the dissemination of both 
gD-dE3 and gD-dE 1 E3 is similar following i.d., i.n. and intraduodenal inoculation (Table 
5.4.1 .-3.). In addition, the two vectors stimulated similar Ad-specific immune responses 
following both systemic and mucosal administration (data not shown) suggesting that both 
vectors were accessible to all compartments of the immune system. Nevertheless, it is 
possible that gD4.E lE3 induced better immunity following systemic than mucosal 
administration because it may have more easily accessed tissues in which it could express 
gD effectively after systemic immunisation. 
Alternatively, the dE3 virus may have caused more severe inflammation in the 
mucosa than the dEIE3 vector (more severe cytopathic changes in vitro; section 5.2.2). 
This could result in stronger signals for an immune response to develop or a more effective 
uptake of gD by APC in the mucosa or the draining LN-s due to higher cellular infiltration. 
Indeed, exposure of the mucosa to non-inflammatory doses or type of antigen, such as 
soluble antigens and inactivated viruses, often fails to induce immune responses (Lipscomb 
et a/., 1995)- while live replicating pathogens usually stimulate both mucosal and systemic 
immunity following mucosal administration (Ogra, 1996). The systemic immune system 
may be less able to distinguish between harmless antigens and potentially dangerous 
sources of antigen and may respond to weaker immunostimulatory signals as well. For 
example, systemic immunisation with either killed or replicating particulate antigens often 
induces good immune responses (Momson & Knipe, 1996). Therefore, systemic 
immunisation with gD-dE lE3 may have been able to induce better immunity than mucosal 
immunisation. 
Another possibility is that the replicationdefective gD-dE 1 E3 adenovirus might 
not had a chance to express enough g D  in vivo in the mucosa to induce @-specific 
immunity. This may be because the natural early clearance of Ad is very effective (Worgall 
et al., 1997) and the expression of gD is driven by a late promoter. A more invasive 
infection by gD-dE3, due to replication, could have overcome the fast clearance 
mechanisms because it probably resulted in increasing number of cells expressing gD. This 
could result in a higher amount of gD available for uptake by APC in the MALT and the 
draining LN following mucosal infection. Furthermore, the ability of gD-dE3 to produce 
higher amounts of gD during the first day pi.  than the gD-dE lE3 virus (Fig. 5.2.1. 5.2.2, 
5.2.3) may have resulted in very different kinetics of gD-expression in vivo by gD-dE3 and 
gD-dE 1 E3. Consequently, higher levels of gD-specific antibody responses would be 
induced by gD-dE3 compared to gD-dE 1 E3 following mucosal administration (Fig. 5.3.1 1 - 
12). In contrast to rnucosal administration, the replicationdefective virus may have 
induced immunity following systemic administration because the systemic immune system 
may have a lower threshold for the dose of gD it responds to. The above mechanisms could 
explain the efficacy of the replication-defective gD-dE1 E3 virus to induce good 
@-specific immunity following systemic, but not following solely mucosal immunisation. 
6.2.3 Mucosal antibody responses induced by mucosal and systemic 
immunisation with recombinant adenoviruses 
I have shown that both mucosal (i.n. and g.i.) and systemic (i-p. and i.d.) routes of 
immunisation with gD-dE3 were capable of inducing @-specific immune responses. 
However, the different routes stimulated different levels of antibody responses, especially 
with regard to respiratory tract IgA. For example, i.n. immunisation with gD-dE3 was more 
effective than i.d. or i.p. immunisation in inducing respiratory tract IgA responses. In 
contrast, in., i.d. and i.p. immunisation induced similar levels of gD-specific IgG antibody 
in the serum and lung-washes (Figures 5.3.14 & 1 7, Tables 5.3.3, 5.3.4 & 5.5.5). The high 
levels of IgA in the respiratory tract compared to those in the serum following i-n., but not 
after systemic immunisation, and the correlation between the level of IgA in lung-washes 
and the number of IgA ASC in the lung indicated that IgA was mainly locally produced in 
the respiratory tract (Fig. 5.3.14 & Table 5.3.3, Fig. 5.3.17 & Table 5.3.4). Local gD- 
specific IgA levels and the number of gD-specific ASC in the lung correlated with 
protection of the lungs against i.n. BHV-1 challenge. Cotton rats that contained the highest 
levels of respiratory tract IgA in the lung were best protected against i.n. BHV- 1 challenge, 
while the lack of IgA in the respiratory tract corresponded with low levels of protection. 
Intranasal immunisation resulted in better protection against i-n. BHV- 1 challenge than i .d. 
or i.p. inoculation (Fig. 5.5.15 & Table 5.3.5). These findings are consistent with other 
reports and suggest that mucosal IgA is important in protecting the host from a mucosal 
viral infection (reviewed by Murphy, 1994). However, partial protection was sometimes 
observed in the presence of very low levels of mucosal IgA (Figures 5.3.1 1, 5.3.14, 5.5.5, 
5.5.8, etc.). In addition, the titre of @-specific IgA in the lung, and especially in the 
trachea, did not always directly correspond with the number of BHV-1 pfu recovered 
following challenge. These observations suggest that effector mechanisms other than I g A  
may play a role in protection of cotton rats against i n  BHV-1 challenge. 
Antigen-specific IgG can bind and inactivate viruses before they infect the mucosal 
epithelium (Murphy, 1994). Intraderma1 irnrnunisation induced @-specific IgG in the 
serum and the lung (Figures 5.3.14 and 5.3.17), which correlated with partial protection of 
the lung against i.n. BHV-1 challenge (Table 5.3.5). The presence of IgG at mucosal 
surfaces in my experiments, following any route of irnrnunisation, is probably largely due 
to exudation of serum IgG to mucosal surfaces. This is likely since gD-specific IgG levels 
in the respiratory tract of cotton rats correlated with @-specific IgG levels in the serum, 
but not with the number of @-specific IgG ASC in the lung (Fig. 5.3.14 & Table 5.3.3, 
Fig. 53-17 & Table 5.3.4). Several findings in mice support this hypothesis (Papp et al., 
manuscript in preparation; Baca-Estrada, manuscript in preparation; Eis Hubinger et al., 
1993, Wagner er al., 1987). The presence of a few IgG ASC in the lung of cotton rats 
indicated, however, that some of the IgG at mucosal surfaces may have been locally 
produced. In addition, lower levels of IgG in nasal than lung-washes indicated that IgG 
may have more easily transudated through the lung epithelium than the nasal and tracheal 
mucosa. This may be an explanation for why serum antibody is usually more protective 
against pulmonary than nasal infection (Graham et a/., 1993, Mmphy, 1994). Therefore, 
the usually better protection of lungs than of tracheae following immunisation suggest that 
IgG may play a role in the protection of the cotton rat lung against i.n. BHV- 1 challenge. In 
addition, other effector immune mechanisms such as cell-mediated immunity (CMD might 
play a role in an accelerated clearance of B W -  1 from the respiratory tract. 
Data in the literature are consistent with my results regarding the capability of i-n. 
immunisation to induce similar systemic, but better mucosal immunity and protection 
against respiratory mucosal viral challenge than systemic irnmunisation (Gallichan et al., 
1993, McGhee el al., 1 992, Michalek et al., 1994, Tarnura & Kurata, 1996). The reason for 
this observation probably is that following i.n. immunisation, specialised lymphoid tissues 
in the respiratory tract of rodents such as nasal- and bronchus-associated lymphoid tissues 
and lung-associated LN-s serve as inductive sites for antigen-specific immune responses by 
local stimulation with antigen. Antigen-specific lymphocytes stimulated locally are thought 
to leave these inductive sites, enter the systemic circulation and then return to the area of 
stimulation as effector cells. Inflammation may be important in the recruitment of activated 
lymphocytes, while the continued presence of specific antigens within the tissue would 
help retaining recruited antigen-specific cells (Lipscomb et al., 1995). It is not surprising 
therefore, that i.n. immunisation resulted in a higher number of @-specific ASC in the 
lung than i.d. inoculation since persistence of gD in the lung and lung-associated LN is 
more likely following administration of antigen to the respiratory tract. In addition, 
memory lymphocytes stimulated in the respiratory tract may have unique homing 
specificities that favour their entry into the site of stimulation (Lipscomb el al., 1995, 
McDermott & Bienenstock, 1 979, Picker, 1994). 
Although systemic irnmunisation usually does not induce local respiratory tract 
immune responses, i-d. imrnunisation with recombinant Ad induced a few @-specific IgG 
and IgA secreting cells in the lung (Tables 5.3.3-4). It is possible, that local stimulation of 
@-specific lymphocytes could take place in the lung even following i.d. inoculation of 
cotton rats with gD-dE3, since adenoviruses are able to spread systemically to the lung 
tissue following systemic innunisation (Table 5.4.3 and Mittal et al., 1993). Alternatively, 
mild inflammation in the lung caused by a low level of Ad persistence or i.n. BHV-1 
challenge may be enough to recruit gD- and Ad-specific lymphocytes to the lung induced 
in systemic lymphoid tissues. In fact, initiation of a mild inflammatory response in the lung 
can result in the accumulation of antigen-specific lymphocytes in the lungs of animals 
immunised via an extrapulmonary route (Hillam et al., 1985, Lipscomb et al., 1995). 
Despite the presence of gD-specific antibodies in the respiratory tract following i.d. 
and i.p. inoculation, intranasal immunisation better protected cotton rats against i.n. BHV- I 
challenge than systemic imrnunisation. This protection correlated with high levels of gD- 
specific IgA in the respiratory tract following i.n. administration of the recombinant 
adenovirus. Therefore, although I can not exclude the possibility that gD-specific CMI may 
have played a role in protection of the lungs against BHV-I challenge, it is likely that the 
mechanism of protection against i.n. BHV-1 challenge involved @-specific antibodies, 
especially mucosal IgA. 
6.2.4 Mucosal antibody responses induced by the gastrointestinal route of 
immunisation 
Based on the concept of the common mucosal immune system (CMIS) (Mestecky 
et al., 1994) and the success of oral adenoviral immunisation of military recruits against 
acute respiratory distress syndrome (ARDS) (Top et al., 1 97 1 a), g.i. irnmunisation with 
recombinant Ad expressing gD was expected to induce mucosal immunity and protection 
of the cotton rat respiratory tract against i.n. BHV-1 challenge. Indeed, administration of 
gD-dE3 by the oral and intraduodenal routes induced @-specific antibody in the serum 
and the respiratoly tract (Figures 5.3.1 1 & 5.5.4). In addition, intraduodenal-oral (Table 
5.3.3) and intraduodenal (Table 5.5.6) administration of gD-dE3 could also induce gD- 
specific ASC in the lung. I found no other report in the literature on induction of immunity 
to a foreign protein in the respiratory tract following g.i. irnmunisation with recombinant 
adenovirus. However, wt HAd and other viruses have been shown to induce immunity in 
the respiratory tract following g-i. irnmunisation (Bender et al-, 1996, VanCott et al., 1994; 
reviewed by Mestecky et ol., 1994). 
According to the concept of the CMIS, antigen-specific lymphocytes stimulated in 
the gut following enteric irnmunisation would disseminate systemically and seed distant 
mucosal sites such as the respiratory tract. Before discussing the CMIS as a mechanism of 
induction of @-specific immunity in the respiratory tract, it is important to consider that 
gD antigen may not have exclusively stimulated lymphocytes in the gut mucosa. First, I can 
not exclude the possibility that a low amount of Ad may have directly entered the 
peritoneum fiom the surface of the needle used in an intraduodenal injection, even though 
there was no evidence of virus inoculum leaking fiom the gut dwing or following injection 
to the duodenum (Evans blue dye). Even if minimal leakage took place, virus could access 
and express gD in different organs, inducing systemic gD-specific immune responses. 
Although the procedure of intraduodenal imrnunisation is widely used in rodents, I have 
not seen this issue addressed. This possibility could be examined by administering traces of 
recombinant Ad i.p. and monitoring whether any immune response develops. In addition, 
there is a possibility that animals that had received intragastric inoculation regurgitated 
some virus, resulting in exposure of the respiratory tract to infection and foreign gene 
expression. Although there was no evidence of virus suspension in Evans blue dye 
spreading to the pharynx or further into the respiratory tract following administration of the 
virus in the oesophagus, adenovirus isolation results indicated that gD-dE3 may have 
spread to the respiratory tract. The amount of gD-dE3 virus in the lung 3 days following 
intragastric immunisation was similar to that following i.n. inoculation (Tables 3.4.1-3). 
Others have also suggested that live virus may have spread to the respiratory tract 
following oral or intragastric administration (Huard et al., 1995, Kanesaki et al., 199 1, 
Schwartz et al., 1974, Tacket et al., 1992). Therefore, an oral capsule that delivers Ad 
directly into the stomach, and does not release virus till the capsule enters the gut may be 
necessary if one needs to use a completely enteric immuaisation procedure. This way the 
possibility of regurgitation of virus from the stomach would be reduced. Even then, 
however, systemic adenoviral dissemination may take place following enteric 
administration, which would result in @-expression not only in the gut mucosa, but also in 
systemic lymphoid tissue. My results clearly demonstrated that adenovirus spread 
systemically following either intranasal, intraduodenal or oral routes of administration with 
gD-dE 1 E3 and gD-dE3. This resulted in live infectious Ad (and potentially @-expression) 
in the lungs as well as other organs (Table 3.4.1-3). These data suggest that both 
replication-defective and replication-competent adenoviruses have the capability to cross 
the mucosal (or lung) barrier and potentially infect other mucosal or systemic sites. It is 
possible, that many viruses have such capabilities for dissemination, such as rotavirus 
(Uhnoo el al., 1 990). This issue should be fiuther investigated in vaccination and in tumor- 
and gene-therapy research to address safety concerns and to understand basic 
immunological mechanisms of induction of mucosal immunity. 
Although gD-speci fic antibody induced in the respiratory tract, after g. i. 
immunisation with recombinant Ad, can not be exclusively explained by the migration of 
an tigen-speci fic lymphocyte precursors to 
CMIS was, at least partly, responsible for 
remote mucosal sites, it is very likely that the 
the presence of mucosal antibody responses in 
the respiratory tract following intraduodenal inoculation (Fig. 5 S.8 and Table 5.5.6). 
Adenoviw- and @-specific ASC were induced in the mesenteric LN (Table 5.5.1) and 
Ad-specific antibodies were detected in gut washes (data not shown) following g.i. 
inoculation with recombinant adenovirus. It is possible that gD- and Ad-specific 
lymphocytes primed in the Peyer's patches of the gut or in the mesenteric LN rmgrated to 
the lung where they became plasma cells. It would be interesting to find out whether gD- 
specific ASC or memory T cells can be recruited into the lung without the presence of 
BHV-1, gD or local inflammation caused by virus infection in the lung. Such research 
would clarify whether antigen persistence, local inflammation or the homing specificities 
of lymphocytes are more important in the accumulation of antigen-specific lymphocytes in 
the lung. Whether immune responses in the respiratory tract induced by the g.i. route of 
immunisation with gD-dE3 are mainly due to the migration of lymphocytes induced in the 
gut or also to the spread of the virus itself to other mucosal sites also require fbther 
studies. 
Local stimulation of @-specific immunity in the respiratory tract seems very 
important in the protection of cotton rats against in. BHV-1 challenge. In contrast to 
complete protection following i.n. imrnunisation, only partial protection of the lung was 
observed against BHV-1 challenge in most animals imrnunised by the g.i. route (Table 
5.3.2). Protection results varied following intmduodenal immunisation depending on the 
experimental design (Table 5.5.2 and Fig. 5.5.19). My findings are in accordance with 
other reports showing that i.n. delivery of live vaccines is often more effective than 
gastroenteric administration in protecting the respiratory tract against challenge (Brownlie 
el al., 1993, Collins et al., 1990, Couch el al., 1996, McLean et a[., 1996, Meitin et al., 
1994, Tamura & Kurata, 1996). It is possible that following g.i. immunisation only a few 
viruses could access mucosal inductive sites due to dilution of the inoculum and effective 
non-immune exclusion of the virus in the gut. I used high (lo8) pfu of gD-dE3 for g.i. 
inoculation of cotton rats to overcome such effective clearance; however, even more virus 
or the development of new delivery techniques may be necessary to obtain similar levels of 
immunity and protection in the lung following g.i. as those following i.n. inoculation. It is 
also possible that human adenovirus, especially the dE3 vector, does not replicate as well 
in the cotton rat gut (no data available) as in the respiratory tract (Pacini et a/., 1984). 
Nevertheless, the capability of g.i. immunisation to induce immunity in the respiratory tract 
is remarkable and has a great potential as a vaccine strategy against respiratory tract 
diseases. It would be important, however, to further explore what the mechanism of 
induction of immunity is at a distant mucosal site. 
6.2.5 The duration of antibody responses induced by recombinant adenovirus 
An important requirement fkom a good vaccine is that it should induce long-lasting 
protective immune responses. Antibody responses induced by immunisation with subunit 
protein vaccines are usually of short duration and repeated inoculations are necessary to 
maintain high antibody levels. One great advantage of recombinant adenoviruses over other 
vaccination strategies is their capability to deliver subunit viral proteins in vivo in such a 
manner that the antigens will be presented to the immune system similar to that following 
natural viral infection. This may change the regulation, and increase the levels and duration 
of immune responses to the heterologous antigen. 
Although mucosal viral infections usually stimulate immunity of shorter duration 
than systemic infections (Slifka & Ahmed 1996), long term humoral responses and 
protection fkom mucosal viral challenge have been reported following mucosal 
administration of live viruses or viral vectors (Gallichan el a[., 1993, Hyland et nl., 1994, 
McNeal & Ward, 1995). My results also suggest that immunity induced by i.n. 
administration of gDdE3 in cotton rats may be long lasting: gD- and Ad-specific antibody 
responses were maintained at high levels for at least 12 weeks following immunisation 
(Figures 53-19 & 5.5.1 1). Antigen-specific ASC in the lung and the bone marrow were 
present at similar levels at 12 weeks as at 3 weeks following immunisation (Tables 5.3.6 & 
5.3.4). Furthermore, complete protection of the lungs was achieved at 3 and 12 weeks 
following immunisation. It would be interesting to determine the capability of recombinant 
human adenoviruses to induce long term immunity in an animal model with a longer life- 
span than that of rodents. 
Long term antibody responses and protection against challenge may be due to the 
presence of ASC maintained for a long period of time in the bone marrow, draining 
mediastinal LN or the lung following respiratory viral infection (Hyland et al., 1994, Jones 
& A&, 1987, Liang et al., 1994). My results indicate that significant numbers of 
@-specific ASC persisted for at least 3 months in cotton rats following i.n. immr;nisation 
with gD-dE3 (approximately lo3 in the lung, lo3 in the bone marrow and 10' in the 
spleen). The numbers were calculated by assuming that there are approximately 2 million 
lymphocytes in the lung, 150 million in the bone marrow and 50 million in the spleen of 
cotton rats. These data suggest that at least as many gD-specific ASC seed systemic sites 
following i.n. immunisation with gD-dE3 as those retained in the lung. 
Antigen-specific antibody continues to be produced in the bone marrow and in the 
lung for several years after the last exposure to antigen (Bice et al., 1993, Bice et at., 199 1, 
Slifka & Ahmed, 1996). It is possible that the microenvironment of the bone marrow and 
the lung can provide the right signals and cytolunes to sustain antibody-secreting plasma 
cells for long periods, even for years. In fact, antibody-secreting plasma cells from the bone 
marrow are as long lived as memory B cells (Manz et al., 1997). ASC are known to 
selectively express syndecan, which binds collagen and fibronectin (Lalor et al., 1992). 
This may help retain ASC in the lung interstitiurn, alveoli, alveolar septa or pleura or to be 
scattered in the mucosa of the upper respiratory tract (Bice el al., 1 987). It is more likely, 
however, that memory B cells are involved in the mechanism of maintenance of long-term 
antibody responses. Memory B lymphocytes induced by immunisation with gD-dE3, 
recirculating throughout the lymphoid system, are perhaps exposed to persisting antigen in 
the lung, lung-associated LN, mediastinal LN or systemic lymphoid tissue. They would 
then proliferate, develop into ASC and plasma cells. In the meantime they would lose their 
capability to repeatedly recirculate in the lymphoid system and to enter lymph nodes via 
high endothelial venules: they would rather enter the bone marrow or the lung, which lack 
such venules. It has been suggested that ASC preferentially migrate to the bone marrow or 
remain restricted to the site of persisting antigen, while memory B cells freely recirculate 
(Bachmann et al., 1994). Although inflamed lungs non-specifically recruit both T and B 
cells, the presence of specific antigens within the tissue is an important factor in retaining 
recruited immune cells in the lung (Lipscomb et ol., 1995). 
The mechanism of maintaining antibody levels and the number of antigen-specific 
ASC in the lung may be the result of the continuing presence of gD in the lung or draining 
LN. Indeed, 2 out of 7 cotton rats tested contained infectious adenovirus 3 weeks following 
i.n. immunisation with gD-dE3. In addition, the capability of certain viruses, such as 
adenoviruses, to induce long-term systemic immune responses following mucosal 
administration may be associated with their ability to spread systemically (Oualikene et al., 
1994, SIiflca & Ahrned, 1996; and Tables 5.4.1-3). Therefore, adenovirus - and 
consequently gD - may persist at different sites in the systemic lymphoid tissue. Indeed, 
infectious dE3 Ad was isolated fiom different tissues 4 weeks following i n .  inoculation of 
cotton rats (Ouaiikene et a[., 1994). Adenoviral DNA was detected in the nasal mucosa for 
70 days p.i., while foreign gene expression continued for 18 days following i.n. 
administration of a replication-defective recombinant Ad2 virus (Zabner et al., 1994). In 
some cases, expression of the foreign gene was observed for 12 months in skeletal muscle 
of mice following i.m. administration of Ad (Stratford-Perricaudet et al., 1990). Moreover, 
HAd shedding has been observed for several months following infection (Fox et al., 1969, 
Fox et a!., 1977). The site of adenoviral persistence is not known. Adenoviruses may be 
able to persist in vivo in lymphocytes (Flornenberg et al., 1997) such as they do in vipo 
(Hornenberg et al., 1996, Silver & Anderson, 1988). In addition, antigens such as 
adenoviral proteins and gD may be associated with dendritic cells in the form of antigen- 
antibody complexes (Tew et al., 1980, Unanue, 1993). 
Direct evidence that maintenance of B cell memory depends on antigen persistence 
has come fiom the finding that memory responses decay rapidly when primed lymphocytes 
are adoptively transferred in the absence of antigen; cotransfer with antigen lead to 
maintenance of memory (Gray, 1994, Gray & Skarvall, 1988). However, antigen 
persistence is not the only possible mechanism to explain long term immunological 
memory. There is evidence that qualitatively special long tern memory B and T cells may 
exist, independently of persisting antigen (Sprent, 1 994). Maybe, such memory B cells 
would be restimulated by local antigenic challenge, proliferate and become plasma cells in 
the lung. Understanding the mechanism of maintenance of long tern immunological 
memory is important for the development of more efficacious vaccines. 
Studies about immunity induced by recombinant adenoviruses has only recently 
been started in animals of long life-span or in humans (Table 3.1). It is not known whether 
mucosal or systemic irnmunisation with recombinant adenoviruses can induce long-term 
immune responses in such species. Studying the mechanism of immunological memory 
should help design appropriate vaccination protocols to utilise the potential of recombinant 
adenoviruses expressing gD in inducing long-term protection against BHV- 1 infection in 
cattle. 
6.2.6 gD-specific T cell responses induced by recombinant adenoviruses 
Virus-specific humoral immune responses are known to play an important role in 
preventing secondary viral infections and extracellular spread of virus within the host, 
while cell mediated immunity usually contributes to the control and resolution of already 
established infections. Cytotoxic T cells have been shown to reduce the replication of 
certain viruses and protecting animals f?om disease caused by mucosal or systemic viral 
challenge (Zinkernagel, 1993). In some viral infections, CD4+ T cells play a relatively 
minor role in the protection against disease (Zinkernagel, 1993). However, the induction of 
antigen-specific c D ~ +  T cells is essential for inducing humoral immunity against most 
protein antigens since B cell responses to most viral antigens are T cell dependent 
(Bachrnann & Zinkemagel, 1996, Zinkemagel, 1993). T cells also produce cytokines and 
are able to provide help for CTL (Fitch et a/., 1993). 
Antigen-specific T lymphocytes are known to proliferate in vine upon presentation 
of antigen. Although proliferation is not a specific effector function of T cells, proliferation 
assays have been widely used to assess the overall imrnunocompetence of an animal. Data 
obtained from such assays may reflect proliferation of CTL, cytokine-producing c D ~ +  T
cells or bystander B cells. Nevertheless, the population that constitutes proliferating spleen 
cells is usually antigen-speci fic C D ~ +  lymphocytes. They can also amplify bystander 
proliferation in an antigen-specific manner. 
I was able to consistently demonstrate low and not always significant, levels of gD- 
specific proliferative responses of spleen cells in every experiment following immunisation 
with gD-expressing recombinant adenoviruses (Fig. 5.3.6 or not shown). To optimise the 
conditions for proliferative responses of cotton rat spleen cells, many culture-conditions 
and antigen doses were tested. Proliferative responses to Concanavalin A and antigen- 
specific proliferative responses to the Ad vector itself were good, showing that the cause of 
low gD-specific proliferative responses was not unsatisfactory in vino culhxe conditions. 
Instead, the proliferation assay simply may not be an optimal assay for assessing the level 
of @specific T-cell activation. Cytokine production by T lymphocytes may better 
represent the potential of immunisation to induce gD-speci fic CMI. Indeed, immunisation 
of mice with gD-dE3 induced only low or no proliferative responses but high numbers of 
gD-specific IFN-y cytokine producing cells in the spleen and the lungs (Papp et al., 
manuscript in preparation). Immunisation of mice with plasmids carrying the gene of gD 
was also able to induce only low @-specific proliferative responses, while they induced 
high IFN-y production of spleen and LN cells (Lewis et al., 1997). In contrast, purified gD 
in an oil-based adjuvant formulation was capable of consistently inducing higher 
proliferative responses and IL-4 pioduction by spleen cells of mice than control-inoculation 
(Baca-Estrada et al., 1996). In cattle, immunisation with the gD or tgD protein usually, but 
not always, induces @-specific proliferative responses in spleen cells (Tikoo et al., 1995b, 
Baca-Estrada and Marlene Snider, personal communication). In sheep, i.d. or intrajejunal 
immunisation with gD-dE3 induced Peyer's patch and spleen cell proliferative responses of 
high SI in some animals and lower or none in others (Philip Griebel et al., manuscript in 
preparation). These references indicate that gD is capable of inducing T cell proliferative 
responses, but depending on the experimental set-up and the animal model used, this assay 
may not reflect the differences in gD-specific T cell induction between immunised and 
control groups. 
It is also possible that, the genetic background of cotton rats is such that certain 
antigens such as gD, may induce low proliferative responses of their spleen cells, and 
maybe low T cell activation in general. Certain individual cattle and sheep, and certain 
strains of mice are low-responders to gD antigen (Philip Griebel, Sylvia van Drunen-Littel 
van den Hurk Maria Baca-Estrada and Jeffrey Lewis, personal communication). 
Immunisation of cotton rats with recombinant Ad expressing haemagglutinin (HE) of 
coronavirus also induced very low spleen cell proliferative responses in cotton rats (Baca- 
Estrada et al., 1 995). To test whether gD expressed by adenoviruses in vivo can induce 
CMI, reagents for measuring cytokine production or development of other assays (e.g., 
delayed-type hypersensitivity assay) in coaon rats would be necessary. 
Although gD of herpesviruses is known to induce proliferative responses and gD- 
specific cytokine production in different animal models (mentioned above), no @-specific 
CTL responses has been demonstrated following either HSV or BHV infection, or 
immunisation with gD using different delivery systems (Johnson, 199 1, and Baca-Estrada, 
Jeffrey Lewis and Sylvia van Drunen-Littel van Den Hurk, personal communication). I 
could not detect @-specific C'TL responses from spleens of cotton rats immunised with 
gD-dE3 either (data not shown). In contrast, gB of BHV-1 (Maria Baca-Estrada, personal 
communication) and gB and gC of HSV (Gallichan et al., 1993, Witrner et a/., 1990) can 
stimulate CTL responses in mice. To understand why measuring @-specific CTL 
responses has been unsuccessful needs fiu-ther investigations. In addition, the role of gD- 
specific CMI in the protection against infection or disease caused by BHV-1 in cotton rats 
and cattle remains to be studied. 
6.3 Effect of pre-existing adenovirus-specific immunity on immunisation with 
recorn binant adenovirus 
For gD-specific immunity to develop it is crucial that cotton rat cells become 
infected with recombinant adenovirus and express the gD protein. Since Ad-speci fic 
neutralising antibody can prevent an infection by adenovirus and Ad-specific CMI may 
limit the duration of foreign gene expression, it is not surprising that pre-existing Ad- 
specific immunity reduced the efficacy of immunisation with gD-dE3 in cotton rats. Active 
Ad-specific immunity significantly inhibited the development of @-specific antibody 
responses following immunisation with gD-dE3 and the protection of cotton rats against 
BHV-I challenge, while only a slight inhibition of the efficacy of immunisation was 
observed by passive transfer of Ad-speci fic antibody. 
These results are consistent with data in the literature. Although the effect of 
passive and active vector-specific immunity has rarely been compared, observations 
indicate that active immunity to a live vector usually more significantly reduces the 
efficiency of foreign gene-expression or the development of antigen-specific immune 
responses than passive transfer of Ad-specific serum antibodies (Andrew, 1989, Johnson et 
a[., 1993, Kundig el al., 1993, Yang et aL, 1995a). It would be interesting to determine 
whether passive transfer of vector-specific antibody in a natural situation (maternal 
antibody) would inhibit the efficacy of imrnunisation with live recombinant vectors in new- 
born cotton rats. In this case, maternal antibody would be transferred both through the 
placenta (mainly IgG) and through milk (mainly IgA) and may affect immunisation with 
recombinant Ad differently than passive transfer of merely serum IgG into an adult rat. In 
addition, pre-immunisation with lower doses of HAdS, which probably resembles a natural 
infection better than that with high doses used in my experiments, may not interfere with 
the success of imrnunisation with recombinant adenovirus vaccines (such as in Xiang et al., 
1996). 
Intranasal administration of 2 x 10' pfi  wt HAd5 almost completely blocked the 
development of @-specific immune responses following i.n. imrnunisation with gD-dE3. 
This suggests that in each experiment where I used the same route for a secondary 
imrnunisation as for a primary immunisation with gD-dE3, the second immunisation might 
have not provided much booster effect. Although gD-specific serum antibody levels were 
sometimes slightly higher following a second immunisation than those following primary 
immunisation (data not shown), this increase may only reflect the kinetics of the immune 
responses developing following the first imrnunisation. In fact, both gD- and Ad-specific 
serum-IgG levels kept rising beyond the timepoint when primary antibody responses were 
assessed 3 weeks following immunisation (Figures 5.3.19 and 5.5.1 t ). Whether the affinity 
of mucosal antibody was significantly increased by a second mucosal immunisation with 
recombinant Ad remains to be further investigated. 
There are several possibilities to improve the efficacy of a second immunisation 
with gD. First, a primary immunisation with recombinant Ad later followed by 
immunisation with gD using a different delivery system (liposomes, DNA, etc.) may give 
better results than immunisation twice with recombinant Ad by the same route. Second, 
Ad-specific neutralising immunity may be circumvented by the administration of a second 
adenovird vector of an alternate serotype (Mack et a!., 1997, Mastrangeli et al., 1996). 
Third, a primary oral and a secondary i.n. immunisation might provide better immune 
responses than immunisation twice intranasally. Fourth, if the immunisations with gD-dE3 
are far apart in time, expression of gD following the second imrnunisation may not be 
blocked and @-specific immune responses may be enhanced. Iwnunisation with gD-dE3 
twice, several months apart were not performed, but my results suggest that by 3 months 
following the first imrnunisation with adenovirus the inhibitory effect of Ad-specific active 
immunity decreased even if the two immunisations are performed by the same route (Fig. 
5.5.12). 
The mechanism by which Ad-specific immunity inhibits the efficacy of 
immunisation with recombinant adenovirus may involve neutralisat ion of the recombinant 
adenovirus or accelerated elimination of recombinant Ad-infected cells by HAdS-specific 
CTL. Since neither serum nor lung antibody levels were found to decrease during a 3 
month period following immunisation (section 5.3.5.2), it is possible that other Ad-specific 
effector immune responses declined in the respiratory tract, allowing more extended gD- 
expression following immunisation with gD-dE3. For example, gB-specific Cm responses 
in the spleen declined following i.n. immunisation of mice with recombinant Ad 
expressing gB (Gallichan er a!., 1993) even though @-specific memory CTL were present 
in the lymph nodes draining the vagina for more than a year. The duration of Ad-specific 
CTL responses in the respiratory tract is not known. 
Data in the literature support the notion that immune responses specific for live 
viral vectors decline with time. Although the efficacy of imrnunisation with recombinant 
vaccinia virus was inhibited for at least 9 months following the first infection with 
vaccinia, the level of inhibition was lower at 5-9 months than at 7-42 days following 
infection (Kundig er a[., 1993). In addition, although the efficiency of heterologous gene- 
expression in the lung or liver was lower following the second administration of 
recombinant adenovirus, inhibition of foreign gene expression was less evident 12 weeks 
than 4 weeks after the first administration of recombinant adenovirus (Setoguchi et a!., 
1994). Therefore, it may be more efficacious to apply a booster immunisation with 
recombinant Ad at a later timepoint following the first immunisation to achieve high levels 
of immune responses to the vaccine antigen. 
Considering the importance of local mucosal immunity in protection against 
viruses, the possibility existed that i.n. exposure to wt HAd5 would not inhibit 
immunisation by the g.i. or intraduodenal route as much as it inhibits i.n. immunisation. 
Interestingly, the efficacy of intraduodenal-oral and intraduodenal immunisation was also 
decreased by pre-imrnunisation with wt HAd5 (Figures 5.5.4 and 5.5.8). The most likely 
explanation for such distant inhibition is that some wt Ad was swallowed during i.n. 
immunisation or was transported to the gut through the circulation, which then induced 
Ad-specific immunity in the GALT and mesenteric LN. Indeed, adenovirus was detected in 
the gut and mesenteric LN following i.n. administration of adenovirus (Table 5.4.3). 
Adenovirus-specific neucralising antibody in the gut could reduce infection of the gut with 
gD-dE3 following g.i. immunisation. Alternatively, Ad-specific CMI may have restricted 
both the quantity and duration of gD-expression. This may have caused the presence of less 
gD-specific ASC in the rnesenteric LN than in animals without pre-existing HAd5-specific 
immunity (Table 5.5.1). It is also possible that Ad-specific immunity in the gut or 
antibodies in the serum have inhibited the systemic dissemination of gD-dE3 following g.i. 
administration, which, as I have suggested before, may have played a role in the induction 
of systemic and respiratory mucosal immunity. Another explanation for the inhibitory 
effect of i.n. administration of wt HA& on immunisahon by the g.i. route is that i.n. 
HA&-infection induced Ad-specific immunity in the gut by the common mucosal immune 
system. Lymphocytes specific for Ad induced in the lung- or nasal-associated lymphoid 
tissue or draining LN-s of the respiratory tract may have migrated to the gut and mediated 
Ad-specific immunity against gD-dE3 infection in the gut. 
In summary, passive transfer of Ad-specific antibodies had a lower inhibitory effect 
than active Ad-specific immunity on the development of @-specific immunity induced by 
immunisation with gD-dE3. Therefore, a recombinant adenovirus vaccine may be more 
efficacious in young animals, which only have maternal antibodies, than in older animals, 
which may have encountered live Ad and have developed active Ad-specific immunity by 
the time of immunisation. 
6.4 General conclusions and future applications 
Recombinant adenoviruses have a great potential to induce mucosal immunity and 
protection against respiratory viral infections. Replication-defective and replication- 
competent recombinant adenoviruses expressing gD or tgD of BHV-1 could induce @- 
specific systemic and mucosal immune responses and confer at least partial protection 
against i.n. BHV-1 challenge in the cotton rat. However, the characteristics of the antigen, 
the replication capability of the vector and the route of immunisation had a significant 
impact on the level of immune responses. The highest levels of immunity and protection 
were achieved by i.n. irnrnunisation with the replication competent vector expressing the 
authentic form of gD. Pre-existing active Ad-specific immunity significantly inhibited the 
efficacy of immunisation while passive Ad-specific antibody interfered less with the 
success of immunisation. 
The information in this thesis should be helpful in designing and testing 
recombinant adenovirus vaccines used in the cattle industry. Application of live human 
Ad-based vaccines may be somewhat limited, however, because of safety concerns for the 
human population. To partly overcome safety problems in cattle, a bovine adenovirus 
vector expressing gD of BHV-1 has been constructed (Suresh Tikoo, manuscript in 
preparation) and will soon be assessed for its capability to induce immunity and protection 
against BHV- 1 challenge in cotton rats, sheep and cattle. Similar safety concerns to human 
adenoviruses wilI have to be addressed, however, to use the bovine live vector as a 
commercial vaccine in the fbture. 
The results of my studies may also be usefid for vaccine research in other animal 
species and humans. Although the immune system of every species is somewhat different, I 
may have been able to identify and confirm basic feahues of adenovims vector-induced 
immunity that could be applied to different biological systems. Funhennore, results in this 
thesis may also contribute to other applications of human adenoviruses since the influence 
of Ad-specific immunity on the efficacy of recombinant human adenovimses and the 
systemic dissemination of Ad vectors raise a great concern in both gene- and tumor-therapy 
research. 
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